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APPENDICES 
SYNOPSIS 
The initial aims of this investigation were to develop a 
reliable assay system for measuring serum 1,Z5-dihydroxyvitamin D 
[1,Z5(OH)ZD] concentrations and to establish a normal range in 
young healthy adults. Compared with young healthy individuals, the 
elderly population are indeed vitamin D deficient. 
Vitamin D deficiency was also demonstrated in a group of 
elderly osteomalacic patients. Slight improvements in osteomalacia 
was achieved by one month of treatment with vitamin D3' or alpha-
calcidiol with or without calcium supplements. The improvements 
were small and occured slowly. A significant increase in the 
strength of bone seems unlikely to occur in the short term. On the 
present evidence the combination of alphacalcidiol and calcium 
supplements seems no better than vitamin D3 or alphacalcidiol alone 
although it may require closer monitoring to avoid hypercalcaemia. 
In a group of elderly patients with osteoporosis and femoral 
neck fracture (FNF), serum osteocalcin concentrations rose 
significantly in the first week after fracture fixation. The change 
in osteocalcin correlated well (p < 0.001) with the change in serum 
1,Z5(OH)ZD concentration. Histomorphometric measurements of the 
extent of osteoid correlated better with osteocalcin than alkaline 
phosphatase. 
Serum concentrations of 1,Z5(OH)ZD were \:also reduced in elderly 
patients with FNF irrespective of the p r e s e ~ c e e of osteomalacia and 
therefore cannot be used as a screening test for osteomalacia in 
this patient group. Reduction of 1,Z5(OH)ZD was not due to a 
reduction in vitamin D binding protein. It is suggested that the 
low rate of bone turnover in these elderly patients reduces the 
requirement of vitamin D. 
) ,"''': 
Of the ten elderly patients who had u n d e ~ t t laryngo- x 
pharyngeal surgery all developed hypocalcaemia. This immediate 
post-operative decrease, due to a rapid reduction in circulating 
PTH concentrations, lead to an overall increase in urinary calcium 
excretion. Serum concentration of 1,25(OH)2D also fell post-
operatively thus potentiating the hypocalcaemic state in these 
patients. Thus, it is important to give parenteral feeding 
supplemented with calcium and vitamin D, preferably alphacalcidiol. 
If delayed then profound as well as prolonged hypocalcaemia can 
occur. 
The human osteosarcoma cell 20S metabolised 25(OH)D3 in a 
substrate concentration and time dependent manner to produce 
products which were secreted into the extracellular medium. These 
products eluted from HPLC with a retention time coincident with 
24,25(OH)2D3 and exhibited an UV absorption spectrum characteristic 
of a vitamin D sterol. Mass spectroscopy analysis indicated at 
least two products were synthesised by the cells. One was identical 
to 24,25(OH)2D3; the other appeared to be an unsaturated tri-
hydroxylated derivative of vitamin D3. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 CALCIUM HOMEOSTASIS 
Calcium plays an important role in a variety of cellular 
and organ functions, in particular muscle contraction, blood 
clotting, hormone release and action, cell motility and cell 
growth and division. Calcium constitutes approximately 1.% of 
the body weight of an adult man. A substantial amount of 
total body calcium (99%) is ~ o b i l i s e d d in bone and teeth, 
in the form of hydroxyapatite, [Ca1o(P04)6(OH)2]' and since 
calcium has little or no ability to form covalent compounds 
the body is able to sustain a small amount in the intra- and 
I 
extracellular compartments. Bone also contains a 
considerable amount of non-crystalline calcium phosphate and 
carbonate, as well as small amounts of other salts and it is 
the movement of calcium from this source which maintains 
intra- and extracellular calcium concentrations. Calcium 
concentrations differ greatly in these compartments; 
ex tracellular calcium is around 2. 2mM, whereas calcium in 
the intracellular fluid is less than luM. 
Calcium is present in plasma in 3 forms: ionised calcium 
accounts for around 50% of total extracellular calcium, the 
remainder is either bound to plasma proteins (eg. albumin) 
or associated with the anionic groups of a variety of 
organic acids, such as calcium citrate. These forms assist 
in the maintenance of extracellular calcium concentration 
within the normal range of 2.2-2.5mM, thus ensuring that 
there is always a constant source of calcium available to 
the cells. 
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Figure 1.1 illustrates an example of nonnal calcium 
balance in adult man. On an average dietary intake of 
l00Omg, around 30-35% is absorbed in the small intestine. 
There is no net gain or loss of calcium from bone because of 
the two processes of bone formation and bone resorption 
which involve the movement of calcium into and out of bone, 
respectively. In a young adult, these two processes are 
balanced, i.e. skeletal homeostasis is maintained. An 
equivalent amount of calcium must therefore be excreted 
daily in the urine to maintain overall calcium balance. Only 
when there is an imbalance between these two systems does 
bone serve as a calcium reservoir. The magnitude of this 
calcium exchange -is difficult to estimate, but it becomes 
significant when the calcium imbalance, whether in the 
hyper- or hypocalcaemic state, persists for a long period 
and metabolic bone disorders develop. 
One additional excretory route of calcium, not shown in 
figure 1.1, is through the skin. Calcium ions are a normal 
component of sweat, and around 30-12Omg of calcium are 
excreted via this route each day. 
Calcium has two major functional roles in human 
physiology. Firstly, it has a structural role as exemplified 
by the strength and rigidity that it, in the fonn of calcium 
salts, contributes to the human skeleton. Its second role is 
that of a "second messenger" which mediates cellular 
responses to a wide range of stimuli in a manner analogous 
to the regulatory actions of the cyclic nucleotides. Calcium 
has the ability to associate reversibly with anionic 
structures present on intra- and extracellular proteins and 
on phospholipid bilayers of membranes, and it is this 
ability which allows regulated calcium fluxes in and out of 
cells. 
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FIGURE 1.1. An example of normal calcium homeostasis in an 
individual with a dietary intake of 1000mg of elemental calcium. 
There is no net movement of calcium between the skeleton and the 
extracellular fluid (ECF), thus urinary excretion of calcium is 
200mg to maintain zero external calcium balance. 
(from: Brown et ai, 1987. Recent Prog. Horm. Res. 43, pp337-96). 
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The calcium binding proteins found intracellularly 
differ to those found in the extracellular space. 
Intracellular calcium binding proteins recognise and bind to 
the low concentrations of messenger calcium that appear in 
the cell. They are small proteins in which several oxygen-
containing anionic groups are arranged in a conformation 
that bind tightly to calcium at micromolar concentrations. 
One such example is calmodulin (Means and Dedman, 1980) , 
which is found in every nucleated cell type examined. It 
binds calcium ions and by doing so modulates the activities 
of a variety of enzymes, in particular those involved in 
cyclic nucleotide metabolism, protein phosphorylation, 
muscle contraction, microtubule assembly and calcium flux. 
This contrasts with the calcium receptor on the cell surface 
which possess the dicarboxylic acid garrma-carboxyglutamic 
acid, which is able to form a complex with the higher 
(millimolar) calcium concentrations found in the 
extracellular fluid. These distinctions reflect the very 
large differences in calcium concentrations in these two 
regions of the body. 
The control mechanism responsible for maintaining normal 
calcium homeostasis involves the interplay between two 
hormones, namely parathyroid honnone (PIH) and 1,25-
dihydroxyvitamin D [1,Z5(OH)ZD], which act either directly 
or indirectly on three target tissues: bone, kidney and the 
small intestine. It is worth noting at this point that 
another peptide hormone, calcitonin, is rapidly released by 
the parafollicular or "c" cells of the thyroid gland in 
local response to small increases in plasma calcium 
concentration (White et al, 1984). However, in disorders 
where calcitonin is absent or in excess patients do not 
become permanen tl y hypercalcaemic or hypocalcaemic, 
respectively. This would suggest that its overall 
contribution to calcium homeostasis is minor compared with 
that of PIH or the vitamin D metabolite. At pharmacological 
- 3 -
doses calcitonin is able to reduce plasma calcium and 
phosphate concentrations by effectively inhibiting bone 
resorption and increasing renal calcium and phosphate 
clearance. In view of the uncertainty in its physiological 
role no further mention will be made of calcitonin. 
The purpose of this chapter is to give the reader a 
general insight into the mechanism of action of both PTH and 
1,25(OH)2D in the maintenance of calcium homeostasis. 
1. 2. PARATHYROID HORMONE 
Parathyroid hormone (parathormone, PTH) is synthesised 
within the chief cells of the parathyroid gland. It 
comprises of 84 amino acid residues in a single peptide 
chain, and contain no disulphide bonds, no carbohydrate 
, m o ~ j . t i e s s or any other covalently bound structure (Cohn and 
Elting, 1986). The amino acid sequence of bovine, porcine 
and human PTH have been established, although the 
conformational structure is still uncertain. The differences 
among them prevent complete irrmunologic cross-reactivity. 
This accounts for the difficulties in developing 
radioirrmunoassays for the measurement of human PI'H using 
antisera directed against the more readily available bovine 
or'porcine peptides. 
Indirect techniques, other than crystallography, have 
suggested that the molecule is folded in such a manner to 
produce a two domain structure linked by a linear region 
(figure 1.2). Biological activity of the hormone resides in 
the first third of the molecule (1-34) and this occupies one 
domain. Removal of residues 1 and 2 renders this amino-
terminal region biologically inert. The inactive carboxy-
terminal portion (41-84) produces the second domain and to 
date no biological activity has been assigned to this 
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FIGURE 1.2. The proposed tertiary and secondary structures of 
bovine PTH. Left and centre: The 3D distribution of mass as 
visualised by dark-field electron microscopy. The view of the 
molecule pictured in the centre is rotated 90° clockwise relative 
to the view on the left. Right: The predicted distribution of ~ ~
helix (sine waves), ~ ~ -sheet (saw-tooth), ~ ~ -turn (T), and random 
coil (---) in bovine PTH. Structural predictions illustrated in 
the view on the right suggest that the region marked N represents 
the biologically active amino-terminal portion of the molecule and 
that marked C the inactive carboxyl-terminal region. 
(from: Cohn and Elting, 1983. Recent Prog. Horm. Res. 39, pp181-
203). 
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region. Linking both domains is the connecting 'stalk' 
(amino acid residues 35-40) which have been shown to be the 
region which enzymes cleave PTH with ease. 
1.2.1. BIOSYNTHESIS AND SECRETION 
The synthesis of PTH, a 9500dalton molecular weight 
peptide (Habener and Kronenberg, 1978) is depicted in figure 
1.3. Like many other peptide hormones PTH is synthesised on 
polyribosomes as a larger inactive precursor molecule (115 
amino acids) termed pre-proparathyroid hormone (pre-proPTH). 
As the growing peptide chain emerges from the ribosome, the 
hydrophobic 25-amino-acid terminal sequence associates with 
the endoplasmic reticulum (ER) membrane, in accordance with 
the signal hypothesis, allowing the pre-proPTH to enter the 
cisternal space of the ER during translation. This N-
terminal leader sequence is removed, either during or 
immediately after completion of synthesis, thus liberating 
an intermediate molecule of 90 amino acid residues, the pro-
parathyroid hormone, pro-PTH. During translocation to the 
Golgi area the pro-PTH molecule undergoes post-translational 
cleavage of 6 amino acid sequences, yielding the native 84 
amino acid PTH molecule. Enclosed in secretory vesicles the 
newly synthesised PTH has 4 fates: 
(1) Irrmediate secretion- PTH passes to the liver where it 
undergoes post-secretory proteolysis, leaving a 33 amino 
acid peptide which represents the biological and irrmuno-
logically active fragment. It is this fragment which is 
responsible for the peripheral actions of PTH. 
(2) Degradation in the cell by late post-translational 
proteolysis between amino acids 33 and 34. 
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FIGURE 1.3. Schema depicting the proposed intracellular pathway 
of the biosynthesis of Pm. Pre-ProPm, the initial product of 
synthesis on the ribosomes, is converted into ProPTH by removal of 
1) the NH2-terminal methionyl residues and 2) the NH2-terminal 
sequence (-29 to -7) of 23 amino-acids during and within seconds 
after s ~ t h e s i s , , respectively. By 20min after synthesis, ProPm 
reaches the Golgi region and is converted into Pm by 3) removal 
of the NH2-terminal hexapeptide. PTH is stored presumably in the 
secretory granule and is either partially degraded within the cell 
, 
4) when secretion of the hormone is suJ>ressed by high serum 
calcium concentrations or 5) is released into the circulation in 
response to a fall in serum calcium. The time needed for these 
events to take place is given below the schema. 
(from: Habener and Kronenberg, 1978. Federation Proc. 37, pp2561-
66). 
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(3) Transportation into storage pool although relatively 
little hormone is stored in the gland, or 
(4) Complete degradation in the parathyroid gland. 
There is no evidence to suggest that either of the PI'H 
precursor molecules or the "pre" or "pr?" peptide sequences 
are secreted into the circulation (Habener and Kronenberg, 
1978). 
The major physiological regulator for PTH synthesis and 
secretion is extracellular calcium concentration. Although a 
rise in plasma calcium s4resses PI'H secretion complete 
inhibition is not seen. There is evidence to suggest that 
intracellular stores of PI'H may be regulated by a 
degradative pathway that is stimulated by high or inhibited 
by low extracellular calcium concentrations (Habener et ai, 
1975). It is not known which enzymes within the parathyroid 
gland are responsible for the degradation of PTH but certain 
lysosomal enzymes, in particular the cathepsins, have been 
implicated (MacGregor et ai, 1979). Fragments of the hormone 
produced during intracellular degradation have been detected 
in the·circulation and some of these have been shown to have 
immunoreactive properties (Potts et ai, 1982). 
1.2.2. MECHANISM OF ACTION 
Like many other peptide hormones, PTH acts by binding to 
a specific cell surface receptor and this interaction 
activates the intracellular adenylate cyclase system and 
hence the production of cyclic adenosine monophosphate 
(cAMP) (Stryer and Bourne, 1986). The binding of PI'H to the 
receptor molecule (figure 1.4) initiates the activation of 
the membrane-bound G proteins (formally known as the N 
proteins). 
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FIGURE 1.4. The activation of the adenylate cyclase 
system by Pm. 
Refer to text for description of steps. 
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Before activation, the G proteins are in a quiescent 
s ta te with all three polypeptide subtmi ts, ~ ~ , ~ ~ and ~ ~ , 
associating with the GDP molecule, denoted G D P - ~ ~ ~ ~ ~ (Stryer 
and Bourne, 1986). Upon activation by the hormone-receptor 
complex, GTP binds to the ~ c h a i n n which in turn dissociates 
from the ~ ~ and ~ ~ chains to form G ~ - G T P P and G , ~ ~ respectively 
wi th the loss of GDP. The G.c-GTP then stimulates the 
activity of adenylate cyclase resulting in the accelerated 
production of cAMP from adenosine triphosphate (ATP). Raised 
cAMP induces specific metabolic events, one of which is to 
increase intracellular calcium. The role, therefore, of the 
G ~ ~ ~ molecule is to present ~ - G T P P to the receptor-hormone 
complex. Once stimulation of adenylate cyclase is achieved, 
GTP is hydrolysed to GDP thus terminating activation and the 
G D P - ~ ~ ~ molecule reforms. 
The major sites for the receptor-mediated actions of PTH 
are in bone and kidney. In the hypocalcaemic state (Figure 
1.5) PTH exerts its major effect on the distal nephrons of 
the kidney by producing an increase in renal tubular 
reabsorption of calcium whilst inhibiting calcium 
reabsorption in the proximal convoluted tubule. The 
combination of the two leads to a decrease in calcium 
clearance. However, PTH also inhibits phosphate reabsorption 
in the proximal tubule thus producing an increase in renal 
phosphate clearance, phosphaturia. The adaptive value of the 
latter requires further explanation. 
PTH also exerts its effect on bone (figure 1.5) by 
releasing calcium, in conjtmction with phosphate, in to the 
extracellular fluid. If phosphate concentration is allowed 
to increase, further movement of calcium from bone will be 
retarded; but in addition to this effect on bone, PTH also 
decreases tubular reabsorption of phosphate, thus permitting 
the excess phosphate to be eliminated in the urine. 
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FIGURE 1.5. The action of PTH on bone and kidney in response to 
low extracellular fluid (ECF) calcium. 
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Therefore, calcium can be mobilised from bone without a 
major disturbance in phosphate concentrations. 
Another ftmction of Pl'H in the kidney is to stimulate 
the synthesis of the vitamin D metabolite, 1,25(OH)2D, by 
activation of the 25(OH)-1 alpha-hydroxylase. The mechanism 
of this activation is unclear but may be related to a fall 
, 
in intracellular phosphate. 
1.3 VITAMIN D 
In the early 1900s rickets was one of the most coomon 
diseases of infancy and childhood. Investigations by 
Mellanby in 1919 led to the discovery that this disease 
could be cured and prevented by the administration of cod 
liver oil (Mellanby, 1919). The beneficial effect of 
stmlight on healing rickets was also demonstrated in the 
early 19OOs. Since cod liver oil was known to contain 
vitamin A, Mellanby (1919) suggested that this was the 
antirachitic substance. However, sceptical of this claim, 
McCollum was able to show that this organic factor was not 
vitamin A, but a group of anti-rachitic substances which 
were detected in several natural oils and designated the 
collective name vitamin D (McCollum, 1922). Collaborative 
work by Windaus and his collegues in the 1930s led to the 
structural identification of these substances (figure 1.6) 
(Windaus et aI, 1936). 
The term vitamin D refers to a group of ten secosteroids 
with anti- rachitic properties, all of which are derivatives 
of the 3(B)hydroxy 9,10 seco 5,7,10(19)triene structure and 
differ only in the C17 side chain (figure 1.7). Of the ten, 
only vitamin D2 (ergocalciferol) and vitamin D3 (chole-
calciferol) are of any significance, both nutritionally and 
- 8 -
FIGURE 1.6. Numbering system for the vitamin D carbons. 
Vitamin D2: (SZ,7E,22E)-9,10-seco-S,7,10(19)22-ergostatriene-
3 ~ ~ -ol. 
Vitamin D3: (SZ,7E)-9,10-seco-S,7,10(19)-cholestatrien-3p-ol. 
CH2 d, 19 10 Ho ,\\,0 3 1 
FIGURE 1.7. The D vitamins 
Not all 10 D vitamins are illustrated. Vitamin D2 (ergocalciferol) 
and Vitamin D3 (cholecalciferol) are the only two commonly known D 
vitamins. The others are known from the literature as biochemical 
"curiosities". 
~ C H 2 2
HO,'\"V 
Ds 
~ 3 3
I 
biologically, to man and, therefore, little or no reference 
will be made to the other eight. 
Vitamin D (in the form of D2 and D3) plays an important 
role in calcium homeostasis, as attested by the fact that 
its deficiency results in poorly calcified bone. Unlike 
vi tamin D2, vitamin D3 can be produced in the skin in the 
presence of sunlight. Only when adequate sunlight is not 
available are people absolutely dependent on dietary intake. 
Approximately 100IU of vitamin D are required per day by a 
healthy adult and only during childhood, pregnancy and times 
*' of stress does this value increase to as much as 400IU per ~ ~
day (Recommended-Dietary Allowances, 1974). 
Few natural foods contain appreciable amounts of vitamin 
D3 and for many people endogenous production, by the action 
of sunlight on the skin, is the most important source of the 
vitamin. Natural dietary sources are fatty fish, such as 
herrings and mackerel, eggs and butter, but the highest 
vitamin D content is present in cod liver oil, approximately 
2ug/g. Vitamin D2 is generally the corrmercially favoured 
source of vitamin D used in the fortification of food 
products such as margarine, infant foods, some yoghurts and 
cereal products because of the ease with which it can be 
synthesised. However, in man, concentrations of vitamin D3 
are normally considered higher than those of vitamin D2 
unless there is a high intake of vitamin pills containing 
D2. Nevertheless, the molecular form in which vitamin D is 
ingested or formed in the skin is relatively inactive in 
maintaining calcium homeostasis and must undergo 
hydroxylation in the liver and kidney to form the active 
hormonal metabolite, 1,25(OH)2D• 
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1.3.1. 'TIlE PHOTOCHEMICAL FORMATION OF VITAMIN D3 
In 1979 Holick and co-workers established that the 
compound 7-dehydrocholesterol (7-DHC), an intermediate in 
cholesterol biosynthesis present in skin, is not immediately 
converted by ultraviolet light to the expected vitamin D3 
(D3) but to a precursor form termed previtamin D3 (pre D3) 
(Holick et aI, 1979). This compound, a double-bonded isomer 
of D3' is quickly converted to D3 (figure 1.8). Further work 
by this group (Holick et aI, 1980) led to the identification 
of the site for the production of this precursor form as the 
epidermis nearest the capillary bed, just beneath the 
epidermal-dermal junction. 
Once preD3 is formed (figure 1.8) from 7-DHC, which 
involves the breakage of the B-ring structure, it is 
thermally converted to D3 by a non-enzymatic reaction which 
appears to be much slower than the initial step (Holick et 
aI, 1980). The greater rate of thermal conversion is due to 
the rapid removal by the circulation of D3 and this drives 
the equilibrium to preD3 conversion. Longer exposure to 
sunlight produces other photoproducts from preD3' the 
biologically inactive compounds tachysterol and lumisterol, 
thus avoiding any danger of endogenous vi tamin D3 
intoxication. Neither tachysterol nor lumisterol is 
transported out of the skin and, consequently, both are 
sloughed off with dead skin. The reaction of preD3 to 
lumisterol is reversible under the influence of sunlight so 
that if preD3 were to be depleted by the thermal reaction, 
more could be produced from lumisterol. 
Once vitamin D3 is formed it is selectively removed by 
way of the dermal capillaries by the vitamin D binding 
protein (DBP) , which has a high affinity for the vitamin. 
This protein was originally termed 'group-specific 
component' or 'Gc protein'. Because DBP has a low affinity 
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FIGURE 1.8. The photosynthesis of PreD3 in human skin and its 
photoisomerisation. 
(1) 7-dehydrocholesterol (2) Previtamin D3 (3) Lumisterol 
(4) Tachysterol (5) Vitamin D3 (6) 5,6-Trans-
vitamin D3 
(from: Holick ~ ~ ai, 1981. Science 211, pp590-93). 
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for preD3, this metabolite remains in the dermis for 
eventual conversion to vitamin D3. The majority of D3 is 
transported on DBP to the liver. Only a small amount of 
vi tamin D is transported on serum albumin, and even a 
smaller amount on lipoproteins (chylomicron remnants) 
(Oueland et ai, 1983). In the liver the newly synthesised 
vitamin will enter a conrnon pool with any vitamin D (02 
and/or 03) from the diet and either undergo hydroxylation if 
needed by the body or will be stored in fat deposits. 
Vitamin D2 is a plant sterol and cannot be produced in the 
skin of animals. It is prepared by the photolysis of the 
sterol ergosterol. 
VITAMIN 0 BINDING PROTEIN 
Vitamin D binding protein (DBP), previously known as Gc 
protein, is a glycoprotein of molecular weight of around 
55,000 daltons (Bouillon and Van Baelen, 1981). It is 
synthesised by the liver as a single polypeptide chain. Each 
DBP molecule has a single binding site for all the known 
vitamin D metabolites; the order of affinity being 25(OH)0-
lactone> 25(OH)O> 24,25(OH)2D> 1,25(OH)20> Vitamin D. The 
affinity for 1,25(OH)20 is approximately 107Mrl whereas 
vitamin D itself binds only with a 100-fold lower affinity 
(Bouillon and Van Baelen, 1982). Two functions have been 
described for this binding protein: 
(1) To facilitate in the skin production of vitamin 03 by 
rapidly removing the end-product. 
(2) To act as a transport protein for parent vitamin 0 and 
its metabolites. 
A third possible role for DBP has been suggested. In 
vitro studies have shown that OBP will form tight 1:1 
complexes with globular actin and is thereby able to 
depolymerise fibrous actin (Van Baelen et ai, 1980). The 
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formation of extracellular actin-DBP complexes may occur in 
vivo after cell rupture but the exact function is still 
unknown. 
1.3.2. THE METABOLISM OF VITAMIN D 
Vitamin D, either in the D2 or D3 form, are metabolised 
in the same manner and are of equal biologic potency, as too 
are their metabolites. 
(i) CONVERSION OF VITAMIN D TO 25(OH)D 
Once in the liver, vitamin D may be retained by the 
tissue (Silver and Berry, 1982) or it may be hydroxylated to 
25-hydroxyvitamin D [25(OH)D], by a mixed function oxidase 
enzyme, located principally in the liver micosomes (figure 
1.9). This vitamin D-25-hydroxylase enzyme requires reduced 
NADP, magnesium ions and molecular oxygen (Bhattacharyya and 
DeLuca, 1974): ie. it is dependent on a cytochrome P450 
system. 25-hydroxylase is regulated by a feedback inhibition 
mechanism so that the product, 25(OH)D, is maintained at a 
relatively low concentration in the serum (2Ong/ml). 25(OH)D 
is the major ciculating form of vitamin D and also the major 
storage form. Accordingly, circulating concentrations of 
25(OH)D are considered to be a reflection of the 
availability of vitamin D and are thought to be the best 
indicator of vitamin D levels. Like parent vitamin D, it is 
unable to stimulate intestinal calcium transport or bone 
calcium mobilisation at physiological concentrations 
(Lawson, 1974). 
(ii) CONVERSION OF 25(OH)D TO 1,25(OH)2D 
The kidney is the major site of 25(OH)D metabolism, the 
most important reaction being the conversion of 25(OH)D to 
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FIGURE 1.9. Schematic summary of the origin of Vitamin D and its 
various biologically active metabolites. 
(from! Deluca and Schnoes, 19S3. Ann. Rev. Biochem. 52, pp411-39). 
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the active hormone 1,25(OH)2D by the renal mitochondrial 
25(OH)D-l alpha-hydroxylase (DeLuca and Schnoes, 1983). This 
enzyme requires internally generated NADPH, molecular oxygen 
and magnesium ions and, like the liver 25-hydroxylase, it is 
a mixed functional oxidase dependent on a P450 system. The 
hydroxylation of 25(OH)D to 1,25(OH)2D (figure 1.9) by the 
tubular cells of the renal cortex, is tightly regulated by a 
variety of factors, most important of which are PI'H, 
extracellular inorganic phosphorus and 1,25(OH)2D itself. It 
is the only naturally occuring form of vitamin D that in 
physiological amounts is capable of maintaining plasma 
calcium concentrations. In fact, 1,25(OH)2D has a biologic 
activity 500-1000 fold higher than that of the precursor 
25(OH)D. 
The kidney also possesses another hydroxylase enzyme, 
25(OH)D-24-hydroxylase which catalyses the conversion of 
25(OH)D to the 24, 25-dihydroxyvitamin D (24,25(OH)2D) 
metabolite (Tanaka et al, 1979). This enzyme is known to be 
activated by 1,25(OH)2D under conditions where 1,25(OH)2D 
concentrations are adequate. In this manner 1,25(OH)2D has a 
negative feedback on its own production. Both 1,25(OH)2D and 
24,25(OH)2D may undergo an additional hydroxylation to form 
1,24,25-trihydroxyvitamin D (Holick et al, 1973). Upon 
oxidative cleavage of the side chain, 1,25(OH)2D forms a C-
23 carboxylic acid, calcitroic acid , which is biologically 
inactive (Esvelt et al, 1979). Production of this acid in 
target tissues may be an important mechanism for the 
inactivation of the biologically potent 1,25(OH)2D. 
26-Hydroxylation of 25(OH)D producing the 25,26-
dihydroxyvitamin D metabolite can also occur (Suda et al, 
1970) but the function of this metabolite remains unknown. 
It has only a slight action on intestinal calcium transport 
and little activity on bone mineralisation and mobilisation 
(Lam et al, 1975). 
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Table 1.1 illustrates the different vitamin D metabolites 
present in blood and their respective concentrations. 
(iii) MINOR METABOLITES OF 25(OH)D 
Other metabolites of 25(OH)D have been isolated and 
identified and these are sunmarised in figure 1.10. These 
metabolites were isolated either from in vitro incubations 
or from animals given large doses of vitamin D in vivo and, 
consequently, the metabolic significance of these 
metabolites are unknown. 
(iv) METABOLIC EXCRETION OF VITAMIN D 
Little is known about the excretory pathway of vitamin D 
and its metabolites. Although bile represents the major 
excretory route (DeLuca and Schnoes, 1983), only small 
amounts of 25(OH)D, 1,25(OH)2D and two dehydration products 
of 1,25(OH)2D have been positively identified (Onisko et ai, 
1980) • 
1.3.3. REGUlATION OF VITAMIN D METABOLISM 
The synthesis of 1,25(OH)2D is under stringent control 
so that the renal output of 1,25(OH)2D is related to the 
body's need for calcium. Pm is the principal regulator of 
the renal synthesis of 1,25(OH)2D. The stimulation of 1-
alpha-hydroxylase activity by PTH is enhanced under 
conditions of decreased extracellular calcium (figure 1.11a) 
although the exact mechanism is still uncertain. This 
increase in 1,25(OH)2D production restores plasma calcium 
concentration by stimulating calcium absorption in the 
intestine, notably in the regions of the duodenum and upper 
jejunum, and also by mobilising calcium from bone. Once 
plasma calcium concentration is restored PIH secretion is 
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LAaLE 1.1. Some characteristics of the major Vitamin D3 
metabolites in plasma from normal individuals. 
(from: Kanis, 1982. J. Bone Joint Surge 64, pp542-60) 
Plasma Turnover rate Production rate 
Concentration ( t ~ ) ) (estimated) 
(ug/L) (days) (ug/day) 
Vitamin D3 4-30 1-2 
25(OH)D3 5-50 5-20 10 
1,25(OH)2D3 0.02-0.04 1-3 0.2 
24,25(OH)2D3 1-5 12-31 1 
25,26(OH)2D3 0.2-1.2 3-6 1.5 
1,24,25(OH)3D3 0.01 tmknown tmcertain 
FIGURE 1.10. Minor metabolites of Vitamin D3' 
(from: DeLuca and Schnoes, 1983. Ann. Rev. Biochem. 52, pp411-39). 
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FIGURE 1.11a. Sequence of events following low plasma calcium 
concentration. The net effect is to elevate plasma calcium 
concentration without affecting plasma phosphate concentration. 
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supressed thus leading to the decreased synthesis of 
1,25(OH)2D. Elevated 1,25(OH)2D concentrations also inhibit 
the synthesis of Pm by the parathyroid glands by 
interacting with the preproPm gene (Russell et al, 1986). 
Another regulator of 1,25(OH)2D synthesis is 1,25(OH)2D 
itself which inhibits the 1 alpha-hydroxylase. This feedback 
inhibition st:irm.!.lates the renal Z4-hydroxylase enzyme to 
produce Z4,25(OH)2D which is biologically less potent than 
1,25(OH)ZD ( T a ~ a k a a et al, 1979). 
Other factors which seem to influence 1,25(OH)2D 
production include plasma phosphate concentration (Tanaka 
and DeLuca, 1973), sex hormones, and possibly calcitonin and 
magnesium ions (Rude et al, 1985). In situations where there 
is low plasma phosphate, but normal calcium concentration, 
the production of 1,25(OH)ZD is enhanced, without the 
secretion of Pm (figure 1.11b). 1,25(OH)ZD will, therefore, 
stimulate intestinal absorption of phosphate (as well as 
calcium) and mobilise phosphate and also calcium from bone. 
In the absence of PTH, hypercalciuria is potentiated and the 
kidney reabsorbs all filtered phosphate. This sequence of 
events' results in an increase in serum phosphate without 
appreciable elevation of plasma calcium. 
Whether extracellular calcium directly regulates 
1,25(OH)2D production is still uncertain. It is firmly 
established that increased calcium down-regulates the 
secretion of PTH and that PTH can directly stimulate 
production of this metabolite. Thus, any changes in calcium 
that alter PIH secretion can indirectly affect 1,25(OH)2D 
synthesis. Consequen tl y , direct ef f ec ts of calcium on its 
production are difficult to assess. However, in vivo results 
from Bushinsky et al (1985) suggest that serum calcium can 
regulate 1,25(OH)2D independently of PIH and phosphorus. 
This conclusion was drawn from data obtained from rats 
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FIGURE 1.11b. Sequence of events following low plasma phosphate 
concentration. The net effect is to elevate plasma phosphate 
concentration without affecting plasma calcium concentration. 
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infused with high levels of Pl'H. Whether calcium has a 
strong regulatory effect when Pl'H is normal, rather than 
high, and how calcium actually affects plasma 1,25(OH)2D are 
questions which still need to be answered. 
1.3.4. MECHANISM OF ACTION OF 1.25(OH)2D ON TARGET TISSUES 
1,25(OH)2D is the most potent vitamin D metabolite in 
stimulating calcium transport in target tissues, namely bone 
and intestine. Evidence to date imply that these two organs 
are not the only sites for 1,25(OH)2D action. In general, it 
is possible to classify target tissues with 1,25(OH)2D 
receptors into three broad groups: Table 1.2. Walters et al, 
1983; Haussler et al, 1985). 
(a) Tissues where 1,25(OH)2D receptors may regulate calcium 
and phosphate translocation across epithelial barriers. 
These include intestine (Zile et ai, 1978), bone (Walters et 
al, 1982), kidney (Christakos and Norman, 1979), placenta 
(Zerwekh and Breslau, 1986), rnamnary and egg shell glands 
(Bell and Freeman, 1971). 
(b) Tissues concerned with the regulation of the vitamin D 
system. These include kidney, skin (Strumpf et al, 1981), 
parathyroid (Wecksler et al, 1980) and possibly the 
pituitary (Haussler et ai, 1980). 
(c) Tissues where the role is currently unknown e.g. 
pancreas (Christakos and Norman, 1979), uterus (Walters et 
ai, 1983), thymus (Reinhardt et ai, 1982), fibroblasts (Pike 
and Haussler, 1983) and activated lymphocytes (Provvedini et 
ai, 1983). 
The mechanism of action of 1,25(OH)2D complies with that 
of the classical steroid hormone-receptor model. The 
majority of unoccupied 1,25(OH)2D receptor is apparently in 
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TABLE 1.2. Relevant tissues and cells that possess the 
1,Z5(OH)ZD receptor. 
(from: Haussler et ai, 1985. Vitamin D: A Chemical, 
Biochemical and Clinical update) 
Category Tissue Specific cell 
types 
Established cell 
lines 
Calcium 
Control 
Intestine 
Bone 
Kidney 
Absorptive epithelial Intestine-407 (H) 
Osteoblast 
Distal/Proximal 
epithelial 
ROS 17/Z.8 (R) 
llC-MKZ (M) 
U.C-PK1 (p) 
Endocrine Parathyroid Chief 
Other 
Pancreas 
Pituitary 
Ovary 
Breast 
Skin 
Bone 
Marrow 
Thynrus 
Brain 
B-cells 
Somatomarnmotroph 
? 
Epithelial 
Epidermal 
GH3 Tumour (R) 
Chinese hamster ovary 
MCF-7 carcinoma (H) 
3T6 fibroblast (M) 
Monocyte HL-60 leukaemia (H) 
Reticular/T-lymphocyte HSB-Z lymphoblast (H) 
Specific neurons 
(H) Human 
(P) Porcine 
(M) Mouse 
(R) Rat 
the cytosol. 1,25(OH)2D enters the cell and associates 
noncovalently but stereospecifically with the tmoccupied 
receptor (figure 1.12). This association strengthens the 
binding capacity of the receptor and the receptor-hormone 
complex moves into the nucleus where it locates and binds to 
high affinity upstream activating sequences of DNA that 
control vitamin D regulated genes. Altered DNA transcription 
then results in enhanced or repressed levels of various 
mRNAs, examples of which include an increase in the mRNA 
which codes for the vitamin D-dependent calcium binding 
protein (Wasserman and Taylor, 1966) and a decrease in 
collagen mRNA. 
A list of all the genes that are known to be regulated 
by 1,25(OH)2D are shown in Table 1.3. These induced 
proteins, either singularly or in combination, are thought 
to perform the diverse biological functions of the hormone 
in the various target tissues. Thus, some target cells (i.e. 
the kidney) may primarily inactivate 1,25(OH)2D and commence 
trans-epithelial calcium transport. Bone cells respond by 
inducing a range of proteins which are required for the 
complex process of bone mineralisation and remodelling. This 
will be discusssed in section 1.4. Finally, cells of the 
haematopoietic system and transformed cells appear to 
respond to 1,25(OH)2D in a variety of ways involving 
differentiation and proliferation. 
RECEPTOR FOR 1,25(OH)2D 
This monomeric receptor has been conserved throughout 
evolution with immunocrossreactivity between fish, avian and 
mammalian 1,25(OH)2D receptors (Pike et aI, 1983). The 
entire sequence of the human intestinal receptor to 
1,25(OH)2D has been established (Baker et aI, 1988) and the 
DNA-binding domain of this molecule shows strong homologies 
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FIGURE 1.12. Proposed mechanism of action of 1,25(OH)2D in 
stimulating intestinal calcium transport: calcium is either 
packaged near the terminal web into vesicles or is taken up by 
mitochondria. Calcium is then extruded by a sodium-dependent 
process. 
(from: DeLuca and Schones, 1983. Ann. Rev. Biochem. 52, pp411-39). 
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An effect of 1,25(OH)2D on transcription has thus far been 
demonstrated only for the genes encoding preproPIH, 
calcitonin, c-myc and the calcium-binding proteins 
calbindins D9K and D28K. 1,25(OH)2D modifies granulocyte-
macrophage colony-stimulating factor mRNA post-trans-
criptionally and also has post-transcriptional effects on 
the mRNA expression of both calbindins. For the other genes, 
it is not known whether 1,25(OH)2D modulates gene 
transcription or induces the synthesis of other factors that 
alter the accumulation of mRNA after transcription. 
(from: Reichel et ai, 1989. N. Engl. J. Med. 320, pp980-91) 
with that of the DNA-binding domains of other steroid 
hormone receptors, particularly within the DNA-binding 
domain. This suggests that the 1,25(OH)2D receptor may 
belong to the same supergene family as all the other classic 
steroid-hormone receptor proteins. 
The 1,25(OH)2D receptor is a c y ~ o p l a s m i c c protein of 
molecular weight between 50,OOO-60,OOOdaltons and has a 
sedimentation coefficient around 3.1-3.7S (Pike and 
Haussler, 1979). It binds specifically, and with high 
affinity to the 1,25(OH)2D metabolite and mediates its 
actions in the nucleus of the target cells (Deluca and 
Schones, 1983). The hormone binding site is separate from 
the DNA binding domain (Pike, 1984) however, both contain 
reactive sulphydryl groups in or near :heir biuding domains 
and the DNA binding site is highly sensitive to proteolysis 
(Allegretto and Pike, 1985). 
MECHANISM OF ACTION: 
(1) Actions of 1,25(OH)2D on the intestine 
The mechanism whereby 1,25(OH)2D stimulates intestinal 
calcium absorption is well established. The stimulation of 
calcium binding proteins such as calbindin-D, by 1,25(OH)2D 
facilitates the passive diffusion of calcium from the 
intestine and with the assistance of the calcium pump, 
calcium passes into the blood (figure 1.12). Induction of 
these binding proteins is known to be strictly dependent 
upon the regulated production of 1,25(OH)2D (Christakos et 
ai, 1981) although synthesis of these proteins is not 
optimal until after maximum stimulation of calcium transport 
by 1,25(OH)2D (Spencer et ai, 1976). 
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There is significant transport of calcium into the 
intestinal mucosa cell before the detection of any calcium 
binding proteins. Work by Bikle et al (1978) showed that 
inhibi tors of protein and RNA synthesis did not block the 
ability of 1,25(OH)2D to stimulate calcium movement by the 
chick intestinal mucosa which suggest that the stimulation 
of calcium transport in situ and in vitro are not totally 
dependent on the synthesis of new proteins and that other 
factors must be responsible. 
Another calcium binding protein, calmodulin, is also 
found in the intestinal epithelium and may play a major role 
in calcium absorption. Although total calmodulin 
concentrations are not increased in the intestine (Thomasset 
et aI, 1981), there is a redistribution of calmodulin to the 
brush border membrane when the tissue is stimulated with 
1,25(OH)zD (Bikle et al, 1984). This effect is coupled to an 
increase in calcium transport and is blocked by specific 
calmodulin antagonists. 
An alternative mechanism for the action of 1,25(OH)2D on 
intestinal calcium absorption has been proposed by Matsumoto 
et al (1981) and involves the alteration of the membrane 
lipid composition by the hormone. O'Doherty (1979) first 
demonstrated that 1,25(OH)ZD stimulated the enzymes involved 
in the phosphatidylcholine deacylation-reacylation cycle in 
duodenal villus cells of the rat intestine. Matsumoto et al 
--
showed that 1,25(OH)2D acts specifically on the brush border 
membranes by causing increases in 
(a) the total phosphatidylcholine content, 
(b) the rate of incorporation of arachidonate into 
phosphatidyl-choline and also 
(c) the amount of linoleic acid in the phospholipid 
fraction. 
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These observations were consistent with findings of 
O'Doherty (1979). This led subsequently to a proposal for 
the alternative mechanism of action of 1,25(OH)2D on the 
intestine which involved the retailoring of the fatty acid 
composition of the villus cell membrane. This would modify 
general properties of the membrane, such as fluidity and 
permeability and perhaps these modifications would enable 
the passive diffusion of calcium into the cell. 
Although the conventional classical hormone-receptor 
model is more favoured, it is possibile that the three 
mechanisms described above may interplay in the actions of 
1,25(OH)2D on the intestine. 
(2) Actions of 1,25(OH)2D on bone 
The cellular basis for the direct effect of 1,25(OH)2D 
on bone has been obtained from in vitro studies because of 
the difficulty in demonstrating bone remodelling in vivo. 
This metabolite is well characterised as an essential 
hormone for the regular mineralisation of new bone and as a 
potent bone-resorptive agent. This will be dicussed in 
section 1.4.2. 
(3) Actions of 1,25(OH)2D on cell growth and differentiation 
There is growing evidence to support the idea tha t 
1,25(OH)2D has additional activities in tissues not 
primarily related to mineral homeostasis. Receptors to 
1,25(OH)2D have been demonstrated in a variety of tissues 
but of particular interest cells of the monocyte/macrophage 
series and in activated, proliferating Band T lymphocytes; 
quiescent lymphocytes do not seem to possess such receptors 
(Manolagas, 1985). In vitro experiments suggest that 
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1,25(OH)2D promotes the differentiation of monocytes towards 
the macrophage phenotype (Olsson et ai, 1983) and also 
enhances the phagocytic activity of macrophages in culture. 
Activated lymphocytes have also been shown to be affected by 
1,25(OH)2D. This hormone is a potent inhibitor of 
interleukin-2 and interferon production by these cells 
(Manolagas, 1985). These discoveries indicate that 
1,25(OH)2D interacts with the immune system and therefore 
might play an important role in the regulation of the immune 
response. 
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1.4 BONE 
The ability of bone to serve a dual function, the first 
acting mechanically as a scaffold for the organs of the body 
and the second playing a role in the maintenance of mineral 
homeostasis, is achieved by its capacity to be constantly 
remodelled throughout life and yet still retain its strength 
and durability. As a living tissue, bone is unique in that 
it is not only rigid but it is also light enough to be moved 
by the coordinated action of muscles. This is due to the 
presence of two major types of bone which are strategically 
positioned (figure 1.13). Cortical (or compact) bone, 
composed of densely packed mineralised collagen laid down in 
layers, provides rigidity and is found in a majority of 
tubular bones. It has the familiar structure of Haversian 
systems or osteons. Trabecular (or cancellous) bone is 
spongy in appearance and is made up of a series of 
interconnecting plates of bone, each perforated by holes 
rather than bars. This bone provides strength and elasticity 
and constitutes the major portion of the axial skeleton 
(Revell, 1986). 
In the normal healthy adult, the process of remodelling, 
where old bone is replaced by new bone, takes place 
primarily on cancellous bone surfaces, and to a lesser 
extent along the walls of the Haversian canals. It occurs in 
discrete units called Basic Multicellular Units (BMUts) each 
of which has a co-ordinated sequence involving activation of 
bone resorbing cells (osteoclasts), resorption of bone 
matrix and mineral, activation of bone formation cells 
(osteoblasts), and formation of new bone and its subsequent 
mineralisation (figure 1.14). Each remodelling unit replaces 
approximately O.OS-O. l mn3 of bone and requires around 3 
months to complete its task. The duration of the activation 
phase is a few days; of the resorption phase, 3 to 4 weeks, 
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FIGURE 1.13. Longitudinal section of the human femur to show 
dense cortical bone, the compacta; spongiosa showing fine 
trabeculae; and marrow cavities between both the trabeculae and 
within the cortical bone. 
(from: Vaughan, 1975. The physiology of bone, Oxford University 
Press, London). 
FIGURE 1.14. Bone remodelling sequence. The quiescent surface is 
covered by resting osteoblasts. The resorption surface has 
osteoclasts (oe). In the reversal phase the osteoblasts (OB) move 
in and deposit osteoid. In late formation, mineralisation has 
occured to complete the cycle. 
o Old bone; ~ ~ New bone; [J Osteoid. 
(from: Martin et ai, 1988. Bailliere's elin. Endocrinol. Metab. ~ , ,
ppl-9) • 
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and of the formation phase, 3 to 4 months (Bordier, 1976). 
However, this time lengthens to 4-6 months in older adults 
and in some patients with bone disease it has been found 
that this time period could be as long as 30 months. 
Surfaces of osseous tissue on which there is active 
deposition of bone show a narrow zone of osteoid tissue 
which differs from bone matrix in that it is not calcified. 
As the osteoblasts deposit the uncalcified matrix the lacuna 
gradually fills thus producing a wide osteoid seam. The 
interface between the calcifed bone and the osteoid is 
termed 'the calcification front'. Mineralisation commences, 
os teoblasts produce less matrix and the osteoid seam, 
initially wide narrows and eventually disappears. Thus, 
there is neither a gain nor loss of bone. 
This process of bone resorption followed by equal bone 
formation is known as coupling and each EMU is excavated and 
filled to a precise pattern. However, very little is known 
about how the osteoclast cells are activated and how the 
bone volume excavated is determined. Even less is known 
about the mechanism \vhich triggers the osteoblasts to appear 
at the excavated site and to lay down exactly the same 
amount of bone that has been resorbed by the osteoclasts. 
Bone remodelling is an active process which is regulated 
by several hormones as well as local factors generated 
within bone and bone marrow. Most if not all metabolic bone 
diseases occur because there is an imbalance between bone 
formation and resorption. 
1.4.1. 'IHE CELLS OF BONE 
The two main cells responsible for the turnover of bone 
tissue are derived from two separate cell systems. The 
- 23 -
osteoblast, the cell responsible for bone fonnation, is a 
product of the osteogenic cell line, one of several lines of 
the stromal system of bone and marrow (figure 1.15), whereas 
the osteoclast, the cell mainly responsible for bone 
resorption, is derived from mononuclear phagocytic cell 
line, a product of the haemopoietic system. A third bone 
cell, the osteocyte, is considered to be an inactive 
osteoblast cell which has become embedded in the bone matrix 
and whose primary function is to 'coornunicate' with other 
osteocytes as well as osteoblasts on the surface. The 
relationship of all three cell types to the bone surface are 
shown diagrarnatically in figure 1.16. 
1.4.1a THE OSTEOBLAST CELL 
Active osteoblasts occur as a continuous layer of cells 
which are cuboidal and contain intracellular organelles 
typical of cells vigorously engaged in protein synthesis-
i.e. abundant ER, a prominent Goigi apparatus and eccentric 
nuclei rich in RNA. They fonn functional gap junctions with 
neighbouring osteoblasts and with subjacent osteocytes 
processes and they contain numerous microtubles and bundles 
of actin filaments along the inner surface of the plasma 
membrane (Revell, 1986). 
The primary function of the active osteoblast is to 
synthesise the extracellular bone matrix components. Figure 
1.17 illustrates the major components synthesised by this 
cell type. Type I collagen (possessing two oc'l and one 0(2 
chains) is the major protein synthesised and is almost the 
exclusive collagen of the bone matrix. It represents at 
least 90% of the total organic matrix of bone. Type III and 
V collagens are generally associated with blood vessels 
found within the bone. 
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FIGURE 1.15. The origin of bone cells. 
(from: Revell, 1986. Pathology of bone, eds. Springer-Verlag) • 
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FIGURE 1.16. Schematic representation of bone cell types. 
(from: M a r t i ~ ~ et al, 1988. Bailliere's Clin. Endocrinol. Metab. l, 
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The osteoblast cell is rich in alkaline phosphatase and 
it is this enzyme which is the hallmark of the active cell. 
However, the function of this enzyme still remains unclear 
but it may be involved in maintaining low extracellular 
concentrations of inorganic pyrophosphate (PPi) since PPi is 
an inhibitor of calcification. Osteoblasts release small 
vesicles from their plasma membranes and these become 
embedded in the extracellular matrix. The enzyme is located 
on the outer membrane of these vesicles (Posner, 1985). 
In addition to collagen molecules, osteoblasts 
synthesise and secrete other protein components of the bone 
matrix (figure 1.17). These are referred to as the non-
collagenous proteins, of which osteocalcin is the most 
abundant and the best characterised (Lian and Gundberg, 
1987). Also known as bone Gla protein and ~ - c a r b o x y g l u t a m a t e e
protein, osteocalcin contains 49 amino acids (5,800 Da) of 
which three are the vitamin K dependent amino acid '0-
carboxyglutamic acid (Gla). In the presence of calcium these 
three residues allow specific conformational changes in the 
osteocalcin molecule, changes which promote osteocalcin to 
bind to hydroxyapatite and subsequently accumulate in the 
bone matrix (Lian and Gundberg, 1987). Only a small amount 
of osteocalcin, which can be measured by the conventional 
radioimmunoassay method, is found circulating in blood. The 
precise biological function of osteocalcin is uncertain but 
it may play a role in regulating mineral deposition and 
crys tal growth. 
Another noncollagenous protein synthesised by the 
osteoblasts is osteonectin, a phosphoprotein which is 
analogous to fibronectin because it binds to both calcium 
and collagen fibres. This protein, therefore, forms the 
potential link between these two major constituents of bone 
(Russell et ai, 1983) and there is strong evidence for its 
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FIGURE 1.17. Products of osteoblasts. 
(from: Russell et ai, 1983. Osteoporosis: a multi-disciplinary 
problem. Academic press, London). 
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involvement in the mineralisation of the bone extracellular 
matrix (Termine et ai, 1981b). Other phosphoproteins have 
been identified but are not yet fully characterised. They 
are known as the 75,000 Da, 62,000 Da and 24,000 Da bone 
phosphoproteins. All are relatively acidic proteins but the 
latter differs from the other two in that it has a high 
hydroxyproline content which is unusual for a noncollagenous 
protein. It may well be a fragment of a collagenous protein 
rather than a distinct low molecular weight bone cell 
product. The function of these three phosphoproteins are 
unknown (Termine et ai, 1981a). 
Proteoglycans, glycosaminoglygans and sialoproteins have 
also been shown to be produced by the osteoblast but their 
respective functions are still uncertain. 
Not all proteins found in the bone matrix are 
synthesised by osteoblasts. Albumin, 0(2HS-glycoprotein and 
transferrin are derived from blood and have been reported to 
be deposited in bone at the time of mineralisation. It is 
presumed that these proteins bind to hydroxyapatite crystals 
and subsequently become trapped in the matrix as 
mineralisation is completed. However, the functions of these 
proteins, if any, are unknown (Russell et ai, 1983). 
Each osteoblast carries out a cycle of matrix synthesis, 
afterwhich it becomes inactive and either becomes buried in 
the bone tissue as an osteocyte or it remains on the surface 
as an inactive osteoblast. 
1-.4.1b. THE OSTEOCYTE CELL 
The osteocyte, derived from the osteoblast, lies within 
the mineralised bone and is in contact with other osteocytes 
and also with osteoblasts on the bone surface by extensive 
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projections, or canaliculi. The osteocyte may be involved in 
the control of mineral exchange between bone and plasma. 
1.4.1c. THE OSTEOCLAST CELL 
Osteoclasts are multinucleated cells which are rich in 
lysosomal enzymes, such as acid phosphatase and cathepsins 
but, in contrast to osteoblasts, their rough ER is much less 
well developed (Martin et ai, 1988). They occur either 
singularly or in a small group on the inner surface of 
resorbing trabecular and compact bones. When in contact with 
the bone surface, the plasma membrane of the osteoclast 
which is immediately adjacent to the bone matrix shows deep 
invaginations with numerous microvilli. This ruffled border 
forms a tight physical bond with the bone and is considered 
to be the area of active resorption. Adjacent to this region 
is the 'clear zone', a region which has moderately dense 
granular cytoplasm and lacks any organelles. This is in 
contrast to the ruffled region which is dense in 
mitochondria and lysosomes and contains smooth and coated 
vesicles, phagosomes and residual bodies. 
Osteoclasts synthesise and release various substances 
which are capable of resorbing the bone matrix (Revell, 
1986). These are illustrated in figure 1.18. Possible 
mechanisms involved in bone resorption include the local 
production of acid (as H+ as a result of carbonic anhydrase 
activity or as lactate) and of calcium chelating organic 
anions such as citrate. These assist in the ability of the 
os teoclas t cell to dissolve the bone mineral phase. The 
osteoclasts also produce lysosomal acid hydrolases and 
proteinases such as collagenase and it is thought that these 
are involved in the degradation of the matrix components. 
However, much still needs to be learnt about how these 
enzymes function. 
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FIGURE 1.18. Products of osteoclasts. 
(from: Russell et aI, 1983. Osteoporosis: a multi-disciplinary 
problem. Academic press, London). 
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There is now strong evidence to show that osteoblasts 
participate more directly in the removal of bone matrix, 
rather than the osteoclasts. Work by Chambers and Fuller 
(1985) clearly shows that osteoclasts can only resorb bone 
and not the bone matrix. If the osteoid layer is removed by 
preincubating with collagenase then osteoclasts can proceed 
to resorb bone. Extensive studies have demonstrated that 
osteoblasts release latent collagenase as well as a 
proteinase called tissue plasminogen activator (tPA) , into 
the matrix (Sakamoto and Sakamoto, 1986; Hamilton et aI, 
1985; Martin et aI, 1985). tPA is able to generate plasmin 
from plasminogen (Hamilton et aI, 1985) which in turn is 
capable of activating latent collagenase to degrade the bone 
matrix. 
1.4.2. FACl'ORS REGUlATING BONE REMODELLING 
The majority, if not a11, of the information on the 
control of bone remodelling has been obtained from studying 
the effect of various hormones and other factors on either 
the formation and resorption of foetal or newborn rodent 
bone in culture or the effects on cultured osteoblast-like 
cells. It is very difficult to obtain a homogeneous layer of 
osteoclasts because of the .difficulty in removing 
fibroblast-like cells. 
The humoral control of bone remodelling results from the 
combined interaction of many factors. These can be divided 
into four main groups. Although the effects of some of these 
factors have been well established there are a few in which 
a specific role is uncertain (Russell et aI, 1983; Martin et 
aI, 1988b). 
(i) THE CALCIUM REGULATING HORMONES 
At the cellular level both PTH and 1,25(OH)2D have 
similar effects on bone remodelling. Their major effect on 
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bone is to increase bone resorption and to have a direct 
inhibitory effect on formation. Calcitonin, however, is a 
specific hormonal inhibitor of bone resorption. 
Pm: 
Pm has been shown to be a potent stimulator of bone 
resorption (Raisz, 1965) but the presence of receptors for 
PTH on the osteoclast cell have not been demonstrated. 
Al though there is no convincing evidence to show that it 
acts directly on the osteoclasts or their precursors, 
studies using organ cultures of bone have noted an increase 
in both the activity and number of osteoclasts in the 
presence of this hormone (Raisz, 1965; Holtrop et aI, 1974). 
The well documented in vitro effects of PTH includes (a) 
stimulating carbonic anhydrase activity (Minkin and 
Jennings, 1972) and citric acid production (Vaes and 
Nichols, 1971) thereby decreasing the pH of the resorbing 
environment and (b) encouraging lysosomal enzyme release 
from the osteoclasts. It now seems likely that PTH acts on 
the osteoclast indirectly via the osteoblast lineage. 
Unlike the osteoclasts, osteoblasts possess high-
affinity plasma membrane receptors for PTH (Partridge et aI, 
1981). Studies have shown that after several minutes of 
exposure to Pm these cells increase their adenylate cyclase 
activity, cAMP accumulation and intracellular calcium 
uptake. At the same concentration PTH also inhibits both 
matrix synthesis, including bone collagen synthesis, and 
alkaline phosphatase acti vi ty • However, the intracellular 
messenger(s) for PTH action is still unknown although 
studies have shown that the cyclic AMP analogues 8-bromo 
cyclic AMP and dibutyryl cyclic AMP and the 
phosphodiesterase inhibitor isobutylmethylxanthine mimic 
these effects of PTH. 
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Recently, a PTH-like peptide has been described in 
extracts of tumours and in culture medium from tumour cell 
lines obtained from patients presenting with humoral 
hypercalcaemia of malignancy (Suva et al, 1987). This factor 
has great homology with PIH, in particular within the N-
terminal region and, like PIH, will stimulate adenylate 
cyclase activity in both renal membranes and osteoblast-like 
cells. Al though iIImunochemically and chromatographically 
distinct from PTH, this PIH-like peptide of 141-amino acids 
might nevertheless interact with the PTH receptor. If this 
is the case it would explain the potent resorbing activity 
of this peptide. 
1,25-DIHYDROXYVITAMIN D: 
1,25(OH)2D has an important role in normal bone growth 
and mineralisation. Like PTH it is a potent stimulator of 
bone resorption, increasing the number and activity of 
osteoclasts in organ cultures and yet the presence of 
1,25(OH)2D receptors in the osteoclast or its precursor has 
not been demonstrated. It is generally thought that 
1,25(OH)2D, like PIH, induces bone resorption indirectly by 
stimulating the osteoblast to release a soluble factor which 
increases osteoclastic bone resorption (McSheeny and 
Chambers, 1987). 
Although receptors to 1,25(OH)2D has been demonstrated 
in osteoblasts its exact role in bone formation is still 
controversial. In bone organ culture and in osteoblastic 
cell cultures 1,25(OH)2D stimulates osteocalcin synthesis 
(Price and Baukol, 1980) and decreases collagen synthesis 
but can either increase or decrease alkaline phosphatase 
activity depending on the dose administered and the stage of 
growth of the cultures used. The interrelationship between 
osteocalcin and 1,25(OH)2D in bone formation is still 
unclear and the physiological significance of reduced 
collagen synthesis in the presence of 1,25(OH)2D is 
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interesting since the same hormone promotes normal growth 
and development in vivo. 
Several studies have suggested that another vitamin D 
metabolite, such as 25(OH)D or 24,25(OH)2D, may stimulate 
bone growth and development. 25(OH)D is the most abundant 
vitamin D metabolite in bone and is associated with areas of 
active mineralisation (Wezernan, 1976). 
CALCITONIN: 
Calcitonin directly inhibits bone resorption by 
inhibiting osteoclastic activity but does not affect 
osteoblasts directly. 
(ii) LOCAL FACTORS 
PROSTAGlANDINS 
Prostaglandins (PGs) , particularly of the E series, are 
synthesised by the osteoblast and are potent bone-resorbing 
agents (Klein and Raisz, 1970). In vitro studies have shown 
that synthesis is stimulated by epidermal growth factor and 
p l a t e l ~ t - d e r i v e d d growth factor. PGs are direct stimulators 
of bone formation as well as resorption and therefore could 
play an important role in the coupling mechanism. However, 
their exact physiological role is still not established. 
CYI'OKINES 
A variety of monokines and lymphokines have been shown 
to act directly on bone to promote resorption and inhibit 
bone collagen synthesis in vitro (Raisz et aI, 1975). The 
term OAF (osteoclast activating factor) was introduced to 
describe the substance which was present in the supernatant 
of activated proliferative lymphocytes and which had 
powerful bone resorbing activity (Horton et aI, 1972). It is 
now inappropriate to use this term since more than one 
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factor was present in the supernatant. The cytokines, as 
they are now known, which are capable of stimulating bone 
resorption include interleukin-l (IL-l) and tumour necrosis 
factor alpha and beta, and like PTH and 1,25(OH)2D, they do 
not have a direct effect on osteoclasts but their actions 
are mediated by osteoblasts (Martin et ai, 1988). Their 
synthesis has been linked with the production of PGs by the 
osteoblasts but their physiological importance, if any, is 
still unclear. 
( iii) GROWI'H FACTORS 
Growth factors may play an important role in bone 
formation by stimulating the growth and development of the 
osteoblast precursor cells. Cultured rat osteoblast-like 
cells possess receptors to epidermal growth factor (EGF) and 
in the presence of EGF, DNA and prostaglandin E2 synthesis 
are increased whilst synthesis of type I collagen and 
alkaline phosphatase activity are both inhibited. 
Transforming growth factors alpha and beta (TGF'" and f.> ), 
platelet-derived growth factor (PDGF) and EGF are powerful 
stimulators of bone resorption (Raisz et ai, 1980; Tashjian 
et ai, 1985). Although the effects of EGF, TGFO(and ~ ~ on 
mouse calvaria appear to be dependent on endogenous 
production of prostaglandins further studies using foetal 
rat long bones have shown them to be independent of 
prostaglandin synthesis. It is difficult to explain these 
actions since the physiological role(s) for these factors 
are unknown. 
There is a possibility that PDGF may have a role in the 
healing of fractures since this factor is secreted by 
platelets and has been shown to stimulate both DNA and 
protein synthesis in cultured rat calvaria (Canalis, 1981). 
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1.4.3 BONE DISEASE IN THE ELDERLY 
The loss of bone mineral (osteopenia) is a normal 
feature in the ageing process and occurs when the two active 
processes of bone formation and resorption become 
dissociated in favour of net resorption. The amount of 
trabecular bone in the vertebrae begins to decline in the 
third decade of life whereas loss of cortical bone occurs 
much later (Revell, 1986). This loss of mineral from bone is 
proportionately greater and begins a decade earlier in women 
than in men (Woolf and St John Dixon, 1988). This could be 
related to the period of accelerated bone loss accompanying 
menopause which superimposes upon the age-related bone loss. 
The ultimate result is that by the age of 90years women have 
lost around one fifth of their original peak cortical bone 
mass and 40-50% of their peak trabecular bone mass. Contrast 
this with the loss of less than 5% of peak cortical bone 
mass and 10-25% of peak trabecular bone mass in men. As a 
direct consequence, bone strength decreases and fracture 
risk increases with age (Newton-John and Morgan, 1970). 
There is a negative calcium balance in the elderly, 
especially in elderly women (Heaney et a1, 1982). Intestinal 
absorption of calcium declines with advancing age (Bullamore 
et al, 1970; Gallagher et al, 1979) and may be attributed to 
either a fall in circulating concentrations of 1,25(OH)2D or 
to an imbalance between bone formation and resorption. In 
the former hypothesis the decreased secretion of 1,25(OH)2D 
is brought on by age-related decreases in renal function. 
Malabsorption of calcium follows and this stimulates the 
secretion of PTH which in turn increases renal secretion of 
1,25(OH)2D. Although concentrations of the active vitamin D 
metabolite is maintained the elevated PTH concentrations 
cause an increase in bone resorption. 
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In the latter hypothesis, however, the imbalance between 
formation and resorption is due either to reduced physical 
activity, age, oestrogen deficiency or some unknown factor 
(Heaney et ai, 1982). PIH secretion is supressed because 
calcium released from the skeleton exceeds that which is 
taken up by the skeleton, and, as a consequence of this 
1,25(OH)2D synthesis is supressed. Calcium malabsorption 
therefore develops·. 
Although the reason for the deterioration in intestinal 
calcium absorption is not known with certainty it appears 
that vitamin D may play an important role. Vitamin D 
deficiency in the elderly has been noted (Baker et ai, 1980; 
Lips et ai, 1982) although not all investigators have 
confirmed this finding (Meller et ai, 1985). It is quite 
clear that a healthy individual cannot obtain enough vitamin 
D through dietary sources alone and, therefore, exposure to 
sunlight or dietary supplementation is necessary to ensure 
adequate vitamin D status (Parfitt et ai, 1982). These 
factors therefore have a great influence on vitamin D status 
in the elderly: 
(i) Diminished exposure to sunlight 
(ii) Reduced dietary intake of vitamin D, and 
(iii) Intestinal malabsorption of fat-soluble vitamin D. 
Because not many foods are fortified with vitamin D the body 
store of vitamin D is more dependent on the cutaneous 
synthesis of D3. 
Skin thickness decreases linearly with age after 20 
years (Tan et ai, 1982). The age-related changes take place 
principally in the dermis, namely the shrinking and sagging 
of the elastic fibres in the papillary dermis (Montagna et 
ai, 1979), the marked reduction in 7-dehydrocholesterol (the 
precursor of vitamin D3) and the decreased ability of the 
skin to synthesise PreD3 (Maclaughlin and Holick, 1985). In 
fact, skin obtained from elderly subjects demonstrated only 
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half the ability to synthesise FreD3 compared with skin from 
young individuals. 
The decreasing ability of the skin to synthesise D3 with 
age coupled with a low dietary intake of calcium and of 
vitamin D these factors bring about the observed calchnn 
deficiency in this age group. This deficiency, if 
persistent, will eventually lead to bone disease as the body 
tries to compensate for the imbalance by removing calcium 
from bone. Two such bone diseases which are common in the 
elderly are osteoporosis and osteomalacia. 
(i) OSTEOPOROSIS: 
Osteoporosis is becoming one of the major bone diseases 
in the United Kingdom as well as in other western countries. 
It is now considered to be a ''heterogeneous disorder" thus 
making it unlikely that any single element is the causative 
factor. However, risk factors are known and these are 
sumnarised in Table 1.4. The two major risk factors for 
osteoporosis are loss of ovarian function and peak adult 
bone mass (Lindsay, 1988). 
Females are at a greater risk of developing osteoporosis 
than their male counterparts, especially slender women. 
Although tobacco smoking is a risk factor the mechanism is 
still uncertain. Smoking disturbs pulmonary function, causes 
some degree of acidosis and, in general, induces an earlier 
L ' f e . s ~ ~ ~
menopause. Excessive alcohol consumption and s e d e n t a r y ~ ~ are 
also factors which may induce osteoporosis. The final risk 
factor is the onset of an early menopause. If these five 
factors are combined in a woman she is surely predisposed to 
become osteoporotic (Lindsay, 1988). 
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~ ~ 1.4. Factors thought to be associated with increased 
risk for osteoporosis. 
(from: Lindsay, 1988. Bailliere's Clin. Endocrinol. Metab. 
l, pp103-24). 
Female sex 
Caucasian or Asiatic ethnicity 
Positive family history 
Low dietary calcium intake (lifelong) 
Early menopause (or Oophorectomy) 
Slim body build 
Sedentary lifestyle 
Alcohol abuse 
Cigarette smoking 
High caffeine intake 
High protein intake 
High phosphate intake 
Secondary causes of bone loss (steroids, 
hyperthyroidism) 
Roughly arranged in descending order of importance 
The transition from osteopenia to osteoporosis commences 
when the degree of bone loss is such that the skeletal 
components no longer ensure their weight bearing function. 
Thus, the underlying defect is an uncoupling between bone 
formation and resorption, favouring an increase in 
resorption. Thus, the net result is loss of trabecular and 
cortical bone mass which leaves behind nonnal but thin 
cortical bone and normal but sparse trabecular bone. 
Eventually a fracture threshold is reached as trabecular 
bone volume diminishes in thickness and it is at this point 
that spinal fractures can occur. 
Detecting the thirming of long bone cortical tissue due 
to osteoporosis, is easy and in advanced cases is visible to 
the naked eye on inspection of good hand or limb 
radiographs. Unfortunately, it is on the vertebrae, where 
detection is most difficult, that bone ageing is the most 
severe. To prevent osteoporosis means to maintain the peak 
bone mass, i.e. the maximum bone mass present at maturity, 
thus preventing repeated spinal compression fractures that 
may lead to loss of stature, a bent back and even kyphosis. 
Osteoporosis is nonnally classified into 
catergories (Riggs, 1985): 
Type I osteoporosis (or postmenopausal osteoporosis) 
three 
Type II osteoporosis (age-related or senile osteoporosis) 
Type III osteoporosis (with secondary hyperparathyroidism). 
Type I osteoporosis (Table 1.5), characterised by 
rarefaction of trabecular bone, affects exclusively women 
aged from 50-65years, in the period following the menopause 
and has been linked with oestrogen deficiency and impaired 
calcium absorption. Such women have normal circulating 
concentrations of 25(OH)D but reduced concentrations of 
1,Z5(OH)ZD (Gallagher et al, 1979; Riggs et al, 1981) 
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TABLE 1.5. Abnormalities of vitamin D metabolism associated 
with various types of involutional osteoporosis. 
(from: Riggs, 1985. Vitamin D: A Chemical, Biochemical and 
Clinical update, pp976-85). 
IYPE DEFINITION MECHANISM 
I Postmenopausal Seconary decrease in 25(OH)D 
osteoporosis 1«. -hydroxylase activity 
IIa Senile Primary defect (mild) in 25(OH)D 
osteoporosis (SO) 1'X -hydroxy lase 
lIb SO with Insufficient substrate 
nutritional vit D 
deficiency 
III Associated with Primary defect (moderate) of 
secondary hyper- 25(OH)D 10( -hydroxylase activity 
. para thyroidism 
implying a defect in the 25(OH)D-1 alpha-hydroxylase 
activity. 
The majority of patients with type I osteoporosis have 
normal or low circulating concentrations of serum PTH. 
However, a small subgroup have been shown to have elevated 
values and these patients are said to have type III 
osteoporosis. 
Type II osteoporosis (senile osteoporosis) occurs in 
individuals over 65years and is due to the loss of both 
cortical and trabecular bone. The major risk factor for 
developing this" type is the initial bone mass (Riggs, 1985). 
Bone mass is greater in men than in women and in blacks 
compared to whites. Thus, osteoporosis is correspondingly 
three to five times more frequent in women than in men and 
is much less frequent in blacks than in whites (Stevenson, 
1988). 
The first clinical indication of senile osteoporosis is 
usually a complication, the fracture. This occurs because 
the bone mass has diminished sufficiently to produce a bone 
density value below the fracture threshold. Elderly patients 
with the lowest bone mineral density values will therefore 
have the greatest risk of fracture and fractures may occur 
on minimal and trivial trauma. Crushed fractures of the 
vertabrae are very comnon in this disorder and it is now 
recognised that osteoporosis is not only the principle cause 
of this spontaneous vertebral compression but is also a 
major contributor to most of the fractures seen in the 
elderly (fractures in the neck and intertrochanteric regions 
of the proximal femur and distal radius or Colles' 
fractures). All these regions have a high proportion of 
trabecular bone. 
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(ii) OSTEOMAlACIA: 
In osteomalacia (and in the juvenile form, rickets) the 
metabolic abnormality results in the failure to mineralise 
newly formed organic matrix. Consequently, trabecular bone 
surfaces have a greater percentage of osteoid and usually an 
increase in the width of the osteoid seams. Such bones 
become weak and· are prone to fracture. The classical 
description of osteomalacia includes bone pain, which is 
worse on weight bearing or pressure, limb weakness, waddling 
gait and the presence of pseudofractures or Looser's zones 
on bone radiographs. Biochemically, serum alkaline 
phosphatase is usually raised as is urinary excretion of 
hydroxyproline. Serum calcium and phosphate may be low or 
normal. 
The development of osteomalacia (and rickets) can be due 
to a number of factors (Table 1.6) but the most common cause 
in the elderly is vitamin D deficiency (Revell, 1986). 
Hodkinson et al (1973) showed that the elderly, especially 
those who are housebound, generally have a low dietary 
intake of vitamin D and that this deficiency can be 
aggravated by not exposing themselves to sunlight. Although 
malabsorption of calcium also occurs in osteomalacia, an 
occurrence related to the reduced concentrations of vitamin 
D, the exact patho-physiology is still uncertain. 
The presence of osteomalacia in the elderly is very 
often in a subclinical form. It is therefore important to be 
able to diagnose these patients before the disease develops 
to a severe form to cause the possibility of fractures. 
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TABLE 1.6. Causes of osteomalacia and rickets. 
(from: Revell, 1986. in: Pathology of bone, eds. Springer-
Verlag). 
A Vitamin D deficiency: 
1. Dietary lack 
2. Low sunlight exposure 
3. Neonatal rickets 
B Vitamin D malabsorption: 
1. Coeliac disease 
2. Postgastrectomy 
3. Small bowel operations 
C Impaired Vitamin D metabolism: 
1. Impaired 25-hydroxylation in the liver 
a) Neonatal hepatitis 
b) Cirrhosis and chronic hepatitis 
2. Impaired 1 alpha-hydroxylation in the kidney 
a) Enzyme defect 
b) Chronic renal failure 
c) PTH deficiency/resistence 
D Increased catabolism: 
Induction of microsomal enzymes by drugs (e.g. 
barbiturates) 
E Inhibition of mineralisation: 
1. Diphosphonates 
2. Sodium fluoride 
3. Aluminium 
F Phosphate depletion and hypophosphataemia: 
1. Negative phosphate balance due to malabsorption, 
haemodialysis, antacids 
2. Excess PTH or lack of Vitamin D 
3. Primary (X-linked) or Secondary (tumour related) 
hypophosphataemia 
(iii) FRACTURE OF THE FEMORAL NECK: 
When standing about one third of the body's weight is 
supported by each hip and the neck of femur is said to be 
loaded normally. Between the ages of 20 and 90 years bone 
mineral density at the femoral neck falls an estimated 58% 
in women and 39% in men (Riggs et al, 1982). This age-
related decline in femoral neck bone mass is correlated with 
decreased bone strength in both sexes although less in women 
than in men. 
As age-related bone mass progresses, especially around 
the femur, an increasing number of elderly men and women 
will have bone density values below the fracture threshold; 
those with the lowest values will have the greatest risk of 
fracture. The majority of femoral fractures occurs when the 
patient falls on the affected hip. What, therefore, is the 
cause of reduced bone strength? 
While it is generally thought that osteoporosis is the 
main cause of reduced bone strength and therefore femoral 
fractures, there are a few cases in which the underlying 
defect is due to osteomalacia, which is usually in the 
subclinical form. However, the prevalence of femoral neck 
fracture with osteomalacia is only about 2% (Wilton et aI, 
1987a). There is no clear biochemical marker to distinguish 
femoral neck fracture patients with osteomalacia from those 
with osteoporosis (Table 1.7). The only means is to biopsy 
every femoral fracture case. 
It is easy to evaluate the incidence of femoral neck 
fractures (FNF) since all patients are hospitalised. In the 
Hospital in-patient enquiry of 1985 over 60% of new cases of 
FNF were over 65 years old (Figure 1.19) and within this 
group the male:female ratio was 1:4. With the increase in 
life expectancy, which is related to the decrease in infant 
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Table 1.7 Clinical-pathologic differences between 
osteoporosis and osteomalacia. 
Osteoporosis Osteomalacia 
Definition Decreased bone mass Demineralised bone 
Symptoms Localised to fracture Generalised musculo-
sites skeletal 
Radiographic Osteopenia, frank Pseudofractures with 
features fractures Looser lines, frank 
fractures 
Pathology Thin and discontinuous Increased osteoid 
bone trabeculae (the non-mineralised 
part of bone) 
Calcium Normal Low or normal 
Phosphate Normal Low or normal 
Alkaline Normal or High 
Phosphatase mild increase 
PI'H Normal or High or normal 
mild increase 
Calcification 
rate Normal Decreased 
1000 
No. 
OF 
PEOPLE 
800 
600 
400 
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FIGURE 1.19. The number of femoral neck fracture (FNF) 
cases in England and Wales in 1985. 
(from: The Hospital in-patient enquiry, 1985). 
Total FN F patients 4,323 
Total deaths 531 
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mortality and also to a decrease in the mortality rate after 
55 years, FNF will have a major impact on the cost of health 
care. 
It should be pointed out just how serious these 
fractures are. As stated previously, the incidence increases 
in patients over 65 years and in many cases other diseases 
often co-exist with the fracture, thereby worsening the 
prognosis. Complications are frequent because of the age of 
the patient and may affect at least 40% of the operated 
patients. The main complications are related to infection, 
to the urinary tract or cardiovascular system. 
Unfortunately, mortality is high, around 17% (Ions and 
Stevens, 1987) and those patients who survive rarely recover 
their independence. In fact, hip fracture is often the event 
that precipitates institutionalisation and as many as 8% of 
all nursing home residents have had a FNF. The economic 
burden of age-related fractures is hugh because of the large 
number of people affected and because of the expense and the 
protracted care that is often required. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1. MATERIALS: 
2.1.1. CHEMICALS 
SIGMA (London) CHEMICALS co. Ltd., Poole, Dorset, U.K. 
Sephadex G-2S and Gl00, Rabbit anti-Bovine Whole Serum, OL-
dithiothreitol (Cleland's Reagent, OTT), Mono thioglycero 1 , 
Oowex-SOW (dry mesh 100-200), ~ , 2 ' - O - b u t r y l a d e n o s i n e e 3'5'-
cyclic monophosphate (Sodium salt), Adenosine 3'S'-cyclic 
monophosphate, 2-mercaptoethanol, Agarose (type I- low EEO), 
Theophylline, Adenine, Adenosine, Adenosine S'-triphosphate, 
Adenosine S'-diphosphate, Imidazole, Gen tamyc in , Bovine 
serum albumin, Ovalbumin. 
TIIE RADIOCHEMICAL CENTRE, Amersham International, 
Little Chalfont, Bucks., U.K. 
2 S - h y d r o x y [ 2 6 , 2 7 - m e t h y l - ~ ] c h o l e c a l c i f e r o l l (176Ci/rnmol), 
1 ~ , 2 S - d i h y d r o x y [ 2 6 , 2 7 - m e t h y l - ~ ] c h o l e c a l c i f e r o l l
(180Ci/rnmol), [ 8 - ~ ] A d e n o s i n e e 3'S'-cyclic phosphate, 
ammonium salt (26.SCi/rnmol), [ 8 - ~ ] A d e n i n e e (22Ci/rnmol), 
[14C]Adenosine 3'S'-cyclic phosphate (268mCi/rnmol).' 
NEW ENGIAND NUCLEAR, Harants, Rants., U. K. 
2 4 R , 2 S - d i h y d r o x y [ 2 6 , 2 7 - m e t h y l - ~ ] c h o l e c a l c i f e r o l l
(160Ci/rnmol). 
FISONS SCIENTIFIC APPARATUS, Loughborough, Leics, U.K. 
HPLC-grade Hexane, HPLC-grade Methanol, HPLC-grade 
Propan-2-o1, Sodium azide, 50 x 9/1Ornm soda glass tubes. 
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RATHBURN CHEMICALS (Walkerburn) Ltd., Walkerburn. 
Peebleshire, Scotland, UK. 
HPLC-grade Ethanol, HPLC-grade Acetonitrile. 
BDH CHEMICAL Ltd., Poole, Dorset, U.K. 
Folin and Ciocalteau's phenol reagent, Aluminum oxide, 
Barbitone sodium, Activated charcoal, Dextran T70 , Amido 
black 10. 
CIS (UK) Ltd., High Wycombe, Bucks., U.K. 
Osteocalcin radioimmunoassay kit. 
IMPERIAL LABORATORIES, Sailsbury, U.K. 
Newborn calf serum, Minimum essential medium- Eagles 0(-
mod if ication with 2g/L NaHC03, Hank's balanced salt 
solution, 0.25% Trypsin/0.02% EDTA solution in Dulbecco's 
phosphate bufered saline, Trypan blue. 
WATERS ASSOCIATES (Ins t.) Ltd., Cheshire, U. K. 
Sep-Pak™(C18) and Sep-Pak™(silica) cartridges • 
. 1BE FOllOWING CHEMICALS WERE KINDLY DONATED BY: 
ROCHE PRODUCTS Ltd., Welwyn Garden City, Hert., U.K. 
Crystalline vitamin D2 and D3, 25-hydroxyvitamin D3' 24R,25-
dihydroxy-vitamin D3' 1 ~ , 2 5 - d i h y d r o x y v i t a m i n n D2 and D3' 
25,26-dihydroxyvitamin D3' 1,24R,25-trihydroxyvitamin D3: 
All vitamin D metabolites were dissolved in HPLC-grade 
ethanol and the concentrations determined by UV spectroscopy 
using an extinction coefficient (E264) of 19,400 ~ 1 1 cm-1 
for the vitamin D2 metabolites and (E264) of 18,300 M-1 cm-1 
for the vitamin D3 metabolites. 
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NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CON'IROL, 
Hampstead, U.K. 
Bovine parathyroid hormone (Stock 77/533) 
All other chemicals were of AR- grade and obtained from 
commercial suppliers. 
2.1. 2. EQUIPMENT: 
HIGH PERFORMANCE LIQUID CHROMA'T(X;RAPHY: 
HPLC was performed using a Beckman HPLC pump fitted to a 
Zorbax-Sil colurrm (4.6mm x 25cm) and a silica guard-pak 
precolurrm module (Waters Associates). Two Zorbax-Sil colurrms 
were used in these procedures. The first was used solely for 
clinical studies and purification of radiolabelled vitamin D 
metabolites and the second for all experimental cell culture 
work. 
Batches of ~ - l a b e l l e d d vitamin D metabolites ranged from 
89-95% purity. Because of the oxidative decomposition of 
radioactivity with time, each batch of radio labelled 
metabolite was purified by HPLC every 4 months prior to use. 
To minimise decomposition, the metabolites were stored in 
HPLC-grade ethanol, under nitrogen and below -20°C in the 
dark. 
CENIRIFUGATION: 
High speed centrifugation was carried out in either the 
MSE Prepspin 75, the Centrikon T-2070 ultracentrifuge or the 
Europa 24M centrifuge with 10 x lOml, 8 x 14ml swing out or 
8 x 50ml fixed angle rotors. The MSE Mistral 3000 bench 
centrifuge and the MSE Microcentaur were used for low speed 
centrifugation. 
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SONICATION: 
The MSE Sonicator was used for all breakage of cell. 
MEASUREMENT OF RADIOACTIVITY: 
Radioactivity in samples was determined using either a 
Packard Tri-carb CD 460 liquid scintillation spectrometer or 
gamma counting efficiency in the region of 40%. 
SPECTROSCOPY: 
Absorbance measurements were made using a Spectroflow 
773 absorbance detector. 
MASS SPECTROSCOPY: 
Mass spectrometry was performed on a AEI MS902 mass 
spectrometry (modified by VG Analytical Ltd.) in combination 
with a VG DS2000 data system. MS conditions were as follows: 
Source temperature = 200°C 
Scan rate = 7s/decade (approx. 14s total scan time) 
Probe heated at a rate of 2°C/s 
2.1.3.' CELL LINES: 
The human osteosarcoma cell line 20S was kindly provided 
by Dr. J. Embleton, Cancer Research Laboratories, University 
of Nottingham. For comparative studies, two rat osteosarcoma 
cell lines, 791T and T278, as well as the transformed human 
macrophage cell line U937 were also used. The macrophage 
cell line was a gift from Dr. G. Leslie, Department of 
Immunology, Queens Medical Centre, Nottingham. 
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2.2. METHODS 1: ASSAY PROCEDURES 
2.2.1. EXTRACTION AND PURIFICATION OF THE VITAMIN D 
MEI'ABOLITES IN HUMAN SERUM 
Biological samples contain a great number of compounds 
which can interfere with the analysis of the different 
vitamin D metabolites, in particular various fatty acids and 
steroids. As 25(OH)D is the most abundant form of vitamin D 
in circulation it is important to separate this metabolite 
from other vitamin D metabolites which appear in smaller 
quantities in serum. Therefore, in order to separate 
successfully the metabolites in question, a purification 
step is required, after extraction and before the 
quantitation of the vitamin D metabolites by competitive 
protein binding assays. This step involves the use of high 
performance liquid chromatography, or HPLC for short. 
(i) EXTRACTION PROCEDURE: 
All glassware was washed thoroughly with detergent and 
distilled water followed by HPLC-grade ethanol and HPLC-
grade hexane to minimise non-specific binding of the vitamin 
D metabolites, in particular the 1,25(OH)2D metabolite. 
HPLC-grade solvents were also used throughout the following 
procedure. 
Recovery tracer for each vitamin D metabolite, 
approximately 3,500dpm «4pg) of 3H- 25(OH)D3, ~ ~
24,25(OH)2D3 and %-1,25(OH)2D3 in a total volume of 45ul 
ethanol, was added to test tubes containing serum or 0·9% 
saline (1-3ml). An aliquot of each tracer was dispensed into 
separate scintillation vials to monitor recovery. These 
vials were stored at 4°C until required. Assay tubes were 
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vortex-mixed briefly and incubated in the dark at room 
temperature for 30min to allow recovery tracers to 
equilibrate. An equal volume of acetonitrile was added to 
each tube, to precipitate serum proteins, and the tubes were 
vortexed for 20sec before finally centrifuging at 2,SOOrpm 
for lSmin. The supernatant fractions were decanted into 
glass tubes containing O·Svol 0·4M K2HP04 solutions (pH 
10·6) and the pellets discarded. The addition of this 
solution to the acetonitrile extracts before column 
chromatography results in the additional removal of lipids 
during the chromatography step (Reinhardt et aI, 1984). 
Column chromatography was accomplished using S8 
cartridges attached to lOmI Lueur-tipped glass syringes 
which acted as solvent reservoirs. Each cartridge has an 
oc tadecy I silane bonded phase packing system which is 
designed for reverse phase chromatography using small 
volumes of solvents. This system has been shown to be a 
convenient and reproducible method of separating the polar 
vitamin D metabolites from low polarity compounds which may 
interfere in their final analysis. 
Each cartridge was prewashed with Sml methanol, followed 
by Sml distilled water. This washing procedure was used 
between sample applications. Samples were decanted 
individually into the solvent reservoirs and slowly 
aspirated through the cartridges. The eluates were 
discarded. It was unnecessary to wash the sample tubes after 
application since greater than 8S% recovery was obtained off 
the columns. Low polarity compounds were eliminated by 
washing each cartridge with Sml distilled water, followed by 
3ml 70% (v/v) methanol in water. These washes remove excess 
salts and water soluble lipids, respectively. The addition 
of 4ml acetonitrile, a more polar solvent, to the cartridges 
eluted all the vitamin D metabolites. Approximately 87-99% 
recovery of each metabolite was achieved by this method. The 
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acetonitrile fractions, collected in glass conical tubes, 
were dried under a stream of nitrogen before storing at 
-20°C in ethanol under nitrogen, until required for the HPLC 
stage. Each C18 cartridge was used four times, being rinsed 
with Sml methanol and Sml distilled water before each sample 
application. 
(ii) HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY 
HPLC was performed on a Waters HPLC apparatus fitted 
with a Zorbax-Sil column (4.6rrm x 2Scm) and a silica guard 
column. The use of HPLC allows rapid separation of the 
vitamin D metabolites under moderately high pressures. 
Zorbax-Sil is a small-particle silica column packing that 
has strong affinity for the hydroxyl group(s) of vitamin D 
and its me tabo li tes. Thus, an increase in the number of 
hydroxyl groups on the vitamin D molecule increases the 
interaction with the silica absorbant and therefore the 
retention time for the metabolite. 
The eluting solvent used for this system was hexane: 
isopropanol: methanol (92:4:4 by vol). Using this straight 
phase solvent system and a flow rate of 2ml/min, all the 
vi tal vi tamin D 
typical elution 
resolution of 
metabolites were sufficiently resolved. A 
profile is depicted in figure 2.1. The 
both the 1,2S(OH)2D2 and 1,25(OH)2D3 
metabolites can be observed, although only partial 
separation was achieved. In general, the D2 analogues elute 
before the complementary D3 analogues. 
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FIGURE 2.1. Typical elution profile of the authentic vitamin D3 
metabolites. 
Vitamin D metabolites were separated on a Zorbax-Sil straight 
phase HPLC column eluted with hexane:methanol:isopropanol (92:4:4 
by volume). Arrows mark the retention times of each metabolite 
determined by u.v. absorption at 264nm. 
Dashed peak represents 1,25(OH)2D2 elution profile. 
Establishment of elution profile for the vitamin D 
metabolites 
O - f ~ \ . c . c . . h O " "
Before a batch of s a m p l e ~ ~ , , the retention time of all 
three vitamin D metabolites was established using known 
amounts of tritiated samples. Initially, the elution profile 
was generated by injecting small quantities of unlabelled 
standards (approximately O.lug/metabolite) on to the column 
and monitoring the retention time by UV detection at 264nm. 
This procedure however was abandoned due to the interference 
of these metabolites with final serum sample values. 
Extensive washing of the column with hexane:isopropanol 
(75:25 v/v) , once the elution profile was obtained, still 
produced excessively high values. Therefore,. a more suitable 
technique of applying known amounts of labelled metabolites 
was employed. 
Approximately 5,OOOdpm of each vitamin D metabolite was 
dispensed into a glass tube and individual scintillation 
vials to monitor recovery. After evaporating to dryness, the 
metabolites were redissolved in lml running buffer and 
applied to the colunm. A stop clock was started 
simultaneously with the injection of the sample and lml 
aliquots (corresponding to 30sec intervals) were collected 
into clean scintillation vials. These vials, along with the 
recovery vials, were monitored for radioactivity and an 
elution profile of the metabolites was obtained. The elution 
profile for the tritiated metabolites, shown in figure 2.2., 
was identical to that of the synthetic vitamin D metabolites 
and because of the minute quantities applied to the column 
«6pg per metabolite) there was no interference with final 
serum values. 
The above method, therefore, was performed for each 
batch of sample runs. Once the profile was established, the 
colunm was washed for lOmin with hexane:isopropanol (75:25 
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FIGURE 2.2. Typical elution profile of the tritiated vitamin 
D-,;metabolites. 
A sample of the tritiated vitamin D metabolites was separated 
on a Zorbax-Sil straight phase HPLC column with hexane: 
methanol: isopropanol (92:4:4 by volume) as the mobile phase. 
See text for procedure. 
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vlv) and the column re-equilibrated with running solvent for 
20min before the first sample application. Each sample from 
the CiS columns was evaporated to dryness and redissolved in 
iml running solvent before applying to the HPLC colunm. 
Fractions corresponding to each metabolite were collected 
into glass conical tubes and evaporated to a small volume 
before storing under nitrogen at -20°C until required for 
assay. The column washing procedure was repeated for every 
three sample applications. 
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2.2.2. PRINCIPLE OF THE BINDING ASSAYS 
The techniques of radioirrmtmoassay are similar to that 
of the radioreceptor assays and to all competitive protein 
binding assays. In brief, the binding assay is based on 
competition between a known fixed amount of radioactively 
labelled ligand and unlabelled ligand for the binding sites 
on the given protein. For example, consider the 25(OH)D 
binding assay. The labelled ligand, ~ - 2 5 ( O H ) D , , will compete 
with unlabelled 25(OH)D for the binding domains on the serum 
vitamin D binding protein (DBP), as illustrated below: 
~ - 2 5 ( O H ) D D
y T ~ ~
. 
- < ~ > >
25(OH)D 
+ 
DBP 
~ ~ .. 
.... 
• 
..... 
Assuming that there is no difference in the affinity of 
both labelled and unlabelled ligand binding to the protein, 
then the percentage radioactivity bound will decrease as the 
concentration of unlabelled ligand increases. When the 
reaction reaches equilibrium any labelled ligand not bound 
to the protein is removed by a phase separation reagent, 
either a second antibody (eg in the osteocalcin assay) or by 
the much used dextran-coated charcoal which adsorbs any free 
ligand. The protein/ligand complex in the supernatant is 
decanted and radioactivity determined by liquid 
scintillation counting. By using known concentrations of the 
unlabelled compound a calibration curve can be constructed 
and used to evaluate the amount of ligand present in unknown 
samples. 
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The following groups of tubes were prepared for each 
binding assay: 
- Tc group for the determination of total activity 
- Cb group for the calculation of non-specific binding 
- 0 group for the determination of maximum binding ability 
of the protein 
- Standard group for the determination of the standard curve 
- Sx group for the samples to be assayed 
- Cbx group for the calculation of non-specific binding of 
the samples 
A standard curve was constructed by plotting the percentage 
of B/Bo against the log of the amount of ligand added to 
each tube, where: 
B = (total counts bound by standards 
- total Cb counts) + Tc 
and 
Bo = (total counts bound by zero standards 
- total Cb counts) + Tc 
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2.2.3. 25-HYDROXYVITAMIN D PROTEIN BINDING ASSAY 
MATERIALS: 
STOCK BUFFER (50Oml) 7.87g sodium barbitone 
4.86g sodium acetate 
0.5g sodium azide 
WORKING BUFFER (lL) •••••••••••• 50ml stock buffer in 850ml 
0.9% saline, pH 8.6. Made 
up to lL with distilled 
water 
GELATINE BUFFER (lg/L) ••••••••• 100mg gelatine in l00ml 
working buffer 
PROTEIN BINDING SOLUTION ••••••• Human serum diluted 1 in 
10,000 fold with gelatine 
buffer (see figure 2.3 for 
serial dilution) 
DEXTRAN-COATED CHARCOAL * . . . . . . .. 750mg charcoal + 75mg 
Dextran T70 in 20ml stock 
buffer at 4°C 
*This is prepared a day before the assay. Dextran is 
preswollen in lOml stock buffer and added, after 15min, to 
charcoal suspended in lOml stock buffer. 
~ - 2 5 ( O H ) D D••••••••••••• ~ ~ •••••••• Approx 45,OOOdpn (in 20ul 
ethanol) per assay tube 
25(OH)D STANDARDS .....•.•...•••• Ranging from 0.03-8 ng/20ul 
(in ethanol) 
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ASSAY PROCEDURE: Protocol 2.1 
All assay tubes were perfonned in triplicate. lOrrm x 
7s£IIl1 glass tubes were labelled according to the protocol. 
Aliquots of approximately 45,OOOdpm 3u-25(OH)D were 
dispensed in to all labelled tubes. Standard curve tubes 
received various concentrations of standard 25(OH)D in 20ul 
ethanol. HPLC-purified sample fractions containing 2s(OH)D 
were evaporated under nitrogen and reconstituted in 300ul 
ethanol. Aliquots (SOul) from each sample were transferred 
to glass counting vials, to assess final recovery, and 20ul 
aliquots were dispensed into labelled assay tubes. Protein 
binding solution (lml) was added to all except tubes 
labelled Tc and Cb• To these tubes lml gelatine buffer was 
added. All tubes were vortex-mixed and incubated at 4°C for 
30min. Tubes were transferred to an ice bath and, to the 
appropriate tubes, 2s0ul charcoal suspension added (stirring 
continuously throughtout the additions). Tubes were vortex-
mixed and incubated at 4°C, and after 20min the tubes were 
centrifuged at 2,sOOrpm for a further 20min at 4°C. Aliquots 
(800ul) of the supernatant fractions were transferred to 
scintillation vials, lOml of scintillation fluid added and 
the radioactivity in each vial counted for smin. 
ASSAY SYSTEM CHARACI'ERISTICS: For a typical standard curve 
The standard curve was constructed by plotting the 
percentage of B/Bo against the log of the amount of 2s(OH)D 
added to each tube. A typical standard curve is shown in 
figure 2.4. Total counts bound in the supernatant of the 
unknowns were corrected for non-specific binding. 
Sensitivity: Defined as the amount of 2s(OH)D required to 
reduce the zero dose binding by two standard deviations 
•••••••••••••• 15 pg/assay tube (i.e. 11.8 pg/ml). 
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PBCnlXllL 2.1. Protein binding assay for 25(OH)D3 
'lUBES STANDARD ~ - 2 5 ( O H ) D 3 3 PROTEIN BINDING BUFFER CHARCOAL 
25 (OH)D1 SOLUTION SUSPENSION (ngl2Ou ) (1ml) (1ml) (250ul) 
0 
- + + - + 
Tc - + - + '1 ... 1 -
Cb - + - + 1 .... \ Mix + Mix Incubate 
1 0.01 + + + Incubate + 20rnin 
2 0.02 + + + + @ 
3 0.1 + + + for + 4°C 
4 0.2 + + + + 
5 0.4 + + + 30min + 
6 1.0 + + + + Centrifuge 
7 2.5 + + + @ + 20rnin 
8 10.0 + + + + @ 
9 20.0 + + + 4°C + 4°C 
Unknowns - + + + + 
~ ~ - - - ~ - ~ - - '------- ------
FIGURE 2.4. An example of a typical standard curve for 25(OH)D 
assay. 
Each point represents the average of triplicate determinations. 
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Mid-point: Defined as the amount of 25(OH)D required to 
reduce the bound tracer by 50% •••••••• 0.36 ng/assay tube 
(i.e. 0.28 ng/ml). 
Specific binding: 
specifically bound 
unlabelled 25(OH)D 
Defined as the proportion of tracer 
to the binding protein in the absence of 
••••••••• 78% (0 IIJ8.fS - Cb T v ~ t s ) . .
Non-specific binding: Defined as the proportion of tracer 
bound to the binding protein in the presence of sOOng of 
unlabelled 25(OH)D .•••••••••••• 1.7% 
SEASONAL CHANGES IN PLASMA 25(OH)D MEASUREMENTS 
Measurements of plasma 25(OH)D concentrations provide a 
precise index of the vitamin D nutritional status in man 
(Stamp and Round, 1974). However, concentrations seem to 
show a marked seasonal variation as demonstrated in Table 
2.1 (taken from Stamp and Round, 1974). Values for autumn 
and surrmer produce similar reference ranges whereas those 
obtained during the spring season were much lower. In view 
of this the normal 25(OH)D range was established as follows: 
Measurements of plasma 25(OH)D concentrations were 
obtained from 36 young healthy individuals (mean age 36; 
range 23-53) throughout the year and these values were 
divided into two groups according to their sampling date 
(Table 2.2): Group A -sampled between May and October and 
Group B -sampled between November and April. In some 
instances 25(OH)D values for groups A and B were obtained 
from the same individual and did show statistically 
significant differences. 
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~ ~ 2.1. Plasma 25(OH)D concentrations in healthy white British subjects of 
both sexes sampled over a period of 22.5 months and grouped according to season. 
(from: Stamp and Round, 1974. Nature 247, pp563-65) 
Population data Season Plasma 25(OH)D (ng/ml) 
Age range Sex No. Mean Range 
18 to 37 Both 27 October - early November 21.3 10.8 - 41.8 
18 to 37 Both 19 Late March 12.9 6.6 - 25.2 
19 to 36 Both 20 Early August 20.4 9.7 - 42.8 
TABLE 2.2. Mean plasma 25(OH)D concentrations from young healthy 
individuals sampled throughout the year. 
Group No. 
A 20 
B 22 
Sampling 
Date 
May - October 
November - April 
ng/ml 
40 
30 
20 
• 
f 
•• 
• 
10 1 
• 
•  
November -
April 
Plasma 25(OH)D ng/ml 
mean range (t 2SD) 
19.5 16.8 - 22.2 
10.5 7.6 - 13.5 
nmolfl 
100 
0 
0 
75 
~ ~
0 
0 
8 
9 50 
8 
& 
0 
0 
'b 25 
May - October 
2.2.4. 24,25-DIHYDROXYVITAMIN D PROTEIN BINDING ASSAY 
MATERIALS: 
STOCK BUFFER ........................ see 2.2.3 materials 
WORKING BUFFER •••••••••••••••••••••• 
" " 
GELATINE BUFFER ••..•••••••••.••••••• 
" " 
PROTEIN BINDING SOLUTION •••••••••••• Human serum diluted 
DEXTRAN-COATED CHARCOAL ............. 
24,25(OH)2D STANDARDS ............... 
~ - 2 4 , 2 5 ( O H ) 2 D D OR* 
1 in 75,000 fold with 
gelatine buffer 
see 2.3.1 materials 
Ranging from 1.33-680 
pg/20ul (in ethanol) 
~ - 2 5 ( O H ) D D ••••••••••••••••••••• approx 3,500dpm in 
20ul ethanol per assay 
tube 
oJ. 
"Initially, labelled 24,25(OH)2D was used for competitive 
binding, but due to the withdrawal of this radioactive 
compound from the market the assay was slightly modified by 
introducing labelled 25(OH)D as the competitor. There was no 
difference in the ability of the unlabelled 24,25(OH)2D to 
bind to the protein (see figure 2.5). 
METHOD: Protocol 2.2. 
The 25(OH)D assay procedure was employed using 
24,25(OH)2D standards to construct a standard curve with 
approximately 3,500dpm «4pg) of tracer. The unknown samples 
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PROmOOOL 2.2. Protein binding assay for 24,25(OH)2D3: 
Using 1 in 75,OOO-foid dilution of human serum. 
'lUBES STANDARD ~ - 2 5 ( O H ) D 3 3 PROTEIN BINDING BUFFER CHARCOAL 
24, 25 (OH)]D3 SOLUTION SUSPENSION (pg/20ul (1ml) (1ml) (250ul) 
0 
-
+ + - + 
Tc - + - + ~ I I -
Cb - + - + 1",,\ Mix + Mix Incubate 
I 1 1.33 + + + Incubate + 20min 
2 2.66 + + + + @ 
3 5.30 + + + for + 4°C 
I 4 10.60 + + + + 
5 21.25 + + + 30min + 
6 42.50 + + + + Centrifuge 
7 85.00 + + + @ + 20min 
8 170.00 + + + + @ 
9 340.00 + + + 4°C + 4°C 
Unknowns 
-
+ + + + 
FIGURE 2.5. Standard curve for 24,25(OH)2D using 75,OOO-foid 
dilution of human serum as binding protein and: 
( .) %-24,25(OH)2D3 and (.) %-25(OH)D3 
Each point represents the average of triplicate determinations. 
% 8/ /8 
100 0 
75 
50 
25 
5 50 
pg 24,25 ( 0 H )2 0 / ass a y tub e 
500 
were reconstituted in l00ul ethanol and after removing 20ul 
aliquots from each sample, to monitor final recovery, three 
20ul aliquots were used for the assay. 
ASSAY SYSTEM CHARACTERISTICS: For a typical standard curve 
Sensitivity: 9.6 pg/assay tube (i.e. 7.6 pg/ml). 
Mid-point: 39 pg/assay tube (i.e. 30.7 pg/ml). 
Specific binding: 49% 
Non-specific binding: 2.2% 
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2.2.5. 1,2S-DIHYDROXYVITAMIN D RADIORECEPTOR ASSAY 
MATERIALS: 
* HOMOGENISING BUFFER ••••••••••• SOOrnM KCl, SOrnM Tris-HCl, 
10rnM Na2Mo04.2H20, SmM OTT, 
l.SmM EDTA pH 7.5 
~ 1 b i s s buffer was prepared without OTT and stored 
at 4°C until assay. DTT was added prior to use. 
'TIlYMIC CYTOSOL SUSPENSION ••••• Each pellet was resuspended 
in Sml homogenising buffer 
and then further diluted to 
give a B/Bt 35% (see figure 
3.1; chapter 3) 
BORIC ACID BUFFER ••••••••••••• O.lM Boric acid + 0.05% BSA 
pH 8.6 
... 
CHARCOAL SUSPENSIONn .......... 1.2g Charcoal + 0.12g 
Dextran T70 suspended in 
l00m1 boric acid buffer 
stirred over night at 4°C 
then centrifuged at 
15,000 rpm for 20min. The 
pellet was resuspended in 
100m! boric acid buffer. 
*This charcoal suspension was stable for at least 
4 weeks at 4°C. 
1,2S(OH)2D STANDARDS •••••••••• Ranging from 
1.25-800 pg/20ul (in 
ethanol) 
~ - 1 , 2 S ( O H ) 2 D D ••••••••••••••••• Approx 3,600dpm (in 20ul 
ethanol) per assay tube 
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ASSAY PROCEDURE: Protocol Z.3. 
Eppendorf tubes were labelled according to the protocol 
and placed on ice. Standard solutions of 1,Z5(OH)ZD, ranging 
from 1.Z5-800 pg/ZOul, were dispensed into appropriate 
tubes. HPLC-purified samples were evaporated under nitrogen 
and reconstituted in 100ul ethanol. Three ZOul aliquots were 
pipetted into labelled tubes and a further ZOul dispensed 
into scintillation vials to monitor final recovery. 
Thymic cytosol suspension was placed on ice and, whilst 
stirring, 450ul aliquots were pipetted into all except the 
Tc and Cb tubes. After- vortexing, tubes were incubated in a 
Z5°C water bath for 45min with gentle shaking. After this 
initial incubation period all tubes were placed on ice for 
5min where they received approximately 3,600dIXl1 ~ ~
1,Z5(OH)2D tracer and, after vortex-mixing, they were 
incubated for a further 15min in a 25°C shaking water bath. 
The tubes were again cooled for 5min on ice and 200ul 
charcoal suspension added to appropriate tubes. The tubes 
were vortex-mixed and left on ice. The tubes were further 
vortexed after lOmin, and after a total of 20min charcoal 
treatment, were centrifuged at 6,OO0rJ:Xl1 for 45sec and 
aliquots (400ul) of each supernatant fraction were decanted 
into scintillation vials. With the addition of lOml volumes 
of scintillation fluid, each vial was vortex-mixed and the 
radioactivity in each vial counted for lOmin. 
ASSAY SYSTEM CHARACTERISTICS: Refer to chapter 3 for typical 
standard curve and assay characteristics. 
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PBCnlX)JL 2.3. Radioreceptor assay for 1,25(OH)2D3' 
TUBES STANDARD THYMIC CYIDSOL BUFFER ~ ~ CHARCOAL 
1,25(OH)rD3 SUSPENSION 1,25(OH)2D3 SUSPENSION (pg/2Ou ) (450u1) (450u1) (200u1) 
0 
- + - + + 
Tc - - + + -
Cb - - + Mix + Mix + Mix Incubate Incubate 
1 1.25 + - Incubate + for + 20min 
2 2.50 + - + 15rnin + on ice 
3 5.00 + - for + @ + 
4 10.00 + - + 25°C + Mix after 
5 20.00 + - 45rnin + + 10min 
6 50.00 + - + + 
7 100.00 + - @ + Cool + Centrifuge 
8 200.00 + - + on + 45sec 
9 800.00 + - 25°C + ice + @ 
4°C 
Unknowns - + - + + 
2.2.6. ESTIMATION OF OSTEOCALCIN CONCENTRATIONS 
IN HUMAN SERUM 
MATERIALS: 
OSTEDCALCIN RADIOIMMUNOASSAY KIT 
supplied the following reagents: 
............. which 
125I Osteocalcin- approximately 74kBq (2 Ci) highly purified 
bovine osteocalcin. 
Anti Osteocalcin antiserum- raised in rabbit by injection of 
bovine osteocalcin. Using the specified 
reconstitution volume the antiserum binds 
50-60% of the added radio labelled 
osteocalcin. 
Osteocalcin standards- ranging from 0.5-27 ng/ml bovine 
osteocalcin. 
Human control serum 
Immunoprecipitating (PR) reagent- contains polyethylene 
glycol, sodium azide, an insoluble complex 
of sheep anti-rabbit gamma globulins and 
non immunized rabbit gammaglobulins 
MEI'HOD: 
All reagents (except PR reagent) were raised to room 
temperature (18-25°C) prior to use. Each sample was 
performed in duplicate. Protocol 2.4. was followed for this 
assay. Briefly, aliquots (l00ul) of standards, control serum 
or unknown samples were dispensed into appropriate tubes. 
Aliquots (200ul) of radioactive osteocalcin (tracer) were 
dispensed into all tubes. Standard and sample tubes received 
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PROI'C.XDL 2.4. Osteocalcin Assay 
TUBES STANDARDS SAMPLES 125I ANTISERUM PR 
OSTEOCALCIN REAGENI' 
(ul) (ul) (ul) (uI) (ml) 
Centrifuge 
Tc - - 200 - - Discard 
~ ~ 100 - 200 - Mix 1 Mix Superna tant 
0 100 - 200 100 Incubate 1 Incubate 
Standards 100 - 200 100 20-24 h 1 15 min ColITlt 
Unknowns 
-
100 200 100 @ 1 @ Pellet 
Control 
-
100 200 100 4°C 1 4°C 
- - - -- -- - - . - - - - . ~ - - - -- -----
aliquots of 100ul of anti-osteocalcin antiserum and all 
tubes were vortex-mixed and incubated for 24h at 4°C. 
1ml PR reagent was added to all tubes, except those of 
the Tc group, and after vortexing, the tubes were incubated 
for a further 15min at 4°C. The tubes were then centrifuged 
at 3,500rpm for 15min at 4°C. The supernatant fractions were 
discarded by inverting the tubes over a sink sui table for 
collecting radioactivity and left inverted on absorbing 
paper for lOmin. Each tube was counted for 100sec for 1251• 
A typical standard curve is depicted in figure 2.6a. 
ASSAY SYSTEM CHARACI'ER1STICS: For a typical standard curve 
Sensitivity: 0.35 ng/ml 
Mid-point: 4.9 ng/ml 
Specific binding: 54% 
Non-specific binding: 3.8% 
Serum samples, including those from young. healthy 
individuals, which were stored for more than one year at 
-20°C demonstrated low osteocalcin concentrations; values 
around 0.5 ng/ml were frequently observed. These low values 
could be explained if the serum samples were frozen and 
thawed a few times or if the original blood samples were 
collected in EDTA bottles. Since the bonding between calcium 
and the GLA residues of the osteocalcin molecule is 
influencing the predicted alpha helical structure, the 
presence of EDTA will lead to the severe loss of 
immunoreactivity. 
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FIGURE 2.6a An example of a typical standard curve for 
the determination of osteocalcin concentrations. 
Each point represents the average of duplicate 
determinations. 
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It is recoomended by the manufacturers to perform the 
assay on serum samples. To investigate whether plasma 
specimens would produce similar results to serum samples 
from the same individual the following experiment was 
performed. 
Blood from 13 healthy individuals were sampled in to 
lithium heparin bottles as well as plain bottles and the 
osteocalcin concentration for each determined. There were no 
significant differences between the two set of results 
(figure 2.6b). Therefore, either serum or plasma samples can 
be used to estimate osteocalcin concentrations. 
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FIGURE 2.6b Differences between serum and plasma osteocalcin 
measurements from 13 healthy individuals. 
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2.2.7. ESTIMATION OF HUMAN VITAMIN 0 BINDING PROTEIN 
IN SERUM (Mancini method) 
MATERIALS: 
VERONAL BUFFER (lL) •••••••••••••• 9.0g barbital nitrate 
0.5g sodium azide 
6.5ml 1M HCL pH 8.6 
1% AGAROSE GEL ••••••••••••••••••• made up in veronal buffer 
and stored at 4°C in lOml 
aliquots 
RABBIT ANI'I-HUMAN OBP ANI'IBODY ••• kindly provided by 
Dr. B. Mawer, 
University of Manchester. 
0.1% AMIDO BLACK STAIN ••••••••••• 19 Amido black (Napthol 
blue black) 
10% ACETIC ACID 
0.9% SALINE 
MEI'HOD: 
1. Preparation of gel: 
450ml 1M acetic acid 
450ml O.lM sodium acetate 
100ml distilled water 
Two lOmm x lOmm glass plates were clipped together with 
a 1-2mm plastic spacer between them in a manner to allow one 
plate to be slightly offset. This enables easy pouring of 
the agarose between the two plates. lOml agarose gel was 
heated until fluid and then placed in a 45°C water bath. 
After the addition of the antibody, the agarose was mixed 
and then· rapidly poured between the two plates until there 
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was only approximately 5mm from the top of the edge. After 
leaving at room temperature for 15min, in order to set, the 
upper glass plate and plastic spacer were removed. The 
agarose plate was transferred to a moist chamber (a 'lunch-
box' containing a small amount of adsorbant paper soaked in 
veronal buffer). This prevents the gel from drying out. 
2. Plating the samples: 
With the aid of a 3mm hole punch and a 25-hole stencil, 
25 holes were punctured in the gel. The loose agarose were 
carefully removed from the wells with a wide pasteur pipette 
attached to a vacuum line. Care was taken at this stage not 
to tear the wells. The gel was then transferred to its 
chamber. 
Serum samples were defrosted and mixed before 
application to the gel. After placing the gel on a white 
background, 5ul of each sample were pipetted into the first 
21 wells. Calibrated standard serum (400·25ug vitamin D 
binding protein/ml) was diluted to 25%, 50%, 75% and 100% 
with veronal buffer and SuI of each dilution pipetted into 
the remaining 4 wells. The plate was again transferred to 
its chamber and left for 48h at room temperature. 
3. Staining the gel: 
After 48h the antigen-antibody complexes were visible as 
precipitated rings. The gel was soaked for 12h in 0.9% 
saline. This eliminated all non-precipitated proteins from 
the gel. The gel was carefully removed from saline and 
rinsed with distilled water. After ensuring that the wells 
did not contain any air bubbles, a damp square of filter 
paper was placed on top of the gel and a further 8-10 layers 
of adsorbant paper on top of that. With the addition of a 
large glass plate a 500g weight was positioned on top of the 
, sandwich'. After 20min the gel was removed and dried with a 
hairdryer. At this stage the gel became transparent. 
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Once cooled, the gel was irrrnersed for 2-3min in 0.1% 
amido black and then washed for S-lOmin in distilled water. 
After a further Smin in 10% acetic acid solution, the gel 
was dried. This procedure stains the precipitated rings blue 
thus enabling the rings to be clearly visible (see figure 
2.7a). 
4. Calculation of samples: 
In order to calculate the diameter of each ring, the gel 
was placed on top of a sheet of graph paper and a magnifying 
apparatus placed in position over the gel. The diameter was 
measured twice- at right angles to compensate for any rings 
which had become askewed during the staining procedure. The 
precipitated rings of antibody-antigen complex have a 
diameter proportional to the concentration of vitamin D 
binding protein in the sample. A standard curve was obtained 
from the mean diameters of the known standards (figure 2.7b) 
and from this the unknowns were calculated. 
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FIGURE 2.7. (a) Typical diagram of an agarose gel depicting 
precipitated rings of the calibrated standards and patients 
samples. (b) By measuring the diameter of each calibrant a 
standard curve can be plotted and the unknowns calculated. 
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2.2.8. ESTIMATION OF PARATHYROID HORMONE CONCENTRATIONS 
IN HUMAN SERUM 
Parathyroid hormone (PTH) estimations were kindly 
measured by the Deparbment of Chemical Pathology and 
Medicine, Derbyshire Royal Infirmary, Derby, UK., using a 
recently available 'e-terminal' PTH radioimmmoassay kit 
purchased from Dac-Cel, Wellcome Diagnostics, Temple Hill, 
Dartford DAl sAH, UK (Ingle et ai, 1987). 
The PTH assay kit comprised of the following 
reagents: 
BOVINE PTH STANDARD in human serum 
ANTI-BOVINE PTH ANTISERUM (raised in guinea-pig) 
12sI-BOVINE PTH 
DONKEY ANTI-GUINEA-PIG ANTIBODY SUSPENSION (linked to 
cellulose) 
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2.2.9. DOUBLE-ISOTOPE CALCIUM ABSORPTION TEST 
(WOOTON AND REEVE, 1979) 
PRarocoL 
(i) Patients received a normal diet on the day before the 
test but water from midnight on the day of the test. 
(ii) At OS.15 an intravenous cannula was inserted into one 
arm, for blood sampling, and infused with 0.9% saline. 
(iii) A fasting 20ml blood sample was taken, half of which 
acted as the isotope 'blank' and the remainder used for 
measuring the vitamin D metabolites. 
(iv) Patient name and the weights of the pre-weighed 
isotope syringes were carefully noted. 
(v) At OS.30 15uCi of 47ealcium (47ea) and 2.5rrmol of 
calcium chloride BP in l00m1 of distilled water were given 
by mouth, whilst 2uCi S5Strontium (S5Sr) was injected 
intravenously as the patient drank. The time of injection 
was carefully noted. 
(vi) Both syringes were re-weighed to ascertain the exact 
weight of isotope given. 
(vii) lOml blood samples were taken at: 
T + 5, 10, 35, 50, 75, 100, 140, lS0, 240, 
300 and 360min. 
(viii) The patient was allowed a standard meal 300min after 
administration of the isotopes. 
(ix) Blood samples were spun at 2400rpm for 6min and 4ml 
aliquots of plasma counted for garrma emissions. 
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The test employs the use of an intravenous dose of 85Sr 
in conjunction with an oral dose of 47 ea. In order to 
calculate accurately the percentage of the oral dose 
absorbed. by the intestine, allowance must be made for the 
removal of 47ea into soft tissue and bone. Since 85Sr 
administered intravenously is distributed in the same manner 
as the oral dose of 47ea, the ratio of activity of the two 
isotopes in plasma is used to calculate the percentage 
absorption (figure 2.8). 
Using a computer program designed for this study, the 
following data were inserted: 
(i) Plasma radioactivity data from gamma-counting of 
the serial plasma samples- simultaneous counts for 
47ea and 85Sr • 
(ii) Background counts for both 47Ca and 85Sr• 
(iii) Counts for standard 47Ca and 85Sr administered. 
(iv) Weights of standards used and their dilutions. 
(v) Weight of each isotope administered to subject. 
The percentage absorption was calculated as a function of 
time. By differentiating this graph, the rate of calcium 
absorption can be calculated for each hour. It should be 
noted that the effect of recirculation of orally 
administered tracer before its clearance into the skeleton 
and excreta is eliminated by a process known as 
deconvolution, so that only oral tracer absorbed during the 
course of the preceding circulation is taken into account. 
This process was included in the computer program. 
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FIGURE 2.8. Changes in plasma activity over a 6h time period 
following administration of oral 47Ca (0) and LV. 85Sr (.). 
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2.3. METHODS 2: EXPERIMENTS ON 20S CEIl..S - s ~ ~ chCo.fh.r ~ ~
The human osteosarcoma cell line 20S was grown in 0(-
modified minimum essential medium (MEM) supplemented with 
10% (v/v) heat-inactivated newborn calf serum (NCS) at 37°C 
in a humidified aenosphere of 95% air and 5% CO2• 
2.3.1. SUBCULTURE AND PASSAGING OF CEIl..S 
Cells were grown at a cell density of 8 x 106 cells/9Ornm 
culture dish until confluent. Growth medium was discarded 
and a few drops of Trypsin/EDTA solution added to the cell 
monolayer. Cells were trypsinised for approximately 5min, 
carefully agitating the culture dish to dislodge cells from 
the surface. Approximately O.5ml fresh growth medium was 
added and the cell suspension transferred to a sterile 
universal bottle. After centrifuging for 10min at 2,OOOrpm" 
the pellet was resuspended in fresh growth medium and the 
cells seeded out at 2 x 106 cells/9Omm dish. Growth medium 
was changed every 2-3 days of cell growth until confluent 
when the procedure was repeated. When grown past confluence 
the majority of the cells floated off the surface and died. 
2.3.2. MEASUREMENT OF CEIl.. VIABILI'IY: 
Trypan blue exclusion (Seglen, 1976) 
Trypan blue (0.4% v/v solution in saline) was mixed with 
equal volume of cell suspension and left for 5min. A drop of 
this mixture was placed on a haemocytometer and a cover slip 
placed on top. The cells were viewed under a light 
microscope. Any damaged cells will have their nuclei stained 
blue because they were unable to prevent the uptake of the 
dye. Viable cells, which are not permeable to the dye appear 
normal colour. Therefore the number of viable and non-viable 
- 68 -
(blue) cells were counted and the viable cells expressed as 
a percentage of total number of cells recorded. This was 
always greater than 95% 
2.3.3. STORAGE AND PROPAGATION OF CELLS 
Cells were harvested, as above, and the resulting pellet 
of cells was resuspended in lml of 5% (v/v) dimethyl-
sulphoxide (5% DMSO) in NCS for every 90rrm dish of cells. 
After transferring the suspension to sterile cryo-tubes, the 
tubes were placed in a -80°C freezer for 2 days after which 
they were placed in a -196°C liquid nitrogen bank for 
storage. 
For the thawing procedure, each cryo- tube was warmed 
rapidly in a 37°C water bath and the contents transferred to 
a sterile universal bottle. An equal volume of growth medium 
was slowly added dropwise whilst shaking the universal. 
Cells were then pelle ted and resuspended in lml of fresh 
growth medium prior to transfer to a culture dish. 
2.3.4. EXTRACTION AND PARTIAL PURIFICATION OF LIPIDS 
FROM CELL MONOlAYER 
Medium was removed from the cell monolayer and the cells 
treated with 4m1 of hexane:isopropanol (3:2 v/v) for 20min. 
This solvent mixture was sucessful in removing lipids from 
cells. The solvent layer was transferred to a glass conical 
tube and the monolayer washed with a further lml of 
hexane:isopropanol (3:2 v/v) for 5min. The extracts were 
pooled and evaporated to dryness under a stream of nitrogen 
before resuspending in lml of 0.9% saline solution. An equal 
volume of acetonitrile was added to the extract in order to 
precipitate any protein and after vortex-mixing, the tube 
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was centrifuged at 1,200rpm for lOrnin. The supernatant 
fraction was applied directly to a prewashed S8 Sep pak 
column (refer to section 2.2.1). The column was washed, as 
described previously, and the acetonitrile fraction 
evaporated down to a small volume (approximately SOOuI) and 
stored under nitrogen at -20°C. 
2.3.5. EXTRACTION AND PARTIAL PURIFICATION OF LIPIDS 
FROM MEDIA 
A mixture of chloroform and methanol was added to a 
known volume of medium such that the final ratio of 
chloroform: methanol: water was 1:1:0.9 (by vol). The lower 
organic phase was removed and evaporated under vacuum using 
a rotary evaporator. The residual lipid extract was 
resuspended by sonication in 0.9% saline solution and the 
above extraction procedure followed. 
2.3.6. HPLC PURIFICATION OF LIPID EXTRACT FROM CELLS 
OR MEDIA 
Purification of lipid extract from initial column 
chromatography was achieved by high performance liquid 
chromatography (section 2.2.1). A UV detector and chart 
recorder was attached to the system to monitor the various 
vitamin D metabolites at 264nm. 
The retention times for the standard vitamin D 
metabolites were determined by injecting approximately O.lug 
of each metabolite on to the column and monitoring the 
retention time by UV detection. Once this was achieved 
satisfactorily, the column was washed thoroughly with 
isopropanol in hexane (25%, v/v), followed by re-
equilibration with eluting solvent. The lipid extract was 
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then injected on to the column and fractions corresponding 
to the 2S(OH)D3, 24,2S(OH)2D3 and 1,2S(OH)2D3 retention 
times were collected separately, evaporated to small volumes 
and stored at -20°C under nitrogen. 
2.3.7. PROTEIN DEI'ERMINATION: Burgi et al (1967) 
Each cell monolayer from a 90mm culture dish was scraped 
in 4m1 of phosphate-buffered saline (PBS: 0.14M NaCI, 7.37mM 
Na2HP04' 2.68mM KCI, 1.47mM KH2P04' 0.49mM MgCI2) and 
transferred to a conical tube. After centrifuging at 
3,600rpn for 10min, the pellet was resuspended in 4ml of 
O.lM NaOH and tranferred to a 37°C water bath to dissolve 
the protein. Aliquots (200ul) were assayed for protein by 
the Lowry Folin microassay method • 
Alkaline reagent: Sml 2% Na2C03' O.Sml 1% CuS04 and 
O.Sml 2% NaK Tartrate 
-Made up just prior to use. 
Folin's reagent: O.Sml Folin-Ciocalteau's reagent 
4.Sml O.lM NaOH 
Samples for protein determination were pipetted in 
duplicate into a 24-well microassay plate and to these SOul 
aliquots of alkaline reagent were added. After Smin at room 
temperature SOul of Folin's reagent was added to each sample 
well and the samples left for a further 20min at room 
temperature. The absorbance at 620nm was read against a 
reagent blank, consisting of 200u1 O.lM NaOH, SOul of 
alkaline reagent and SOul of Folin's reagent. 
A calibration curve was constructed using 1mg/ml BSA (in 
O.lM NaOH) as standard protein. A suitable range of 10-
lSOug/well was used. Volumes were made up to 200uI/well with 
O.lM NaOH. 
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2.3.8. PREPARATION OF CYTOSOL FROM OSTEOSARCOMA CEllS 
2.5 x109 cells were grown to near-confluence in growth 
medium. After preincubation for 24h in MEM without NCS (to 
remove the serum vitamin D binding protein from the 
incUbate) cells were washed twice with PBS and trypsinised 
to dislodge them from the plates. The cell suspension was 
centrifuged at 2,OOOrpm for 10min at 4°C and the resulting 
pellet was placed on ice. 
The remainder of the procedure was carried out at 4°C. 
The pellet was washed five times with ice-cold isotonic 
buffer (O.25M Sucrose; 50mM Tris-HCI, pH 7.4; 25mM KCI; l2mM 
Thioglycerol; 5mM MgCl2 and 1mM EDTA) and then finally 
suspended in hypertonic buffer (O.3M KCl; 10mM Tris-HCL, pH 
7.4; 1.5mM EDTA and O.5mM orr). After 10min in hypertonic 
buffer the cell suspension was subjected to five rounds of 
freezing and thawing using liquid nitrogen. An aliquot 
(lOul) of the resulting suspension was viewed under low 
power magnification to confirm cell disruption. 
The broken cell suspension was centrifuged at 3,OOOrpm 
for 10min to remove cell debris and the supernatant fraction 
centrifuged at 25,OOOrpm for 1h to yield a cytosolic 
fraction. This supernatant fraction was stored in aliquots 
(2mI) at -20°C until required for analysis. A similar 
procedure was followed to obtain a cytosolic fraction from 
U937 cells. A calf thymic cytosol fraction was prepared as 
described by Reinhardt et al (1984). 
2.3.9. ALKALINE PHOSPHATASE AcrIVITI IN 20S CELL 
Cytosol fraction from 20S cells was prepared as 
described previously. For comparative purposes a cytosolic 
fraction from U937 cells was prepared in the same manner. 
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content was measured by the method of Burgi et al (see 
section 2.3.7). The protein content of the U937 cytosol was 
lower than that of the 20S cytosol (0.78 mg/ml compared to 
2.5 mg/ml) and this was taken into account during the 
remaining procedures. An aliquot of each cytosolic fraction 
(with equal protein content) was dispensed into clean glass 
tubes. Alkaline phosphatase activity was measured by 
incubating eachcytosolic fraction with p-nitro-phenyl 
phosphate buffer ( 5 O m ~ ~ glycine, pH 10.5; 5.5rnM p-nitrophenyl 
phosphate, sodium salt; O.5rnM MgC12) for 30min at 37°C. As 
control the phosphate buffer was incubated with hypertonic 
buffer (see section 2.3.8). In the presence of alkaline 
phosphatase the colourless substrate is converted to the 
yellow p-nitro phenol (figure 2.9). 
FIGURE 2.9. Hydrolysis of p-nitrophenyl phosphate 
(colourless in alkaline medium) to p-nitrophenol (yellow in 
alkaline medium) by alkaline phosphatase (AP). 
p- nitrophenyl 
phosphate 
AP 
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Alkaline phosphatase activity was also measured in the 
culture medium. Because NCS contains alkaline phosphatase, 
20S cells were grown to confluence in growth medium and then 
transferred to serum-free medium. Small aliquots of medium 
was removed every 6h and alkaline phosphatase activity 
determined. 
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2.4. EXPERIMENTATION 
2.4.1. CEILUlAR RESPONSE OF 20S C : E I ~ S S TO Pm 
1. Incubation medium: a) MEM + 10% NCS + luCi 3H-adenine 
b) MEM + 2% NCS + O. 2mM Theophylline 
c) MEM + 2% NCS + 6nM PI'H 
2. Hank's balanced salt solution (Ca and Mg free) 
3. Carrier solution- containing lmM of the following 
Adenine, Adenosine, ADP, ATP and cAMP 
4. Recovery tracer- 14C_cAMP 
Cells were plated out at a cell density of 10 x 103 
cells/35rrm culture dish in 3ml growth medium. Medium was 
changed every 2 days until the time of experiment. Cells 
were incubated with 2ml of incubation medium (a) for 2h, 
after which the medium was discarded and the cell washed 
twice with 2ml Hank's balanced salt solution before 
incubating for a further 10min with the following: 
Control dishes •••••• 0.5ml incubation medium (b) + 
0.5ml (MEM + 2% NCS) 
3mM Pm dishes •••••• 0.5ml incubation medium (b) + 
0.5ml incubation medium (c) 
1.5mM PTH dishes •••• 0.5ml incubation medium (b) + 
0.25ml incubation medium (c) + 
0.25ml (HEM + 2% NCS) 
Reactions were stopped by transferring reaction media to 
labelled conical tubes and adding 1.2M TCA (1ml) to the cell 
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monolayer. After a few minutes the TCA solution was removed 
and added to the appropriate tubes containing the reaction 
media. The cells were discarded at this atage. Approximately 
6,OOOdpm of recovery tracer was added to all tubes, and into 
a scintillation vial to monitor final recovery. After 
vortexing, tubes were centrifuged at 2,OOOrpm for lOmin and 
the supernatant fractions dispensed into clean tubes. All 
fractions were neutralised with 300ul of 4M KOH solution 
before the addition of SOul of carrier solution. Tubes were 
then stored at -20°C until chromatography. 
Stage 1: Using Dowex-sOW (strongly acid cation exchange 
resin) constituted in 1M HCl and poured into glass pipettes 
plugged with cotton wool to make Sam x ls0cm columns. All 
columns were washed with distilled deionised water until the 
pH of the elutes were within the pH 6.0 region. 0.8ml of 
distilled deionised water was added to all tubes and after 
vortex-mixing, the contents of each tube were decanted onto 
the Dowex columns. The eluate from this, and two succesive 
washes with 1ml water were discarded. Water (3ml) was then 
added to each column and the eluates collected into clean 
labelled scintillation vials. 
Stage 2: Using neutral alumina (aluminium oxide). O.2ml of 
imidizole-HCl (pH 7.5) was added to each of the 3ml 
fractions collected from the Dowex columns which raised the 
pH 7.5. The contents in each vial were vortex-mixed before 
decanting onto a column containing 0.6g neutral alumina that 
had been washed previously with 8ml of O.lM imidizole-HCl pH 
7.5. Each eluate was collected directly into a clean 
scintillation vial. An additional 1ml of O.lM imidizole-HCL 
pH 7.5 was added to the columns and collected into the 
vials. The contents of each vial were freeze-dried before 
the addition of lOml of scintillation fluid and counting for 
both ~ ~ and 14C. 
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2.4.2. BINDING STUDIES WITH 20S CYTOSOLIC FRAcrION 
Incubation with ~ - v i t a m i n n D metabolites: 
Aliquots (500ul) of 20S cytosol were incubated with 
either %-25(OH)D3 or %-1,25(OH)2D3 (approx 80,OOOdpm in 
10ul ethanol/incubation tube) at 25°C for 30min. Equivalent 
volumes of hypertonic buffer and human serum, diluted 1 in 
10,000 fold with gelatine buffer (refer to section 2.2.2), 
were used as controls. All samples were cooled on an ice-
bath and treated for 20min with 200ul of dextran-coated 
charcoal suspension (see section 2.2.2) to remove any %-
vitamin D metabolites not bound to the protein. After 
centrifugation at 2,OOOrpm for 20min the resultant 
supernatant fractions were counted for radioactivity. 
Since these initial studies showed high ~ ~ counts in the 
tubes containing cytosol and ~ - 2 5 ( O H ) D 3 3 the experiment was 
repeated but using cytosol which had previously undergone an 
overnight incubation at 4°C with an equal volume of rabbit-
antibovine whole serum. Incubation with this antibody will 
form precipitated complexes with any serum proteins which 
may be present in the cytosolic preparation. After pelleting 
the precipitate by centrifugation at 6,000rpm for 3min, the 
supernatant fraction was incubated with %-25(OH)D3 for 
30min then the sample was applied on to a G-25 sephadex 
colurrm. 
Preparation of Sephadex™ G-25 and G-100 colurrms: 
Two dextran gels were employed; G-25 which was used to 
separate radiolabelled vitamin D metabolites bound to the 
cytosolic protein from the unbound (free) radioactivity, and 
G-100 for molecular weight determination of the radio-
labelled bound protein. 
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Sephadex bead gels were pre-swollen as instructed by the 
manufacturer, in column buffer (100mM Tris-HC1, pH 7.4 
containing 0.01% (w/v) sodium azide). A Sephadex G-25 column 
(25cm x lern) and a Sephadex G-l00 column (85ern x 1.4ern) were 
prepared and allowed to equilibrate in column buffer before 
determination of their exclusion volumes. The G-l00 column 
was then calibrated with proteins of known molecular weight. 
Two mixtures of proteins were prepared in column buffer: 
Mixture A contained 200ul of the following proteins: 
Cytochrome c (lOmg/ml) ••••••••••• MW 17,000 
BSA (lOmg/ml) ••••••••••• MW 66,000 
Immunoglobulin G (lOmg/ml) ••••••••••• MW 250,000 
Mixture B contained 200ul of the following proteins: 
Ovalbumin (lOmg/ml) ••••••••••• MW 45,000 
Aldolase (lOmg/ml) ••••••••••• MW 160,000 
Cytidine (lmg/ml) ••••••••••• MW 243,000 
Mixture A was applied onto the G-l00 column and lml 
fractions collected immediately after application. Each 
fraction was monitored at 280run wavelength using quartz 
spectrophotometer cells. Collection was stopped when three 
absorption peaks were recorded. The column was washed with 
20rnl of column buffer and mixture B applied as before. 
20S cytosol was incubated with 3a-25(OH)D3, as 
previously described. At the end of the incubation period 
the reaction mixture was applied to the G-25 column and 1ml 
fractions collected. Aliquots (l00ul) of each fraction were 
counted for radioactivity. The fractions corresponding to 
the exclusion volume were pooled and applied to the G-l00 
column. Again 1ml fractions were collected and analysed for 
radioactivity. 
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For comparative purposes this procedure was repeated 
using (a) cytosolic fractions from U937 cells, (b) thymic 
cytosol (refer to section 3.1.1 for preparation) and 
(c) human serum, diluted 1 in 1,000 times in gelatine buffer 
(section 2.2.5). 
Analysis of cytosolic protein by Sucrose density gradient 
centrifugation: 
Two solutions of sucrose, at 4 and 24% (w/v) in 0.3M KCl 
were used to create continuous sucrose density gradients in 
six 16.5ml centrifuge tubes Oem x 1.25em). The following 
samples (500ul total volume) were applied to the top of each 
gradient: 
Tube 1 
Tube 2 
Tube 3 
Tube 4 
Tube 5 
Tube 6 
A mixture of 300ul BSA (lOmg/ml) and 200ul 
hypertonic buffer 
A mixture of 300ul Ribonuclease (lOmg/ml) and 
200ul hypertonic buffer 
A mixture of 300ul Ovalbumin (lOmg/ml) and 200ul 
hypertonic buffer 
500ul of 20S cytosol, previously incubated with 
~ - 2 5 ( O H ) D 3 3 and applied onto a G-25 column 
500ul of U937 cytosol- as for tube 4 
500ul of human serum (diluted 1 in 1,000 fold with 
hypertonic buffer- as for tube 4 
The tubes were spun simultaneously at 4°C for 56h at 
30,000rpn. Tubes were unloaded from the bottom using a 
peristaltic pump and 200ul fractions collected. For tubes 1 
to 3, fractions were collected in plastic disposable tubes. 
Fractions obtained from these tubes were subjected to the 
Lowry-Folin assay (refer to section 2.3.7), to identify the 
position of each protein in the gradient. Because of the 
non-specific binding of the vitamin D metabolites to 
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plastic, fractions from tubes 4 to 6 were collected into 
glass tubes and 100ul aliquots from these fractions were 
monitored for radioactivity. 
2.4.3. IMMUNODIFFUSION ANALYSIS OF 20S CYTOSOLIC PROTEINS 
The following double irrmunodiffusion analysis was 
performed to examine the possibility that there may be some 
contamination of serum p r o t e ~ n s s in the cytosolic preparation 
and therefore some radioactively bound 25(OH)D3 might be 
associated with these proteins. 
Imnunodiffusion was carried out on a lOrrm x lOrrm glass 
plate using 1% agarose gel (Axelsen et ai, 1979). Rabbit 
antibovine whole serum (2ul) was placed in the centre well 
(figure 2.10) and the following samples (2ul aliquots) were 
positioned in the remaining wells: 
20S cytosolic protein 
Newborn calf serum (NCS) 
Bovine serum albumin (BSA) 
1 in 1,OOO-fold 
dilution of stock. 
0.25 mg/ml 
After 48h at 4°C in a moist chamber a n t i g e n ~ a n t i b o d y y
complexes were visible as precipitated lines. The procedure 
for staining the gel is similar to that outlined in section 
2.2.7. The gel was dried and stained for lOmin in Coomassie 
Brilliant Blue R (0.1% w/v) in acetic acid/methanol/water 
(1:5:5 by volume) and destained in acetic acid (7% w/v) and 
methanol (5% w/v) to remove non-cross reactive proteins. The 
gel was dried and analysed. 
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FIGURE 2.10. Diagram showing the position of each of the 
proteins on the immunodiffusion plate. 
ab represents rabbit antibovine whole serum, NCS newborn calf 
serum and BSA bovine serum albumin. 
NCS 
cytosolic 
protein .<==> 
<==> <==> @ 
BSA 000 
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2.4.4. INVESTIGATION INTO THE METABOLISM 
OF 2S(OH)D3 BY 20S CELLS 
Cells were maintained in culture in 90mm culture dishes 
at a cell density of approximately 2 x 106 cells/dish in 
growth medium. Once cells were near confluent, medium was 
removed and the cells washed well with MEM before incubating 
for 18h in serum-free medium. The time and concentration 
dependence of 2S(OH)D3 metabolism was measured after this 
initial serum-free incubation using ~ - 2 S ( O H ) D 3 3 (170Ci/rnmol) 
as radioactive precursor. 
After the initial incubation, cells were again washed in 
serum-free medium before incubating for 3h in serum-free 
medium containing SOnM ~ - 2 S ( O H ) D 3 3 (in ethanol) or vehicle 
(ethanol alone). The reaction was stopped by cooling the 
culture dish and removing the media. Lipids were extracted 
from cells and media, as described in sections 2.3.4 to 
2.3.6, and the vitamin 0 metabolites isolated using 
prewashed C18 Sep-Pak cartridges. Separation of the vitamin 
o metabolites was performed by HPLC. 
Time and concentration experiments were performed under 
similar conditions. Cells were exposed to SOnM ~ - 2 S ( O H ) D 3 3
for different time periods (ranging from lOmin to 3h) whilst 
for the concentration studies cells were incubated for 3h 
with concentrations of 3H- 2S (OH)D3 up to O.SuM. 
The effect of dibutyryl cyclic AMP (dbcAMP) on the 
metabolism of 2S(OH)D3 was also investigated. Near-confluent 
cells were washed with serum-free medium before incubating 
overnight with either serum-free medium containing lmM 
dbcAMP or in serum-free medium alone. The following day 
cells were incubated for 3h in serum-free medium (with or 
without dbcAMP) containing various concentrations of ~ ~
2S(OH)D3· 
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Identification of unknown vitamin D metabolite 
by mass spectroscopy 
The identity of the product which eluted with 
24,25 (OH) 2D3 was identif ied by mass spec troscopy • Large 
scale incubations involving eighty culture dishes (140mn 
diameter) were carried out to isolate the unknown 
metabolite. Approximately lOuM of 25(OH)D3 was used for each 
culture dish. The fraction corresponding to the 24,25(OH)2D3 
from the HPLC column was rechromatographed a further three 
times. After the fourth step fractions corresponding to the 
unknown metabolite were pooled, evaporated to dryness and 
redissolved in ethanol for UV and mass spectroscopy. An 
aliquot (15ul) was placed into the probe of a MS902 mass 
spectometer and this was evaporated to dryness before 
introducing into the system. The probe was heated at a rate 
of 2°C/sec to the point where a good signal was produced. 
The spectrum was examined on the mass spectrometer 
oscilloscope and its spectrum compared with those produced 
from the authentic vitamin D metabolites, 25(OH)D3' 
24,25(OH)2D3 and 1,25(OH)2D3. 
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CHAPI'ER 3 
DEVElDPMENT OF AN ASSAY SYSTEM FOR 'IHE 
MEASUREMENT OF SERUM 1,25(OH)2D 
3.1 INTRODUCTION: . 
The development of an assay system which measures serum 
concentrations of 1,25(OH)2D has its share of problems. 
Concentrations of this metabolite in serum are extremely 
low; normal values are within the range of 20-S0pg/ml. The 
presence of other vitamin D metabolites at concentrations 
two or three orders of magnitude greater than 1,25(OH)2D, as 
well as non-specific factors, possibly lipids, tend to 
interfere with its measurement. It is therefore essential to 
develop an assay system which will be able to overcome these 
problems. One of the first assay procedures to be reported, 
by Brumbaugh et al (1974), utilised the chick intestinal 
cytosol-chromatin receptor system to create a competitive 
radioreceptor assay for 1,25(OH)2D. Although modified by 
Eisman' et al in 1976, the assay was laborious requiring a 
lengthy hormone purification scheme. Due to the instability 
of the receptor protein, this had to be prepared frequently 
which meant a regular supply of rachitic chicks. Therefore, 
other methods which would overcome these problems were 
sought. 
By the early 1980s methods such as radioirmrunoassays 
(e.g. Clemens et al, 1978), several radioreceptor assays 
(e.g. Eisman et al, 1976, Reinhardt et al, 1984), a bioassay 
(Stern et al, 1978) and an isotope-dilution-mass 
fragmentographic method (Bjorkhem et al, 1979) were 
reported. Due to the expensive and time-consuming techniques 
of mass fragmentography and the bioassay, these methods have 
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been abandoned and the most favoured methods for routine 
determination -of serum 1,25(OH)2D concentrations have been 
the radioimmunoassays and radioreceptor assays, both of 
which utilising chromatographic techniques, in particular 
high-performance liquid chromatography (HPLC) for extraction 
and purification of the vitamin D metabolite before 
quantification. 
The aims of this present study were to compare the 
efficiency of an antibody to 1,25(OH)2D with a cytosolic 
receptor derived from calf thymus, in the assay of serum 
concentrations of 1,25(OH)2D and to establish a normal range 
in a group of healthy adults. 
3.2 METHODS: 
In order to reduce non-specific binding, all glassware was 
treated as described in section 2.2.1. 
3.2.1 PRODUCTION OF ANTISERA: 
Antisera were raised in sheep against 1,25(OH)2D3-3-
hemisuccinate coupled to bovine serum albumin (BSA), as 
described by Clemens et al (1978) for the 25-hemisuccinate 
derivative. 
3.2.2 PREPARATION OF THYMIC CYTOSOL: 
Thymus gland cytosol was prepared as described by 
Reinhardt et al (1985) modified as follows. 
Thymus gland was removed from a 6-week old calf and 
washed in 0.9% ice-cold saline. The glands were cut into 
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small cubes, frozen in liquid nitrogen and stored at -80°C 
until required. Under these conditions there was no loss in 
receptor activity for at least one year. 
The following steps were carried out at 4 °C. Thyrrrus 
glands were homogenised (25% w/v) in homogenising buffer 
(500mM KC1; 50mM Tris-HC1, pH 7.5; 10mM Na2Mo042H20; 5mM 
DTT; 1.5mM EDTA) • The homogenate was centrifuged for lh at 
l00,OOOrpm and the cytosol (minus pellet and floating lipid 
layer) was removed and fractionated by the slow addition of 
solid ammonium sulphate to 35% saturation (ie. 19.4g 
(NH4)2S04/10Oml cytosol solution). After stirring slowly for 
30-6Omin, aliquots of cytosol (lOml) were centrifuged at 
15,OOOrpm for 2Omin. The supernatant fractions were 
discarded and the pellets stored under nitrogen at -80 oC. 
The pellets were resuspended in 5ml homogenising buffer 
prior to use in binding studies. 
3.2.3 EXTRACTION AND PURIFICATION OF SERUM 1,25(OH)2D: 
See method section 2.2.1 
3.2.4 RADIOIMMUNOASSAY PROCEDURE: 
-as described by Gray (1983). 
Triplicate glass tubes (lOmm x 75rrm), were labelled 
according to protocol 3.1. Stock antiserum was diluted 
200,OOO-fold using gelatine buffer (5Omg gelatine in 500ml 
of O.lrrmol/L K2P04 , pH 7.4) and this was kept on ice until 
required. Standard 1,25(OH)2D3 in ethanol, ranging from 
1.25-800 pg/20ul ethanol, were dispensed into appropriate 
tubes. Tubes labelled 0, Tc and Cb (refer to section 2.3) 
received the ethanol vehicle. The chromatographed serum 
extracts were reconstituted in l00ul ethanol. An aliquot 
(20ul) from each extract was dispensed into clean 
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~ ~ 3.1. Radioimmunoassay for 1,25(OH)2D3 
. TUBES STANDARD ~ - 1 , 2 5 ( O H ) 2 D 3 3 ANTISERUM BUFFER CHARCOAL 
1, 25 (OH)tD3 SUSPENSION (pg/20u ) (250ul) (250ul) (250ul) 
0 - + + + + 
Tc - + - ++ -
Cb - + - ++ Mix + Mix Incubate 
1 1.25 + + + Incubate + 15min 
2 2.50 + + + + @ ! 
3 5 + + + for + 4°C 
4 10 + + + + 
5 20 + + + 4h + 
6 40 + + + + Centrifuge 
7 80 + + + @ + 20min 
8 160 + + + + @ 
9 320 + + + 4°C + 4°C I 
Unknowns - + + + + 
---
---- -_.-
- -- - -- - --- - - - ------
scintillation vials to monitor recovery and three 20ul 
aliquots pipet ted into appropriately labelled assay tubes. 
Approximately 3,SOOdpm 3r-I-1,2S(OH)2D3 (in 20ul of ethanol) 
was added to all tubes and a clean scintillation vial. All 
tubes except those labelled Tc and Cb received 2S0ul of 
diluted antiserum; tubes Tc and Cb received buffer without 
antibody. A further 2SOul gelatin buffer was added' to all 
tubes and the tubes vortex-mixed. 
After a 4h incubation at 4°C, aliquots (2SOul) of 
dextran-coated charcoal suspension were added to all tubes 
except those of the Tc group. The suspension was made by 
mixing 19 activated charcoal and O.lg dextran T70 with 200ml 
of O.lmol/L potassium phosphate buffer, pH 7.4. After brief 
vortexing, the tubes were further incubated for lSmin at 4°C 
and then centrifuged at 3,OOOrpm for 2Omin. An aliquot 
(SOOul) from each of the supernatant fractions was dispensed 
into scintillation vials containing lOml liquid scintillator 
and the vials monitored for tritium counts. 
3.2.S RADIORECEPTOR ASSAY PROCEDURE: 
. See method section 2.2.1. 
3.3 RESULTS: 
Before the antisera or cytosol 
development of protein binding 
characterised carefully. The three 
Titre, Sensitivity and Specificity. 
3.3.1 TITRE: 
can be used for the 
assays they must be 
important properties are 
Titre was established by measuring the ability of 
varying dilutions of protein to bind ~ - 1 , 2 5 ( O H ) 2 D 3 3 in the 
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absence of 1,25(OH)2D3. Figure 3.1 shows the titre for the 
antiserum and thymic cytosol. In general, the dilution of 
antisera or cytosol which binds 30-50% of radioactivity was 
used for the radioassay since these conditions optimise the 
ratio of sensitivity to precision. Complete binding of ~ ~
1,25(OH)2D3 to the antisera was obtained when the antiserum 
was diluted 200,000 fold and this dilution was used to 
construct a calibration curve; a typical curve is depicted 
in figure 3.2. Dilution of the cytosolic suspension by 5-
fold produced similar radioactive binding (figure 3.1b) but 
this dilution varied slightly for each batch of cytosolic 
preparation. A much wider variation was observed between 
thymuses of different ages (figure 3.3). The correct 
dilution was therefore found empirically for each 
preparation batch and a calibration curve constructed using 
the estimated dilution factor (figure 3.2). 
The performance characteristics of each binding assay 
are outlined in Table 3.1. Both standard curves were 
reproducible from assay to assay with little change in 
either the detection limits (see Table 3.1) or the shape of 
the curves. Maximum binding for both assays were similar but 
non-specific binding, defined as the proportion of ~ ~
1,25(OH)2D3 which will bind to the protein in the presence 
of a l00-fold excess of the unlabelled hormone, was over 
three and a half times greater in the radioimmunoassay. This 
was also reflected in the mid-range of each binding curve. 
3.3.2 SENSITIVITY: 
Sensitivity, defined as the least amount of hormone that 
can be distinguished from no hormone by the antisera or 
receptor, was estimated as 2 standard deviations (2SD) below 
the maximal binding, or Bo value. The receptor assay 
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FIGURE 3.1. 1,Z5(OH)ZD3 binding dilution curves for: 
(A) Antisera raised against the 1,Z5(OH)ZD3-hemisuccinate 
coupled to BSA, and 
(B) The calf thymus receptor. 
Each point represents the average of triplicate 
determinations. Bt represents total added radio labelled 
1,Z5(OH)ZD3• 
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FIGURE 3.2. Standard curves for 1,Z5(OH)ZD3 using: 
(A) Antiserum diluted ZOO,OOO-fold, and 
(B) Thymus 1,25(OH)2D cytosolic receptor. 
Each point represents the average of triplicate 
determinations. 
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FIGURE 3.3. Variation in binding ability of thymuses from 
calves of different ages. 
Y represents thymuses from calves < 16 weeks old; X 
represents > 16 weeks old. • represents thymus frozen for 2 
years prior to cytosolic preparation. Each point represents 
the average of triplicate determinations. 
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demonstrated a sensitivity of 1.27 pg/tube in comparison 
with 5 pg/tube for the immunoassay. 
TABlE 3.1 PERFORMANCE CHARACTERISTICS OF THE CALF 'TIIYMUS 
RECEPTOR ASSAY AND THE RADIOIMMUNOASSAY 
Maximum binding (%) 
Non-specific binding (%) 
Mid-range 0.5Bo (pg/tube) 
Sensitivity 2SD Bo (pg!tube) 
Detection range (pg/tube) 
Thymus receptor 
assay 
n = 10 
93.00 
1.36 
6.50 
1.27 
1.5 - 40 
Radioirrmuno-
assay 
n = 10 
95.00 
4.70 
24.0 
5.0 
5 - 100 
values determined from 10 standard curves and shown as mean 
3.3.3 SPECIFICITY: 
Specificity, defined as the freedom from interference by 
substances other than the hormone, is the characteristic 
which ultimately determines the usefulness of the antiserum 
or receptor. The cross-reactivity of various vitamin D 
analogues other than 1,25(OH)2D3 was examined by comparing 
the ability of the unlabelled me tabo li tes to displace 3H_ 
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1, 25(OH)2D3 from the antibody and the thymus receptor 
(figure 3.4a and 3.4b, respectively). Although both receptor 
and antibody cross-react with other vitamin D compounds they 
do so with low affinity and they still retain their 
specificity towards the 1,25(OH)2D3 metabolite. Table 3.2 
compares the displacement of both systems; the amount of 
1,25(OH)2D3 which result in 50% displacement of the maximal 
binding (Bo) is defined as 1. Results indicate that with 
respect to the antibody although specific for 1,25(OH)2D3 it 
will cross-react with vitamin D compounds which lack the 1-
alpha hydroxyl group- such as 25(OH)D3' 24,25(OH)2D3 and 
25,26(OH)2D3 if presented at a higher concentration than the 
1,25(OH)2D3 metabolite. However, the thymic receptor showed 
little or no specificity towards these analogues. In fact, 
the receptor displayed specificity towards vitamin D 
metabolites which possessed the hydroxyl function at C-1 on 
the A ring and so has equal affinity for both 1,25(OH)2D2 
and 1,25(OH)2D3 (figure 3.4b) reacting poorly with 
metabolites hydroxylated only on the side chain of the 
vitamin D molecule. 
3.3.4 . AFFINI1Y OF 'TIlE BINDING PROTEINS: 
Affinity of the binding protein is the energy required 
for the protein to bind the hormone and is denoted as Ka, 
the affinity constant. The affinity of each binding protein, 
determined by means of the Scatchard plot (Scatchard, 1949; 
Walker, 1977), and outlined in appendix 3, was 
1.7 x1010 L/mol for the antiserum and 4.75 xl010 L/mol for 
the cytosol protein. The Scatchard analysis of total bound 
ligand showed non-linear plots for both proteins, indicating 
the presence of more than one class of binding sites in both 
instances. 
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FIGURE 3.4. Displacement of ~ - 1 , 2 5 ( O H ) 2 D 3 3 from: 
(A) Antisera diluted 200,OOO-fold and 
(B) Thymic 1,25(OH)2D3 cytosolic receptor 
by various vitamin ° metabolites. 
(1) 1,25(OH)2D3 (2) 1,25(OH)2D2 (3) 1,24,25(OH)3D3 
(4) 25(OH)D3 (5) 24,25(OH)2D3 (6) 25,26(OH)2D3 and 
(7) 02 or 03• 
Each point represents the average of triplicate 
determinations. 
A 
<D 
B 
I 
10d 
pg VITAMIN 0 METABOLITE 
~ L E E 3.2. Specificity of the radioimmunoassay and the 
Thymus receptor assay. 
Vitamin D metabolite Calf thymus Antibody 
receptor 
1,25(OH)2D3 1.0 1.0 
1,25(OH)2D2 1.06 13.1 
Vitamin D3 >15,000 >15,000 
Vitamin 02 >15,000 >15,000 
25(OH)03 430 285 
24,25(OH)203 1,4000 570 
25,26(OH)203 >3000 >4300 
1,24,25(OH)303 7.58 >700 
The amount of 1,25(OH)203 which result in 50% displacement 
of the maximal binding is defined as 1.0 
Investigation into the binding behaviour of the 
antiserum with different incubation times and temperatures 
revealed little or no binding during the first three hours 
but a marked increase in binding at 4h (figure 3.Sa). It 
should be noted that an overnight incubation did not 
significantly increase the binding ability of the antiserum 
for the hormone. Different incubation temperatures produced 
different binding curves (figure 3.Sb). At 2SoC the binding 
afffinity of the antibody was lower than that observed at an 
incubation temperature of 4°C. 
3.3. S EFFICIENCY OF THE EXTRAcrION AND PURIFICATION 
PROCEDURE: 
Known amounts of radioactive vitamin D3 metabolites, 
including the ~ - 1 , 2 S ( O H ) 2 D 3 3 metabolite, were added to 
plasma and the procedure for the extraction and purification 
of the metabolites was followed (section 2.2.1). Removal of 
serum proteins by precipitation with acetonitrile was rapid 
and efficient with no loss of the radiolabelled metabolites. 
After the removal of salts and polar lipids using a S8 
cartridge the vitamin D metabolites were eluted with 4ml 
acetonitrile. This volume produced the highest recovery 
value for all metabolites; at this stage in the procedure 
recovery of each radiolabelled metabolite was greater than 
9S% (n = 4). 
The use of a silica Sep-Pak cartridge, rather than the 
HPLC step, to separate the different vitamin D metabolites, 
was investigated (Reinhardt et al, 1984). The eluate from 
the C18 cartridge was evaporated to dryness, redissolved in 
lml hexane/isopropanol (96:4 vol/vol) and applied to a 
silica Sep-Pak cartridge which had been washed previously by 
sequential additions of Sml methanol, Sml hexane and Sml 
hexane/iso-propanol (96:4 vol/vol). The cartridge was washed 
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FIGURE 3.5 (A) Binding ability of the antiserum (diluted 
200,OOO-fold) at different incubation times. (B) Standard 
curve for 1,25(OH)2D3 using antiserum (diluted 200,OOO-fold) 
at 4 0 C (0) and 25 0 C (.) incubation temperatures. 
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with llml hexane/isopropanol (96:4) to elute the 25(OH)D 
metabolite and then with 8ml hexane/isopropanol (94:6) to 
elute the 24,25(OH)2D metabolite. Finally, the cartridge was 
washed with lOml hexane/isopropanol (85:15) which removed 
the 1,25(OH)2D metabolite. The three fractions were 
evaporated to dryness and monitored for radioactivity. The 
results from four separate applications showed that the mean 
recovery of ~ - 2 5 ( O H ) D 3 ' ' ~ - 2 4 , 2 5 ( O H ) 2 D 3 3 and ~ - 1 , 2 5 ( O H ) 2 D 3 3
were 89.3%, 72.6% and 118.5%, respectively. These results 
suggest that there may be some overlap between ~ ~
24,25(OH)2D3 and ~ - 1 , 2 5 ( O H ) 2 D . . Thus, the HPLC step was used 
for purification and separation of the vitamin D 
metaboli tes. 
The radio labelled vitamin D metabolites showed an 
identical elution profile to that of the unlabelled 
metabolites (figure 2.2) and therefore this profile was used 
to determine the retention time for each metabolite. Direct 
application of the radio labelled metabolites to the HPLC 
column produced recovery values which were always greater 
than 87%. Samples from the C18 cartridges were therefore 
subjected to straight phase HPLC. Fractions corresponding to 
the 25(OH)D ( 3 - 6 ~ i n ) , , 24,25(OH)2D ( 7 - 9 ~ i n ) ) and 1,25(OH)2D 
(11-15min) were collected and evaporated to a small volume 
(approx. 200ul) before storing under N2 at -20°C until 
required for quantitative determination. 
The overall recovery (Le. from plasma extraction to 
quantitative determination) for ~ - 2 5 ( O H ) D 3 ' ' ~ - 2 4 , 2 5 ( O H ) 2 D 3 3
and ~ - 1 , 2 5 ( O H ) 2 D 3 3 were 84 + 5.6 % (mean + SD, n = 30), 79 + 
4.9 % (n = 30) and 75 + 6.1 % (n = 30), respectively. 
Analytical recovery of unlabelled 1,25(OH)2D was assessed at 
two levels; when 22pg and 69pg of unlabelled 1,25(OH)2D were 
added to lml aliquots of either control serum or 0.9% (w/v) 
saline solutions. After extraction and purification the 
1,25(OH)2D extracts were determined either by the 
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radioirrmunoassay or by the receptor assay method. Results 
are shown in Table 3.3. 
No detectable levels of 1,25(OH)2D were seen when blank 
saline samples were subjected to the thymic receptor assay. 
This was in contrast with the radioirrmunoassay which 
demonstrated values within the region of 5Opg/ml. It was 
impossible to reduce this value. 
To determine the accuracy of the radioreceptor assay 
pooled serum was divided into 10 x 1ml aliquots. The average 
(+ 2SD) of 1,25(OH)2D concentration was 37.7 + 7.8pg/ml. The 
intra-assay coefficient of variation, calculated as (SD -;-
mean) x 100%, was 10.3%. Assay of the same pooled serum in 
20 successive assays yielded an inter-assay coefficient of 
variation of 13.2%. 
Figure 3.6 shows values for 1,25(OH)2D in human serum 
determined by the radioreceptor assay. In a group of 50 
normal subjects (mean age 36 years; range 19 - 53 years) 
concentrations of 1,25(OH)2D ranged from 20-65 pg/ml with a 
mean (+ 2SD) concentration of 35.9 + 15.6 pg/ml. No sex-
related difference was found (p= NS) nor was there any 
seasonal variation in 1,25(OH)2D concentrations. These 
reference intervals are comparable to those found by other 
investigators, especially with those from European 
countries. 
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IABLE 3.3. Analytical recovery of 1,Z5(OH)ZD from either 
1ml serum or 0.9% saline 
A represents actual values. B represents estimated values. 
0.9% SALINE SERUM 
1,25(OH)2D 1,25(OH)2D 
A B Recovery A B Recovery 
n pg/ml pg/ml (%) pg/ml pg/ml (%) 
Thymus 
Receptor 
Assay 4 0 0 - 0 34.3 -
4 22 17.9 81.4 22 59.7 115.5 
4 69 60.5 87.7 69 89.2 79.6 
Radw-
irrmuno 
assay 4 0 52.5 
-
0 172.5 -
4 22 117.5 
-
22 213.6 -
4 69 121.8 - 69 344.7 -
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FIGURE 3.6 Serum 1,25(OH)2D concentrations from 50 normal 
heal thy adults 
Bold horizontal lines represent the mean + 2SD for all 
values. 
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3.4 DISCUSSION: 
Since the vitamin D metabolite 1,25(OH)2D is important 
in calcium homeostasis, it is essential to establish a 
sensitive and reliable assay system for the measurement of 
serum 1,25(OH)2D in patients with a large variety of mineral 
and skeletal disorders. However, assays have been limited in 
part because of the difficulty in measuring this metabolite 
in serum, or plasma, with any accuracy. This has been 
attributed largely to non-specific factors, such as lipids 
and other vitamin D metabolites, which seem to interfere in 
its assay. 
Over the past decade several assay systems have been 
developed which have overcome these problems by introducing 
extensive extraction and purification schemes prior to 
quantification. The time-consuming schemes involving the use 
of Sephadex LH-20 columns have now been abandoned and 
instead HPLC-based methods are used sucessfully in purifying 
1,25(OH)2D from other vitamin D metabolites before its 
estimation by competitive binding radioassay, either by 
radioimmunoassay or radioreceptor assay. The work presented 
here was designed to compare the efficiency of these two 
assay systems in the measurement of serum concentrations of 
1,25(OH)2D after its extraction and purification by HPLC. 
Radioimmunoassay has proved to be a very sucessful 
method for measuring serum concentrations of 1,25(OH)2D. It 
offers the advantage of producing large quantities of stable 
gamma-globulin which, when stored under appropriate 
conditions, can be used for several years without loss of 
binding ability. This is in contrast to assay systems which 
utilise a cytosol receptor as the binding protein. Because 
of its limited stability, continual preparation of the 
cytosol receptor is necessary. However, this was not seen 
when the thymus receptor was used as binding protein. Once 
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prepared the thymic cytosol protein was stable for up to six 
months at -80°C. Reinhardt et al (1984) showed that intact 
thymus glands stored at -80°C still retained their binding 
ability. This was confirmed in the present study. Cytosol, 
prepared from a gland which had been frozen for two years, 
still demonstrated consistent binding properties (figure 
3.3). The occasional need for new supplies of thymus 
emphasised clearly the importance of the age at which the 
calf must be slaughtered. Insufficient binding activities 
were observed with thymuses from calves older than sixteen 
weeks old (figure 3.3). It is difficult to interpret this 
result because of the uncertainty as to why the thymus 
should possess receptors for 1,25(OH)2D. 
A critical step in the development of an assay system is 
the specificity of the binding protein for the hormone. Both 
assays demonstrated similar specificity towards the 
1,25(OH)2D3 metabolite. The antiserum, raised against the 
1,25(OH)2D-3-hemisuccinate coupled to bovine serum albumin, 
showed cross-reactivity with several vitamin D metabolites 
which appeared in l00-fold excess to the radio labelled 
hormone, in particular analogues which lack the 1 alpha-
hydroxyl group. The relative order of the displacement of 
bound radio ligand by several vitamin D metabolites was 
1,25(OH)2D3 > 1,25(OH)2D2 > 24,25(OH)2D3 > 25(OH)D > 
25,26(OH)2D3 > 1,24,25(OH)3D3. However, parent vitamin D2 
and D3 did not displace the bound radio ligand when added to 
assay tubes in quantities greater than l00ng per tube. 
In contrast, the thymus receptor displayed specificity 
towards vitamin D metabolites which contain an hydroxyl 
function at the C-l position on the A ring, and therefore 
demonstrated identical affinity for both 1,25(OH)2D2 and 
1,25(OH)2D3 (figure 3.2) while reacting poorly with 
metabolites hydroxylated only on the side chain. The 
relative order of displacement for the thymus receptor was 
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1,Z5(OH)ZD3 and 1,Z5(OH)ZDZ > 1,Z4,Z5(OH)3D3 > Z5(OH)D3 > 
Z4,Z5(OH)ZD3 > Z5,Z6(OH)ZD3 > vitamin DZ or D3' 
Under normal circunstances vitamin DZ metabolites 
constitute around 5% of the total vitamin D activity in 
serum (Hughes et al, 1976). However, when considering 
patients on vitamin D supplements, especially when the 
parent vitamin D administered is in the DZ form, then the 
biologically active form will be represented by both 
1,Z5(OH)ZDZ and 1,Z5(OH)ZD3' Because the affinity of the 
antiserum for 1,Z5(OH)ZDZ is less than for 1,Z5(OH)ZD3, the 
radioimmunoassay will underestimate total 1,Z5(OH)ZD. The 
radioreceptor assay, however, has the ability of measuring 
both forms equally and simultaneously and, therefore, will 
not underestimate the true value. 
Investigation into the sensitivity of each assay system 
revealed that the radioreceptor was far more sensitive than 
the radioinmunoassay. The receptor assay was capable of 
detecting as little as 1.5pg of 1,Z5(OH)ZD per assay tube 
with a useful range of measurement of 1.5-4Opg/tube compared 
with 5pg of 1,Z5(OH)ZD per tube for the irrmunoassay and a 
range'of 5-100pg/tube. These detection limits imply that for 
the estimation of serum concentrations of 1,Z5(OH)ZD the 
receptor assay will require less sample volune. Thus, to 
work within the useful ranges, approximate serum volumes 
used. were 1m1 for the radioreceptor assay and 3m1 for the 
radioinmunoassay. The large serum volumes, as in the case 
for the inmunoassay, increases the chance of interference of 
other serum vitamin D metabolites with the assay. 
Although identical extraction and purification 
techniques were performed. for both assay systems, 
interference was still prominent in the immunoassay (Table 
3.3). By no means could this interference be removed and, 
because of this, the radioimmunoassay was abandoned.. The 
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receptor assay, however, proved very sucessful, showing no 
detectable levels of 1,25(OH)2D with blank saline samples 
and an average value of 34.3pg/ml of 1,25(OH)2D with pooled 
serum samples obtained from normal individuals. 
The reproducibility of the receptor assay was confirmed 
by showing low intra- and interassay coefficients of 
variations. In addition, analytical recovery was estimated 
using two amounts- when 22pg and 69pg of standard 1,25(OH)2D 
were added to 1ml aliquots of either saline or pooled serum 
samples (Table 3.3). Recovery was found to be greater than 
75% for both samples. 
The mean value for serum 1,25(OH)2D in normal subjects 
was similar to those values obtained previously with other 
methods. In fact, the normal mean value of 35.9 (SD 7.8) 
pg/ml does not differ markedly from those of Bouillon et al 
(1980) and Hughes et al (1976), both of which utilise a 
radioimmunoassay for the measurement of 1,25(OH)2D, nor with 
Reinhardt et al (1984) who employed the same calf thymus 
receptor protein. Methods differ, however, in that they 
utilised the silica Sep-Pak cartridge rather than the HPLC 
methodology for the final purification step. When this was 
attempted unsatisfactory results were obtained. Recovery 
values for radiolabelled 1,25(OH)2D from the cartridge 
always produced values greater than 100% which implied that 
the radiolabelled 24,25(OH)2D was coeluting with the 
1,25(OH)2D. This was confirmed when the 1,25(OH)2D fraction 
was quantitated by the receptor assay. Normal pooled serum 
produced values far greater than 34pg/ml. 
When serum volumes greater than 1ml were extracted and 
purified by the two Sep-Pak method values were again 
overestimated. This could only be attributed to the lack of 
complete separation of the two vitamin D metabolites. 
However, Reinhardt et al did report that values obtained 
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from normal serum samples spiked with lOng of 24,25(OH)2D 
gave values identical to those of tmspiked samples. Other 
factors must, therefore, be interfering with the assay and 
in order to eliminate these tmknown factors the HPLC method 
was used. 
From the results presented here it is clear that for the 
measurement of serum concentrations of 1,25(OH)2D the thymus 
cytosol radioreceptor assay is acceptable; demonstrating 
high precision, reproducibility and specificity. However, 
extensive purification of the metabolite is necessary 
because serum contains factors, including other vitamin D 
metabolites, which will interfere with the assay. When 
employing this method for clinical situations it was vital 
to perform this assay under strict quality control. This was 
achieved by including reference sera and blank samples 
(saline) in each assay. 
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CHAPTER 4 
INTESTINAL CALCIUM ABSORPI'ION 
AND THE VITAMIN D MEI'ABOLlTES 
4.1 INTRODUCTION: 
The two important determinants of effective calcium 
absorption are (a) the amount of calcium in the diet and 
(b) the efficiency of its absorption (Heaney et ai, 1982). 
It is clearly recognised that 1,2S(OH)2D, the hormonally 
active vitamin D metabolite, stimulates intestinal calcium 
absorption. It could be argued, therefore, that if this 
metabolite is the sole initiator of calcium absorption in 
the gut then the rate of calcium uptake will depend largely 
upon the plasma concentration of 1,25(OH)2D. Would low 
1,25(OH)2D concentration suggest some form of calcium 
malabsorption? 
Methods for the in vivo measurement of intestinal 
calcium 'absorption have employed the use of radio labelled 
calcium isotopes, 45ea and/or 47ea• These techniques are 
based on comparing the disappearance of calcium from plasma 
after intravenous and oral administration. The single tracer 
technique uses 47 ea in monitoring intestinal calcium 
absorption (Bhandarkar et ai, 1961) whereas the double 
tracer method uses both 47ea and 45ea isotopes (Reeve et ai, 
1976) • 
The curves of the disappearance and appearence of the 
two tracers in the blood can be analysed by a process known 
as the deconvolution method to provide, in addition, the 
distributive function of absorptive rates with respect to 
time. There is no doubt that the deconvolution method 
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provides the most information about the absorption process. 
However, this method of using 45Ca and 47Ca as the two 
isotopes was inconvenient in practise because of the six 
weeks delay in calculating the results. The delay is un-
avoidable. To determine the activity of 45ea allowance must 
be made for the 47ea to decay because of its interference in 
the measurement of 45ea • This takes around 6-8 weeks. 
Therefore another rad io labelled isotope, 85Sr , having almost 
identical plasma kinetics over the first 12h after injection 
(Hart and Spencer, 1967) was used in place of 45ea• 
The double tracer deconvolution calcium absorption test, 
employing the 'use of 47ea and 85Sr has been shown to be a 
precise method in determining in vivo calcium absorption 
(Reeve et al, 1975). This method was therefore employed to 
measure intestinal calcium absorption in a selected group of 
patients with various metabolic disorders. Plasma 
concentrations of the vitamin D metabolites were also 
measured to determine whether 25(OH)D or 1,25(OH)2D had any 
relationship with intestinal calcium absorption. 
4.2 PATIENl'S AND MEl'HODS: 
All studies were carried out on a metabolic out-patient 
unit with the informed consent of the 39 patients in this 
investigation. Those patients who were on medication did not 
take any on the day of the test. 
All patients were fasted overnight and on the day of the 
test blood was removed for measurement of the vitamin D 
metabolites (sections 2.2.3 and 2.2.5). The double-isotope 
method was used to assess intestinal calcium absorption 
(section 2.2.9). After the administration of an oral dose of 
45ea and an intravenous dose of 85Sr, blood samples were 
taken at specified intervals into heparinised tubes and the 
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plasma separated. Patients were not allowed lunch until 
after the four hour sample had been taken. Aliquots (4ml) of 
each plasma sample were counted for both radio-isotopes. 
Data from each patient was then submitted to a computer 
programme kindly provided by Dr. JR Greenwell, Department of 
Physiological Sciences, University of Newcastle upon Tyne. 
This programme initially calculates for each isotope the 
percentage of the dose absorbed at a given time during the 6 
hour study. It then calculates the true absorption of 47ea 
into the intestinal tract by a method known as 
deconvolution. The calculation uses a mathematical spline 
curve-fitting procedure to enhance the change in the plasma 
concentration of the oral dose to correct for the clearance 
of the isotopes from plasma using the changing concentration 
of the intravenous isotope. By differentiating this graph 
the rate of calcium absorption can be determined. 
4.3 RESULTS: 
The procedures employed to calcula te the ini tial 
fractional rate ()0 and the total percentage calcium 
absorbed after 6h are outlined in appendix 4. Table 4.1 
shows individual patient responses to the calcium absorption 
test and their measured vitamin D metabolites whereas 
results for the different patient groups are summarised in 
Table 4.2. 
The patients with renal stones (cases 1 to 4), Barter's 
syndrome (case 5), sarcoidosis (case 6) and myeloma (case 7) 
all represented control patients. 
Four patients with osteoporosis were studied (cases 8 to 
11). All had similarly reduced values for both initial 
fractional absorption and total calcium absorbed. These 
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TABLE 4.1. Individual responses to the calcium absorption 
test and their corresponding vitamin D concentrations. 
Case No. Diagnosis 25 (OH)D 1,25(OH)2D Initial Maximal 
(ng/ml) (pg/ml) fracto Absorption 
rate (%.) (%.) 
1 Renal stones 19.3 38.4 31.0 78.2 
2 It 14.1 36.1 37.5 69.4 
3 It 7.1 20.8 6.7 50.9 
4 " 2.9 22.0 16.5 30.6 
5 Bartter I s syndrome 19.5 40.1 42.2 78.0 
6 Sarcoidosis 9.3 37.5 37.8 104.2 
7 Myeloma 11.3 4.2 18.3 53.2 
8 Osteoporosis 7.7 11.2 13.3 39.7 
9 " 33.4 14.6 1.9 34.7 
10 " 3.5 17.3 23.5 43.1 
11 " 6.3 25.7 20.2 58.4 
12 Osteomalacia: controls 4.1 22.5 19.4 32.1 
13 " 9.75 10.9 22.1 51.4 
14 " 3.1 27.3 6.5 25.9 
15 " 3.6 33.4 25.4 55.3 
16 Osteomalacia: on D3 10.2 58.1 53.0 69.9 
17 " 25.5 69.2 40.6 68.9 
18 " 21. 7 37.9 25.1 63.9 
19 " 16.5 41.5 33.3 52.6 
20 " 4.3 19.8 19.8 52.6 
21 " 41.1 53.9 31.1 40.4 
22 " 29.7 37.6 15.0 39.7 
23 " 26.2 68.9 67.1 84.6 
24 Osteomalacia: on 1 6.8 50.2 47.9 83.0 
25 " alpha 9.1 65.7 26.2 46.9 
26 " 2.8 28.0 21.4 52.5 
27 " 3.6 37.8 40.5 72.2 
28 " 3.2 33.6 25.4 55.3 
29 Osteomalacia: on 18.6 34.4 17.6 19.0 
30 " 1 alpha + Ca 2.9 36.2 51.0 91.4 
31 " 11. 7 77.0 24.9 78.1 
32 " 9.1 65.7 26.2 54.3 
33 " 3.0 27.3 6.5 25.9 
34 Hypoparathyroid 9.7 5.3 23.8 48.9 
35 " 16.9 27.4 15.9 48.3 
36 " 6.0 1.8 19.7 45.4 
37 " 4.1 14.0 22.1 54.9 
38 " 9.6 21.3 32.5 94.2 
39 " 17.0 12.1 14.7 49.5 
~ ~ 4.2. Patient group response to the calcium absorption 
test -surrmary of data from Table 4.1. ± SD 
Diagnosis Case No. 25 (OII)D 1, 25 (0II)2D Initial Ma:rlmal. 
ng/ml pg/ml frac rate X AbX 
.. E;f\I\I.t:.Sb. 
Renal stones 1 - 4 10.9 :l; 9.2 29.3 t 9.2 25.4 t. 10.6 57.3 ;t: 21.1 
Bartter's syndrome 5 19.5 40.1 42.2 78.0 
Sarcoidosis 6 9.3 37.5 37.8 104.2 
Myeloma 7 11.3 4.14 18.3 53.2 
Osteoporotics 8 - 11 10.1 :t 8.8 17.2.± 6.2 14.7 i: 9.6 44.0 ;I: 10.2 
Os teoma 1acic 12 - 15 5.2 .± 3.1 23.5 '* 9.5 18.4 ;t 8.3 41.2 :t.14.4 
on no treatment 
Os teomalacic 16 - 23 21.9 ;!:. 11.6 48.1 ;I; 17.2 35.6 *.17.4 64.3 ... 19.5 
on D3 treatment 
Osteoma1acic 24 - 28 5.1 ± 2.7 36.0 ;j; 8.7 34.7 ;t: 11.0 62.0 ;I; 15.1 
on 1 alpha 
Os t e o m a 1 a c i ~ ~ 29 - 33 9.1 ± 6.6 48.1 ± 21.8 25.3 ;t: 16.4 53.7 ;I: 31.6 
on 1 alpha + Ca 
Hypoparathyroid 34 - 39 10.6 ;I: 5.4 13.7 ;!:. 9.6 21.5 ;I; 6.4 56.9 :l; 18.6 
results agreed with those from the four untreated 
osteoma1acic patients (cases 12 to 15). However, there were 
variations in the concentrations of the vitamin D 
metabolites. The osteoma1acic patients had low 
concentrations of 25(OH)D and this was reflected in the 
corresponding low concentrations of 1,25(OH)2D. 
Concentrations of 25(OH)D in the osteoporotic patients were 
varied but 1,25(OH)2D concentrations were below the normal 
reference range in all four patients. 
The eighteen osteoma1acic patients on various vitamin D 
treatments prior to study (cases 16 to 33), produced 
statistically significant increases in their absorption 
rates and percentage absorption compared to their untreated 
counterparts. Values for the different vitamin D metabolites 
were varied especially between the osteoma1acic patients on 
the a1phaca1cidio1 treatment, either with or without calcium 
supplements. It must be emphasised that all medication was 
stopped on the day of the test and so therefore the last 
dose was the previous morning. 
The six hypoparathyroid patients (cases 34 to 39) all 
had low concentrations of 1,25(OH)2D although their 25(OH)D 
values were within the normal seasonal ranges. Initial 
fractional rates were also low but the maximal percentage of 
calcium absorbed after the six hours were within the normal 
range. 
Values for total 25(OH)D and 1,25(OH)2D concentrations 
were plotted against initial fractional absorption (figures 
4.1a and 4.1b) and total percentage calcium absorption after 
6h (figures 4.2a and 4.2b). There was a highly significant 
correlation between the initial absorption rate and plasma 
concentrations of the 1,25(OH)2D metabolite [r = 0.60; 
p<O.OOl]. Total calcium absorbed also showed a significant 
correlation with this metabolite [r = 0.56; p<0.01]. The 
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FIGURE 4.1. The relationship between the initial rate of calcium absorbed and CA) 25(OH)D 
and (B) 1,25(OH)2D concentrations in all groups. 
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25(OH)D metabolite showed no correlation with either of the 
two absorption parameters. A closer relationship between 
1,25(OH)2D and initial fractional absorption [r = 0.75; 
p<O. 001] was observed when patients on the alphacalcidiol 
medication were excluded (figure 4.3a). No such relationship 
was observed between the fractional absorption and the 
25(OH)D metabolite when these patients were removed (figure 
4.3b). 
4.4 DISCUSSION: 
The present finding that plasma concentrations of 
1,25(OH)2D correlate positively with the initial fractional 
calcium absorption rates in a random group of individuals is 
consistent with the strong belief that this vitamin D 
metabolite is an important physiological regulator of 
intestinal calcium absorption. This was further supported by 
the lack of correlation between either of the measured 
parameters of calcium absorption and the 25(OH)D metabolite. 
Previous studies have demonstrated a similar relationship, 
however, data was somewhat restricted to either normal 
individuals (Gallagher et aI, 1979) or patients with primary 
hyperparathyroidism (Kaplan et al, 1977). This study is the 
first to demonstrate such a significant correlation within' a 
wide range of patients, both with and without disorders 
relating to the vitamin D endocrine system. 
The relationship between initial calcium absorption and 
circulating concentrations of 1,25(OH)2D was partially 
masked when data from osteomalacic patients on the 
alphacalcidiol treatment were included. The 1,25(OH)2D 
analogue, alphacalcidiol, has a half life (t,l....) of 
2 
approximately 3 hours, although it varies from patient to 
patient. Since all medication was stopped on the day of the 
test, the effect of the last dose (the previous day's) would 
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FIGURE 4.3. The relationship between the initial rate of calcium absorbed and 0\) 1,25(OH)2D 
and (B) 25(OH)D concentrations -omitting patients on 1 alpha medication. 
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be receding at the time of the study. This was clearly 
demonstrated by the wide diversity of 1,Z5(OH)ZD values 
measured in these patients. However, it is difficult to 
\ , ~ e c . l f y j j on the time period to which the 1,Z5(OH)ZD will 
stimulate intestinal calcium absorption; whether it would be 
a matter of minutes or hours after the alphacalcidiol dose. 
Clearly the increased ability of the intestine to absorb 
calcium in these patients must be due to the medication 
since osteomalacic patients on no treatment demonstrated 
notably reduced absorption values. In fact, these values 
were similar to those observed for the three osteoporotic 
patients. 
Although only four patients in this study had 
osteoporosis they all demonstrated low /intestinal calcium 
absorption. Previous reports have shown that malabsorption 
of calcium is a risk factor for the development of 
osteoporosis (Gallagher et al, 1979; Nordin et al, 1985). It 
has been suggested that this could be due to one of two 
factors. Either that circulating 1,Z5(OH)ZD concentrations 
were low in osteoporotic patients and therefore contributed 
to the malabsorption of calcium or that concentrations of 
1,Z5(GH)iD were normal but the primary problem was an 
absorptive defect in the gut. The former would comply with 
this present study. In these patients osteoporosis was due 
to a primary deficiency in the 1,Z5(OH)ZD metabolite which, 
in turn, caused diminished calcium absorption and eventually 
the negative calcium balance so often seen in this disorder. 
There was a definite tendency for reduced initial 
absorption rates in the six hypoparathyroid patients. 
However, in each case, this retarded start was compensated 
for by an increased rate of absorption later. The reduced 
initial rates corresponded to the low 1,Z5(OH)ZD 
concentrations in these patients and would suggest, I) 
therefore, that the hypoparathyroid state somehow adjusts to 
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I ' 
the low values of 1,25(OH)2D and by doing so alters the 
absorptive pattern for calcium uptake in the gut. Previous 
studies by Haussler et al (1976) also demonstrated reduced 
calcium absorption rates in hypoparathyroid patients. 
The remaining patients, those with renal stones, 
sarcoidosis, myeloma and Bartter's syndrome were chosen as 
control subjects. The stone formers as well as the Bartter's 
patient were selected because their diseases did not relate 
to the vitamin D endocrine system. 
The patient with sarcoidosis represented the hyper-
calcaemic state. Hypercalcaemia in this case was due to the 
excessive extrarenal production of 1,25(OH)2D, the source of 
the which was unknown. This pa tien t was on prednisone 
therapy before the calcium absorption test was performed. 
Prednisone is known to lower plasma 1,25(OH)2D 
concentrations and therefore corrects hypercalcaemia (Bell 
et ai, 1979). This would explain the normal value attained 
for 1,25(OH)2D. Thus, it is possible that the regression of 
hypercalcaemia during prednisone therapy in this patient may 
have o c c ~ e d d because of a reduction in plasma 1,25(OH)2D 
concentration as well as a decrease in intestinal calcium 
absorption. 
Finally, the myeloma patient again represented the 
hypercalcaemic state but unlike the sarcoid patient, 
hypercalcaemia was due to factors, such as PTH or PTH-like 
factors, which caused total bone breakdown. The extremly low 
1,25(OH)2D value in this patient would suggest that PTH-like 
factors, rather than PTH itself, were the sole instigators 
of the \""'0.\ s ~ d d ( ~ k k.. \ ~ r I \ . .
In conclusion, this study has demonstrated that the 
double isotope procedure for measuring intestinal calcium 
absorption is suitable for most clinical studies, in 
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particular When required to investigate malabsorption in 
individuals. With the use of this technique the study has 
clearly demonstrated a close relationship between intestinal 
calcium absorption and the 1,Z5(OH)ZD metabolite. 
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CHAPI'ER 5 
TRFA1MENT OF SUBCLINICAL OSTEOMAlACIA 
IN THE ELDERLY 
5.1 INTRODUCTION: 
Osteomalacia is defined as the defective mineralisation 
of the organic bone matrix. This is histologically 
identified in uncalcified bone as an excess of osteoid. The 
increase in osteoid will undoubtedly lead to an increase in 
both the amount of osteoid covering trabecular surfaces and 
the seam width of the osteoid. Osteomalacia is attributed to 
several factors including a fall in dietary intake of 
vitamin 0, a reduction in the exposure to sunlight, 
malabsorption and the impairment of 1,25(OH)2D synthesis as 
a result in the decline in renal function. All these 
predisposing factors are often seen in the elderly. The 
latter factor would suggest that hydroxyl metabolites or 
analogues would be more useful than the parent vitamin 03 in 
correcting this vitamin ° disturbance and therefore 
osteomalacia. There are a few synthetic vitamin D analogues 
which have been manufactured to treat various metabolic bone 
diseases. One such analogue is 1 alpha-hydroxyvitamin 0, or 
alpl:¥icalcidiol, which by-passes the need for renal 
hydroxylation. However, Zerwekh et al (1974) demonstrated in 
rachitic chicks that alphacalcidiol must undergo 25-
hydroxylation in the liver before exerting its biological 
effects. 
Alphacalcidiol has been demonstrated to be similar to 
1,25(OH)2D in potency and clinical effectiveness, but is 
slightly slower-acting and has a longer duration of action 
in humans (Brickman et ai, 1976). While its therapeutic use 
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in treating hypoparathyroidism and renal osteodystrophy has 
been documented (Russell et aI, 1974; Davie et aI, 1976), 
its benefit in the treatment of osteomalacia is unclear. The 
present study therefore investigates the use of this 
1,25(OH)2D analogue in the correction of osteomalacia in a 
group of elderly patients. It also compares these patients 
with control patients and patients on parent vitamin D3 in 
order to evaluate which treatment would be the more 
advantageous routine in healing subclinical osteomalacia. 
5.2 PATIENTS AND METIIODS: 
The study was based on a group of 38 patients (mean age 
78.8; range 46-91) who presented with subclinical 
osteomalacia over a period of 4 years. These patients, with 
histological evidence to confirm osteomalacia, were randomly 
allocated to one of four treatment progranmes. The first 
group, consisting of nine patients, received 3000IU vitamin 
D3 daily in the form of cod liver oil capsules. The second 
and third groups, both consisting of eleven patients, 
received daily dosage of lug alphacalcidol and 
alphacalcf.diol plus calcium supplements (2Orrmol ea2+ /day: 
Ossopan), respectively. The final group (7 patients) 
received placebo. Patients with cases of severe osteomalacia 
were randomised separately between groups 1-3. Blood was 
sampled before starting treatment and after one month for 
measurement of plasma calcium, albumin, phosphate, 
creatinine, alkaline phosphatase (refer to appendix 2) and 
vitamin D metabolites (see sections 2.2.1 and 2.2.2). 
An iliac crest bone biopsy was performed after treatment 
for one month in order to assess the degree of healing of 
their osteomalacia (refer to appendix 1). The effect of 
treatment in improving intestinal calcium absorption was 
also investigated. A small number of patients from each 
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study group therefore consented to the in vivo calcium 
absorption test (section 2.2.9). 
5.3 RESULTS : 
Individual responses to treabnent are outlined in 
appendix 5 and are shown in figures 5.1 and 5.2. The overall 
responses are summarised in Table 5.1. 
During the one month study period none of ~ h e e patients 
developed hypercalcaemia (f igure 5.1) , nor was there a 
deterioration of renal function. However, alkaline 
phosphatase activity remained elevated (figure 5.1) and in 
the control group values markedly increased after a month 
under investigation [0.01< p <0.05J. 
Patient compliance with treabnent was satisfactory, as 
shown by the significant increases in circulating 
concentrations of 25(OH)D3 (for patients on vitamin D3) and 
1,25(OH)2D (for patients on alphacalcidiol and alpha-
calcidiol plus calcium). Only one patient was subsequently 
excluded from the study for not taking the prescribed 
tablets (see figure 5.2). Pretreabnent values of 25(OH)D 
concentrations were below the normal age-matched reference 
range (refer to section 2.2.3) and did not show seasonal 
variation (figure 5.3). Those patients on vitamin D3 
treabnent demonstrated significant increases in their 
25(OH)D values [p<O.OOlJ after a month of treabnent. In 
contrast to the low pretreabnent concentrations of 25(OH)D, 
basal 1,25(OH)2D concentrations were varied, for all groups 
under investigation, but generally were within the lower end 
of the reference range (figure 5.2). 1,25(OH)2D 
concentrations also increased significantly in patients on 
treatment. Values for the vitamin D metabolites were 
unchanged in the control group. 
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~ L E E 5.1. Summary of b i o c h e ~ i c a l l and histomorphometric responses to t r e a ~ ~ e n t . .
Variable Treabnent Mean at Mean at Significance 
Baseline 1 month Change 95% Confidence P 
(tsn) (± 51)2 Interval 
Calcium Control 2.02 (0-\<1) 2.09 (.Hi) +0.07 -0.07 to +0.22 
(nmol/L) D3 2.13 (021) 2.26 t o . o ~ ) ) +0.13 -0.09 to +0.35 
1 alpha 2.06 (Ol.'i) 2.18 ( , ) - I ~ ) ) +0.12 -0.02 to +0.26 
1 alEha + Ca 2.12 ( ( ) . 2 . ~ ) ) 2.23 (0-11.) +0.11 -0.01 to +0.20 < 0.05 
Creatinine Control 147 L,+') 144 (30) -3 -47.9 to +41.9 
(umol/L) 
°3 103 (30) 111 ('2.1) +8 -6.5 to +22.7 
1 alpba 124 ~ t ) ) 122 (4-5) -2 -18.1 to +13.4 
1 alpha + Ca 93 c ~ t . ) ) 97 ('!.,,) +4 -12.8 to +21.0 
Alkaline Control 423 (l(.,1) 722 b'l) +299 -309 to +906 
Phosphatase 
°3 538 C ~ ' i l j . ) ) 713 (bOZ.) +174 -81 to +430 
(lU/L) 1 alpha 751 970 +219 -405 to +843 
1 alpha + Ca 449 6 .. ~ ) ) 440 (l(,,1f) -9 -149 to +132 
25(OH)D3 Control 14.1 (ra;)) 8.6 l 4 . ' ~ ) ) -5.5 -9.1 to +1.7 
(ng/ml) 
°3 4.7 (H.,) 22.4 { ~ · o } } +17.7 +9.2 to +26.2 < 0.005 
1 alpha 4.6 (t-,) 7.4 ll+") +2.8 -3.6 to +9.2 
1 alpha + Ca 3.6 11:1.' 5.8 h'l4-) +2.2 -1.8 to +6.3 
LAaLE 5.1. Summary of biochemical and histomorphometric responses to treatment contd. 
Variable Treatment Mean at Mean at Significance 
Baseline 1 month Change 95% Confidence P 
(o±. $;b) (:1:$])) Interval 
1,25(OH)2D3 Control 14.3 ( ~ ' 4 ) ) 8.6 ({))) -5.7 -12.2 to +3.4 
(pg/ml) D3 18.2 (l1s) 50.9(\2,") +32.7 +16.1 to +49.4 < 0.005 
1 alpha 16.9 (S".'6) 36.5 tis) +19.6 +16.8 to +22.4 < 0.001 
1 alEha + Ca 12.0 ~ . : r ) ) 46.3 62-,) +34.3 +16.6 to +51.9 < 0.005 
Osteoid Area Control 31.2 {(t.e;) 25.0 ( \ ~ - I ) ) -6.3 +0.1 to -12.7 
(OA) D3 25.3 (110-2.) 18.3 (10- 0 ) -7.0 +0.2 to -14.2 
1 alpha 24.6 (llo·GO 20.0 (Ii-I) -4.6 +0.5 to -9.8 
1 alEha + Ca 26.5 (Ilrol;,) 17.3 ( l l - ~ ) ) -9.2 -0.6 to -17.9 < 0.05 
Osteoid Control 73.1 (,-cH) 60.6 (:n-2,) -12.5 +26.2 to -51.2 
Surface D3 63.0 (tvi) 59.5 ( 2 V ~ ) ) -3.5 +6.9 to -13.9 
(OS) 1 alpha 62.9 (z'fj'·9) 61.3 ( ! - 1 - ' ~ ) ) -1.6 +12.6 to -15.8 
1 alpha + Ca 68.2 (n·CI) 54.9 ('n'-t) -13.3 -6.1 to -20.5 < 0.005 
Osteoid Control 0.41 (o-tt.) 0.38 (0-1<1-) -0.03 +0.10 to -0.07 
Index D3 0.38 (.."II) 0.29 (O.O"!) -0.09 -0.01 to -0.16 < 0.05 
(01) 1 alpha 0.38 ( o . \ ~ ) ) 0.29 to .(4) -0.09 -0.02 to -0.15 < 0.05 
1 alEha + Ca 0.36 (o·\$') 0.30 (o.D"!) -0.06 +0.02 to -0.16 
p values relate to significance on paired t-test 
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FIGURE 5.1. Change in plasma calcium concentrations and 
alkaline phosphatase activity after one month's treatment. 
Dotted horizontal lines represent the normal range. 
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FIGURE 5.2. Change in 25(OH)D and 1,25(OH)2D concentrations after 
one month's treatment. 
Dotted horizontal lines represent the normal range. 
*Patient omitted for not complying to treatment. 
FIGURE 5.3. Plasma 25(OH)D concentrations from elderly 
osteomalacic patients sampled throughout the year. 
Pretreatment values show no seasonal variation. 
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There were no statistically significant differences 
between the three treatment regimes with respect to changes 
in histomorphometric indices (figure 5.4 and Table 5.1). 
Osteoid area showed a decrease with all three treatments but 
this was statistically insignificant in each case. Only 
those patients treated with the alphacalcidiol plus calcium 
combination showed a significant decrease in surface extent 
of osteoid [p<O.Ol]. In contrast, those treated with either 
vitamin D3 or alphacalcidiol alone showed a significant 
decrease in osteoid seam thickness [p<0.05 and 0.01, 
respectively]. There were no significant changes in the bone 
histology of the control patients during the one month study 
period (Table 5.1). 
Individual responses to the in vivo calcium absorption 
test are shown in figure 5.5. The absolute values for 
calcium absorption in the pre-treatment patients were 
substantially lower compared with data obtained from 
patients on medication. However, all three treatment 
programnes showed statistically significant increases in 
absorption rates as well as similar trends in total 
percentage calcium absorption. 
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FIGURE 5.4. Changes in histomorphometric indices over 1 month. 
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5.4 DISCUSSION: 
The high incidence of osteomalacia in the elderly has 
been doctnnented in many studies (Hodkinson et al, 1973; 
Aaron et al, 1974) but many cases probably go unrecognised 
and untreated because the disease is often subclinical. The 
major aetiological factor associated with the high incidence 
of osteomalacia in the elderly is inadequate exposure to 
sunlight, possibly due to immobility in a population whose 
dietary intake of vitamin D is low. Many of these patients 
are either hospitalised for long-term geriatric care or are 
housebound due to a combination of chronic diseases. As well 
as these two factors which play a role in the development of 
osteomalacia others include intestinal malabsorption as well 
as a decline in renal function. Renal problems will 
undoubtedly impair the conversion of 25(OH)D to the active 
hormonal vitamin D metabolite 1,25(OH)2D. Once osteomalacia 
is identified treatment must be administered carefully and 
effectively. 
The present study was devised to investigate the use of 
the s y n t ~ e t i c c derivative of vitamin D3, alphacalcidiol, in 
the effective treatment of subclinical osteomalacia. 
Further, since calcium supplementation in the elderly has 
produced some degree of slowing of age-related bone loss, 
the use of this derivative with calcium supplements was also 
investigated. These actions were compared with those of 
parent vitamin D3 which is conventionally used in the 
treatment of osteomalacia. 
The study has confirmed that all three treatment regimes 
under investigation were safe to administer. No patient 
developed hypercalcaemia during the one month clinical 
trials and those on parent vitamin D3 medication showed no 
indication of vitamin D intoxication. Hypercalcaemia is the 
primary hazard during therapy with any of the vitamin D 
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derivatives and may be associated with potentially serious 
complications, particularly in old age. It is well known 
that prolonged excessive intake of vitamin D can also result 
in deterioration in renal function as well as extra-osseous 
calcification, the latter appearing in many soft tissues 
including kidney, heart, lung and arterial walls (Parfitt et 
al, 1982). The mechanism by which this occurs is still not 
clear although it has been suggested that it is related to 
the enhanced intestinal calcitnn absorption and bone 
resorpti()D. which accompanies hypervitaminosis D. None of 
these symptoms were encountered during the term of the 
present investigation. However, had hypercalcaemia been 
induced by alphacalcidiol this would have easily be reversed 
by simply withdrawing the medication. Because of its short 
half life ( t ~ ~ = 3.4 ~ ~ 0.4 days) the toxic effect would have 
resolved relatively quickly. This does not hold true for the 
parent vitamin. Loss of toxic effects, and therefore 
hypercalcaemia, would exist for appreciably longer, probably 
between 17 to 60 days because of its slow release from 
storage tissues such as adipose and liver. 
Basal alkaline phosphatase activities were invaribly 
raised in all patients indicating that osteomalacia was 
accompanied by high bone turnover. However, none of the 
treatment regimes was able to reduce these values 
significantly possibly due to the short period of 
investigation. In some of the patients on treatment there 
was an initial paradoxical increase in alkaline phosphatase 
activity after one month. This is not necessarily surprising 
since healing of bone may take several months to complete 
and will depend on the initial severity. Approximately 30% 
of patients were still hypocalcaemic after treatment for one 
month although it was evident in most of these patients that 
if treatment had been continued beyond one month they would 
have probably achieved the normocalcaemic state. 
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The plasma concentration of 25(OH)D is a valid index of 
vitamin 0 status in the body (Preece et al, 1975). The 
present study showed quite clearly that, compared with 
healthy adults, patients with osteomalacia were indeed 
vitamin 0 deficient. This statement holds true when sampling 
throughout the year. Basal 1,25(OH)2D values were usually 
reduced in the osteomalacic patients or remained within the 
lower end of the normal reference range. That these values 
increased substantially after vitamin 0 therapy, either with 
alphacalcidiol or parent vi tamin 0 itself, reinforces the 
general idea that the cause of osteomalacia was indeed a 
deficiency in the parent vitamin rather than a defect in 
renal hydroxylation. 
The reduced vitamin 0 status in these patients also 
suggested a decreased absorption of calcium in the 
intestine. Calcium absorptive efficiency has been noted to 
decline with advancing age and has been linked with the fall 
in vitamin D status (Parfitt et al, 1982). Large fractions 
of the middle-aged and elderly population have low 
concentrations of the essential vitamin 0 metabolites (both 
25(OH)D .and 1,25(OH)2D). Thus, any further decline in these 
concehtrations will result in a decline in absorptive 
efficiency. This has clearly been demonstrated here. 
Untreated control patients who consented to the in vivo 
calcium absorption test demonstrated reduced calcium 
absorption in the gut compared with their treated 
counterparts. Treabnent with either of the vitamin 0 
medications obviously led to a positive calcium balance as 
demonstrated by increases in intestinal calcium absorption 
at the time when plasma 1,25(OH)2D concentrations were 
elevated. However, there were no substantial differences in 
the percentage calcium absorbed between patients on either 
of the vitamin D treabnent regimes. The present observations 
therefore confirm that the vitamin 0 analogue is as 
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effective as parent vitamin D3 in the stimulation of 
intestinal calcium absorption. 
There was no evidence to suggest that any of the 
treabment regimes accelerates the rate of healing. Changes 
in bone histology showed a similar trend in all three 
treatments. There was considerable improvement in most 
patients with one exception, the patient on the alpha-
calcidiol treatment who did not take the medication. It was 
interesting to find that alphacalcidiol with the addition of 
calcitnn supplements showed no advantage over the analogue 
alone in the healing process. Previous studies (Hosking et 
aI, 1983) demonstrated slight improvement in bone histology 
after three months of treatment with alphacalcidiol compared 
with vitamin D3. 
To conclude, 
sterols (vitamin 
in the treabment of osteomalacia both 
D3 and alphacalcidiol) performed 
successfully, if not effectively, in bringing about the 
healing process. Both were equally capable of restoring 
calcium absorptive efficiency in the intestine after one 
month's treatment and thus the choice of vitamin D would 
appear arbitary. But, since parent vitamin D is considerably 
less expensive than alphacalcidiol it would seem reasonabe 
to suggest that this should be the treabment of choice. 
However, in cases where renal impairment is present it would 
be advisable to prescribe the 1,Z5(OH)ZD analogue. Whichever 
sterol is used it is advisable to monitor plasma calcium 
concentrations frequently and, if possible, the vitamin D 
metabolites at regular intervals. 
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CHAPI'ER 6 
CHANGES IN OSTEOCALCIN AND VITAMIN D METABOLITES AFTER 
FRACTURE OF THE FEMORAL NECK 
6.1 INTRODUCTION: 
The presence of osteomalacia complicating femoral neck 
fractures is now less frequently seen. In a recent large 
survey of 422 femoral neck fracture cases only 2% had 
underlying osteomalacia (Wilton et ai, 1987a). However, it 
is still an important criterion to identify because of the 
effect it has on fracture fixation and patient mobilisation. 
To date there is no biochemical marker which is able to 
distinguish 
osteoporosis 
means of 
osteomalacia from the almost inevitable 
in this fracture group and, thus, the only 
successfully identifying every case of 
osteomalacia, however mild, is to perform an iliac crest 
bone biopsy on all femoral neck fracture patients. Wilton et 
al (1987b) recently suggested a means of detecting all the 
severe' cases of osteomalacia by employing the combination of 
hypocalcaemia and a raised alkaline phosphatase. However, 
this combination has a high false positive rate since 
alkaline phosphatase, the conventional marker used in 
determining bone turnover, originates not only from bone but 
also from other sources such as the liver. Furthermore, 
alkaline phosphatase is often raised in non-osteomalacic 
elderly patients both with and without fracture (Wilton et 
ai, 1987b, Campbell et ai, 1984). Thus, this marker gives a 
less specific estimation of bone formation. 
Osteocalcin (BGP, bone GIA protein), the major non-
collagenous protein of bone matrix, is produced solely by 
osteoblasts and has been shown to reflect directly the level 
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of new bone formation (Lian and Gundberg, 1988). The 
synthesis of this vitamim K-dependent bone protein, fotmd 
circulating in plasma, is subject to stimulation by 
1,25(OH)2D (Price, 1980). Although its precise biological 
function in bone is still unclear, it has been found to be a 
sensitive indicator of bone turnover in patients with a 
variety of metabolic bone diseases. 
The recent availability of radioirmrunoassays for 
osteocalcin raises the possibility that it may be a more 
specific screening test for osteomalacia than measuring 
serum alkaline phosphatase activity. However, the main 
advantage of measuring serum alkaline phosphatase in this 
instance is that its activity changes little during the 
first week after a fracture (Hosking, 1978) and therefore 
reflects the 'pre-fracture' state. No such information about 
changes in concentration during the immediate post fracture 
period is available for osteocalcin. This chapter describes 
changes in osteocalcin concentrations in the first week 
following a femoral neck fracture and its fixation. It also 
examines its relationship with alkaline phosphatase, the 
vi tamin D metabolites and bone histomorphometry. Indeed, 
this is a necessary step before attempting to assess its 
value, if any, in the screening of subclinical osteomalacia 
complicating femoral neck fracture. 
6.2 PATIENTS AND ME1HODS: 
The study comprised 30 patients (3 males and 27 females; 
mean age 78yrs; range 58-92 yrs) who had sustained a 
traumatic fracture of the femoral neck. The criterion for 
entry into this study was that perioperative investigations 
had excluded osteomalacia. All had osteoporosis. None were 
taking calcium or vitamin D supplements before or during the 
study. Fasting blood samples were taken preoperatively from 
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all patients (within 24h of the fracture), and repeated one 
week later, by which time all fractures had been treated by 
internal fixation. All blood samples were collected into 
lithium heparin and the plasma stored at -20°C until assay. 
Plasma calcium, phosphate, creatinine, albumin 
concentrations and alkaline phosphatase activity were 
measured by standard laboratory techniques and calcium 
concentrations corrected to a plasma albumin level of 40g/L 
(appendix 2). Plasma osteocalcin and PTH concentrations were 
measured by radioirrmtmoassay (sections 2.2.6. and 2.2.8., 
respectively) and the vitamin D metabolites by competitive 
protein binding assays (see appropriate sections). DBP 
concentrations were measured by radial immtmodiffusion 
(section 2.3.5). Free 25(OH)D and 1,25(OH)2D indices were 
calculated as the molar ratio 25(OH)D!DBP x 103 and the 
molar ratio 1,25(OH)2D!DBP x 105, respectively. These molar 
ratios give good estimations of free vitamin D 
concentrations CLips et al, 1985). Iliac crest bone 
biopsies were performed perioperatively on all patients to 
exclude the presence of metabolic bone diseases other than 
osteoporosis. Measured histomorphometric indices were as 
described in appendix 1. 
For comparative purposes, an additional 9 patients (1 
male and 8 females; mean age 81yrs, range 74-89) who 
fulfilled the criterion for entry into this study, were 
included. However, these patients had raised alkaline 
phosphatase activity on admission and were only studied 
once; within 24 hours of their fracture. 
Reference values for osteocalcin, vitamin D metabolites 
and binding protein were derived from a group of age- and 
sex-matched normal individuals (8 males and 13 females; mean 
age 70yrs; range 60-81). Both patients and control subjects 
were studied throughout the year. 
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6.3 RESULTS: 
Individual values of plasma biochemistry and histo-
morphometric indices are outlined in appendix 6 and 
surnmerised in Table 6.1. Changes in plasma calcium, 
phosphate, alkaline phosphatase and creatinine in the first 
week after a femoral fracture are shown in figure 6.1. Only 
four patients had raised alkaline phosphatase activity on 
admission, and in three cases other liver function tests 
were abnormal (ganma GT = 135, 224 and 294 lulL: normal 
range 11-51 IU/L). Alkaline phosphatase activity in the 
majority of patients increased during the first week after 
the fracture but this difference did not reach a statistical 
significance [p = 0.097]. While forty-five percent of 
patients were hypocalcaemic at some stage of this study, 
concentrations of phosphate and creatinine generally 
remained within the age-matched reference range (figure 
6.1). 
Figure 6.2a shows individual changes in osteoca1cin, DBP 
and PTH concentrations, whilst those for free and total 
25(OH)D ~ n d d 1,25(OH)2D are depicted in figure 6.2b. PTH 
concentrations were not measured in all patients, but in 
cases where they were, values remained either undetectable 
or at the lower end of the reference range throughout this 
study. Over half the patients had admission values of total 
and free 25(OH)D and DBP concentrations below the reference 
ranges, although both free and total 1,25(OH)2D were less 
commonly abnormal. All the initial concentrations of 
osteoca1cin lay below the upper limit of the reference 
range, even in those selected because of a raised alkaline 
phosphatase (refer to table in appendix 6). Moreover, the 
increments in osteoca1cin which occured within the first 
week after the fracture also lay below this limit with only 
one exception. In contrast, of the 22 patients with a normal 
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TABLE 6.1. Changes in plasma biochemistry after fracture 
of the femoral neck. 
FEMJRAL NECK FRACTURE 
( n = 30 ) 
PARAMETER Basal 1 week 
mean + 2SD 
Calcium 
(nmol/L) 2.24 (+ 0.14) 2.27 (+ 0.14) 
Phosphate 
(nmol/L) 1.21 (+ 0.32) 1.11 (+ 0.18) 
Alkaline Phosphatase 
(lU/L) 208.5 (+ 143) 269.5 (+ 184) 
Creatinine 
(umol/L) 96.9 (+ 19.4) 104.8 (+ 45) 
Osteocalcin 
(ng/ml) 3.07 (+ 1.8) 3.74 (+ 1.9)")'( 
Vitamin DBP 
(mg/L) 295 (+ 65.3) 347 (+ 77)* 
Total 25(OH)D 
(ng/ml) 6.1 (+ 5.5) 4.3 (+ 2.6) 
Total 1,25(OH)2D 
(pg/ml) 16.5 (+ 12.9) 18.3 (+ 8.8) 
Free 25(OH)D index 
(x 103) 2.32 (+ 1.37) 2.02 (+ 1.5) 
Free 1,25(OH)2D index 
(x 105) 0.78 (+ 0.4) 0.77 (+ 0.46) 
Test of significance between basal and one week values 
* p < 0.01 
REFERENCE 
RANGE 
2.2-2.6 
0.8-1.4 
98-280 
60-120 
3.2-8.1 
284-373 
6.0-17.8 
11.2-30.1 
2.57-9.45 
0.44-1.28 
FIGURE 6.1. Changes in plasma calcium, phosphate, creatinine and 
alkaline phosphatase in the first week after femoral neck fracture 
and its fixation. 
Normal ranges (mean + 2SD) are shown within the dashed lines. 
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alkaline phosphatase activity on admission, five rose to a 
level above the upper limit of normal after one week. 
Of all parameters measured only the concentrations of 
osteocalcin and DBP increased significantly within the week 
following fracture and its fixation [p = 0.0039 and 0.0022, 
respectively]. There were no significant changes in the 
vitamin D metabolite concentrations, neither free nor total. 
Basal values of osteocalcin concentrations did not show 
a significant correlation with alkaline phosphatase (figure 
6.3a), DBP or with total or free values of the vitamin D 
metabolites. Figure 6.3b illustrates the lack of 
relationship between osteocalcin and total 1,25(OH)2D. 
However, there were strong correlations [p<0.001] between 
the changes in osteocalcin concentration and those of total 
and free 1,25(OH)2D (figure 6.4). No such relationship was 
observed with respect to 25(OH)D (figure 6.5), DBP or 
alkaline phosphatase activity. Neither was there a 
relationship between alkaline phosphatase and 1,25(OH)2D. 
There was no statisticailly significant correlation 
between the admission concentrations of osteocalcin or 
alkaline phosphatase and the surface extent of osteoid, an 
index of bone ~ o r m a t i o n n (figure 6.6) or with osteoid area or 
osteoid seam thickness. This is also true when values from 
the nine osteoporotics with elevated alkaline phosphatase 
activity were included. This seemed to be due to some 
patients with apparently adequate bone turnover, as judged 
by the extent of osteoid surfaces, having low values of 
osteocalcin (figure 6.6). However, when these patients were 
stratified according to the prevailing level of total 
1,25(OH)2D, the low osteocalcin concentrations appeared to 
be associated with very low concentrations of this vitamin D 
metabolite (figure 6.7). 
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FIGURE 6.3. Relationship between osteocalcin concentrations 
and (a) alkaline phosphatase activity and (b) total 
1,25(OH)2D concentrations. 
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6.4 DISCUSSION 
Os teocalcin , the vitamin K-dependent protein of bone, is 
synthesised by osteoblasts (Price et al, 1981). Previous 
studies have shown it to be a noninvasive specific marker of 
bone formation in various metabolic bone diseases (Lian and 
Gundberg, 1988) • I t may be a more spec if ic marker than 
alkaline phosphatase because the latter originates not only 
from bone, but also from liver, kidney and placenta. There 
is a tendancy to find raised alkaline phosphatase values in 
the elderly, particularly in those with no evidence of bone 
disease. This is probably attributable to mild liver 
dysfunction. 
In the present study of very elderly patients with 
femoral neck fractures neither osteocalcin concentrations 
nor alkaline phosphatase activity correlated with measured 
histomorphometric parameters of bone formation. Previous 
studies of younger women with osteoporosis (Price et al, 
1980b; Brown et al, 1984) demonstrated a correlation between 
osteocalcin and bone formation. Our patients were much older 
than those in previous studies but since osteocalcin 
concentration tends to rise with age (Delmas et al, 1983a) 
this cannot be an explanation for these findings. The 
problem seemed to be that a significant proportion of these 
elderly patients with bone turnover towards the upper part 
of the reference range had low concentrations of 
osteocalcin. A number of possible explanations for this 
observations need considering. 
Plasma osteocalcin has a short half life (Price et aI, 
1981) and may be depressed by the stress associated with a 
fracture. A similar mechanism has been proposed for the 
reversible depression of DBP (Lips et al, 1985), which was 
also demonstrated in this present study. However, the lack 
of a correlation between these two variables in the week 
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after the fracture argues against a common mechanism. It is 
possible that stress might depress osteocalcin through 
adrenal stimulation since such an effect has been reported 
with the use of glucocorticoids (Lukert et ai, 1986). 
Unfortunately plasma cortisol was not measured in these 
patients, but is likely to be increased. 
Although the precise biological function of osteocalcin 
is still unclear it may play a role in bone mineral 
deposition (Lian and Gundgerg, 1988). No function has been 
assigned to osteocalcin in the circulation and therefore, 
any increase in plasma concentration probably reflects the 
portion of newly synthesised protein not bound to the 
mineral phase of bone (Price and Nishimoto, 1980). With the 
significant rise in osteocalcin concentrations during the 
one week study period one could speculate that this rise is 
a direct effect of the fracture. Even though osteocalcin 
values increased they remained within the lower end of the 
reference range. This is in contrast to the report by Slovik 
et al (1984) who found elevated values in a group of hip 
fracture patients who had undergone similar operative 
treatment. However, the timing of blood sampling was not 
given and it may be that the elevated osteocalcin 
concentrations reflected a later phase of callus formation. 
Another report, from Borsalino et al (1985), also 
demonstrated contrasting data. They showed that osteocalcin 
concentrations reduced significantly in the first five days 
after orthopaedic surgical operations but again sampling 
time after the fracture was not specified. 
The concentrations of osteocalcin tended to be 
associated with very low concentrations of 1,25(OH)2D 
«lOpg/ml). That 1,25(OH)2D may be an important factor is 
supported by the further observations that although there 
was no correlation between the absolute concentrations of 
osteocalcin and 1,25(OH)2D, there was a relationship between 
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the changes in these variables in the first week after the 
fracture. This is consistent with the observation that while 
osteoblast production of osteocalcin is stimulated by 
1,25(OH)2D in cell culture (Price and Baukol, 1980; Silve et 
ai, 1986), it does not appear to be vitamin D dependent. 
There are several possible explanations for the observed 
relationship between osteocalcin and 1,25(OH)2D, as outlined 
in figure 6.8. It may be that as the fracture heals 
calcification of callus results in the slight fall in serum 
calcium (refer to route a in figure 6.8), leading to 
stimulation of PTH secretion and augmentation of 1,25(OH)2D 
production with further enhancement of osteocalcin 
production. Alternatively, the production of the fracture 
callus, by stimulating osteoblastic production of 
osteocalcin, leads to the movement of calcium into bone with 
secondary effects on 1,25(OH)2D synthesis mediated via 
hypocalcaemia (route b of figure 6.8). A direct relationship 
between 1,25(OH)2D and osteocalcin seems most likely since 
in vitro studies on human osteoblast-like cells (Lian et ai, 
1985) and cultures of foetal rat bone (Skjodt et ai, 1985) 
have c o n f ~ r m e d d that 1,25(OH)2D has a stimulatory effect on 
osteocalcin synthesis. 
The necessary increases in PTH and 1,25(OH)2D were not 
seen in the present study but this may reflect either the 
insensitivity of the assays used to small changes or those 
changes may have diminished when sampled a week after the 
fracture. In the case of the vitamin D metabolite, absolute 
concentrations and sequential changes showed considerable 
individual variation and perhaps for this reason the paired 
values for the study, as a whole, did not show a 
statistically significant increase. 
In conclusion, the determination of the precise role of 
osteocalcin in bone, and its physiological role in fracture 
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FIGURE 6.8. Two possible theories for the observed relationship 
between osteocalcin and 1,25(OH)2D during fracture healing. Refer 
to discussion section for explanation. 
Bold arrows indicate route A; dashed arrows indicate route B. 
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healing, require further study. It remains to be seen 
whether osteocalcin is useful in screening very elderly 
patients with femoral neck fractures with osteomalacia. 
Experience with the use of osteocalcin for this purpose is 
surprisingly limited. The generation of diagnostically 
useful raised values may depend critically on the opposing 
effects of 1,25(OH)2D deficiency and the ability of the very 
elderly to increase both PTH secretion and bone formation. 
The timing of sampling is also critical. The present study 
shows that osteocalcin concentrations remain within the 
reference range within the first week after a fracture. 
Other studies where the timing of samples were not stated, 
found elevated values, further complicating, and diminishing 
the diagnostic usefulness of this measurement. 
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CHAPTER 7 
VITAMIN D DEFICIENCY AND FEMORAL NECK FRACTURE 
7.1 INTRODUCTION: 
Despite earlier reports to the contrary (Aaron et ai, 
1974; Jenkins et ai, 1973), a recent large survey has shown 
that osteomalacia is now an uncorrrnon accompaniment of 
femoral neck fractures in the elderly (Wilton et ai, 1987a). 
Moreover, in another population potentially at risk, the 
acutely ill elderly, the prevalence of su1x:.1inical 
osteomalacia also appears to be low (Campbell et ai, 1986). 
It is uncertain whether the decreased frequence of 
osteomalacia reflects improved nutrition of the elderly or 
whether there is some other explanation. The former seems 
unlikely since the limited data which is available suggests 
that circulating concentrations of 25(OH)D are low in the 
elderly both with and without femoral neck fracture (Baker 
et ai, 1979; Brown et ai, 1976; Weisman et ai, 1978;). The 
situation is particularly confused with respect to 
1,25(OH)2D where concentrations have been reported to be 
either low, normal or high (Francis et ai, 1984; Hordon and 
Peacock, 1987; Lips et ai, 1987; Meller et ai, 1985). This 
apparent paradox between the decreasing incidence of 
osteomalacia despite vitamin D deficiency and the currently 
high incidence of osteoporotic femoral neck fractures seems 
to be at variance with the accepted role of vitamin D in the 
maintenance of calcium and skeletal homeostasis. 
In the present study serum concentrations of the 
hydroxylated vitamin D metabolites were measured in elderly 
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patients at the time of presentation with femoral neck 
fractures. Comparisons between those with and without 
osteomalacia have been made in an attempt to assess the 
pathogenetic significance of vitamin D deficiency in this 
age group. 
7.2 PATIENTS AND METHODS: 
The study was based on a group of patients obtained from 
a 4 year screening progranme, designed to detect sub-
clinical osteomalacia in elderly patients presenting with a 
femoral neck fracture. All patients in this present study 
underwent an iliac crest bone biopsy at the time of their 
operation. Osteomalacia was defined as a relative osteoid 
area greater than 5% of the total trabecular area with 
osteoid covering more than 25% of the total trabecular 
surface (Wilton et ai, 1987a). 
A total of three groups were studied. The first group 
consisted of 41 patients with a femoral neck fracture 
without osteomalacia (mean age 79 years; range 59-94 years). 
The second consisted of 26 patients (mean age 82 years; 
range 57-95 years) who had osteomalacia at the time of their 
femoral neck fracture. The third group comprised of 12 young 
osteomalacic patients without fractures (mean age 48 years; 
range 43-58 years) who had been referred to the metabolic 
unit over the same period. 
Fasting blood samples were taken from all patients 
within 24h of admission for the measurement of serum 
calcium, phospha te, creatinine, alkaline phosphatase and 
albumin (refer to appendix 2). Samples for the measurement 
of vitamin D binding protein and vitamin D metabolites were 
taken on a separate occasion but generally within the first 
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few days after admission. For further timing of these 
samples refer to appendix 7. 
Reference values for vitamin D metabolites and binding 
protein were obtained from normal elderly subjects (mean age 
70 years; range 60-82 years), selected from relatives of 
patients attending a metabolic out-patient clinic. These 
patients appeared well and none was known to suffer from 
renal, gastrointestinal or musculoskeletal diseases. 
Reference data was also derived from 45 young normal 
subjects working in the hospital laboratories (mean age 34 
years; range 18-54 years). 
7.3 RESULTS: 
Individual plasma biochemistry and histomorphometric 
indices are outlined in appendix 7. 
Serum concentrations of 25(OH)D and 1,25(OH)2D for all 
the groups under investigation are shown in figure 7.1. The 
( ~ S D ) ) . 
mean 1Serum 25(OH)D and 1,25(OH)2D concentrat1ons of the 26 (:I: ..,.2.) ( t!f. , ) 
normal elderly subjects were 12.8 A ng/ml and 21.6" pg/ml 
respectively while the c o r r ~ s p o n d i n g g values for the 42 young 
(:1: (.Ij..) l±.. q·3) 
normal subjects were JQ.4 ~ ~ ng/ml and 34.6). pg/ml. These 
differences between age groups were significant: [25(OH)D 
p<O.02; 1,25(OH)2D p<O.Ol]. Vitamin D concentrations were 
predictably low in both young and elderly patients with 
osteomalacia. However, a considerable number of the elderly 
controls (who did not have a bone biopsy) and the elderly 
fracture patients without osteomalacia also had equally low 
concentrations of 25(OH)D and 1,25(OH)2D. There was no 
statistically significant difference between the 
measurements of the vi tamin D me tabo li tes in any of the 
elderly groups. 
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FIGURE 7.1. Serum 25(OH)D and 1,25(OH)2D concentrations in 
the elderly patients with fractures, control subjects and 
young patients with osteomalacia. 
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The severity of the osteomalacia, as judged by the 
osteoid area (O.A.) showed no significant correlation with 
either of the vitamin D metabolites [25(OH)D v O.A. r = 
-0.14 p NS; 1,25(OH)2D v O.A. r=O.05 p NS]. The 
relationship between 1,25(OH)2D and osteoid surface for the 
fracture patients without osteomalacia is shown in figure 
7.2. Many of those with low concentrations of 1,25(OH)2D 
also had low rate of bone turnover, as assessed from the 
surface extent of osteoid and this tended to be associated 
with hypocalcaemia. Under these circumstances, osteoid seam 
thickness is difficult to measure with any degree of 
accuracy but where this could be done, in patients with 
osteoid greater than 12.5%, a high proportion of the 
osteoporotic patients with low 1,25(OH)2D concentrations had 
abnormally thick osteoid seams (figure 7.3). This suggests 
that there was a defect in the mineralisation of newly 
formed osteoid, even though osteoid had not accumulated to a 
sufficient extent to fulfil the criteria for a diagnosis of 
osteomalacia. 
Serum concentrations of the vitamin D metabolites and 
DBP have the potential for more rapid change than any of the 
histomorphometric parameters. Therefore, in order to assess 
whether the interval between hospital admission and blood 
sampling was an important determinant for the low 
concentrations of 1,25(OH)2D, both DBP and 1,25(OH)2D are 
shown in relation to the time of blood sampling (figure 
7.4). In neither case was time an important variable, even 
though measurements of DBP were only available from 30 of 
the 41 patients. 
Another important factor to consider is whether the 
stress of a fracture lowers the concentration of DBP which 
might account for the low 1,25(OH)2D concentrations found in 
these elderly fracture patients. Measurements of DBP were 
only available from 56/80 patients and 19/26 elderly 
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FIGURE 7.2. Relationship between serum 1,25(OH)2D and bone 
turnover (extent of osteoid surface). 
o - osteoporotic patients with FNF 
• - osteomalacic patients with FNF 
FIGURE 7.3. Relationship between serum 1,25(OH)2D and osteoid 
index. 
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FIGURE 7.4. Relationships between serum vitamin D binding 
protein (DBP) and 1,25(OH)2D and the delay between admission 
and sampling. 
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Dotted horizontal lines represent the normal reference range 
for DBP and the lower end of the reference range for 1,25(OH)2D• 
controls. Table 7.1 shows the mean concentration of DBP in 
the elderly patient groups and the corresponding free 
1,25(OH)2D indices. Only a fifth of the patients had free 
1,25(OH)2D values below the normal range and this could not 
explain the higher incidence of low 1,25(OH)2D values. No 
correlation was seen between total 1,25(OH)2D and DBP. There 
were no statistically significant differences between DBP 
and free 1,25(OH)2D index in any of the elderly sub groups, 
or between the elderly patients and the younger subjects 
with non fracture osteomalacia. However, there was a go09 
correlation [r=O.91, p<O.OOl] between total and free 
1,25(OH)2D (figure 7.5) which suggest that DBP is not an 
important variable with respect to the low concentrations of 
1,25(OH)2D• 
7.4 DISCUSSION: 
Many of the patients with femoral neck fractures and 
osteoporosis in this study had low serum 25(OH)D and 
1,25(OH)2D concentrations. Moreover, low concentrations of 
1,25(OH)2D do not seem to be inevitably associated with the 
development of osteomalacia. These findings are consistent 
with previous reports of low 25(OH)D (Brown et aI, 1976; 
Baker et al,1979; Meller et al, 1985) and 1,25(OH)2D (Lips 
et al, 1982; Francis et al, 1984) concentrations in patients 
with femoral neck fractures. However, although Meller et al 
(1985) found low concentrations of 25(OH)D in their fracture 
group, the 1,25(OH)2D concentrations were higher than those 
of their normal elderly controls. 
This study shows quite clearly that, compared with young 
healthy controls, the elderly population with or without 
femoral neck fractures, are vitamin D deficient. It was 
surprising to find that many elderly subjects in apparent 
good health also had low concentrations of 25(OH)D and 
-129-
PATIENT GROUP VITAMIN D BINDING PROTEIN FREE 1,25(OH)2D INDEX 
n mg/L x 165 
Elderly normal 
subjects 19 326 (± 45) 0.85 (± 0.42) 
FNF+ 
osteoporosis 41 293 (± 65) 0.78 (± 0.41) 
FNF+ 
osteomalacia 11 316 (± 76) 0.50 (± 0.20) 
Non fracture 
osteomalacia 5 346 (± 75) 0.94 (t 0.32) 
~ L E E 7.1. Vitamin D binding protein and free 1,25(OH)2D indices in the 
elderly patient groups. 
Values represent the mean + SD 
FIGURE 7.5. Linear relationship between total and free 
1,25(OH)2D• 
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1,25(OH)2D. This is in agreement with other studies which 
have not found any differences in the vitamin D metabolite 
concentrations between fracture patients and controls 
(Hordon and Peacock, 1987; Wootton et al, 1982). It has been 
suggested that the vitamin D deficient state may be 
characteristic of old age in general, rather than confined 
to the elderly at risk group. However, the data is at 
variance with the findings of Lips et al (1982) who found 
much lower concentrations of the vitamin D metabolites in a 
similar group of hip fracture patients compared to controls. 
Their observations were attributed to low concentrations of 
DBP, which was probably due to the traumatic effect of the 
fracture (Lips et al, 1985). In this study DBP 
concentrations were normal but this could be attributed to 
the inclusion of patients sampled several days after the 
fracture. 
There are a number of possible explanations why low 
concentrations of 1,25(OH)2D may not invariably be 
associated with osteomalacia. DBP concentrations may be low 
after a femoral neck fracture (refer to chapter 6; Lips et 
al, 1982) although they generally recover within the 
subsequent week (refer to chapter 6). However, most of the 
patients in the present study had normal concentrations of 
DBP and it is unlikely that the low concentrations of 
1,25(OH)2D are falsely low because of the reduced binding 
protein. Although DBP values were not available on every 
subject, the correlation between total 1,25(OH)2D 
concentration and the free 1,25(OH)2D index was so good that 
it makes it unlikely that reliance upon total 1,25(OH)2D 
concentrations incorporates a systematic error. 
Another possible explanation is that the low 1,25(OH)2D 
concentration reflects the presence of Type II osteoporosis, 
which may be an almost universal phenomenon in the very 
elderly and corrmonly presents with proximal femoral 
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fractures. This is characterised by decreased renal 25(OH)D-
1 alpha-hydroxylase activity leading to impaired 1,25(OH)2D 
production and reduced osteoblastic activity (Riggs and 
Melton, 1983). In this respect the low values for the 
surface extent of trabecular osteoid found in the present 
study would be consistent with decreased osteoblast 
function. It may be that in the presence of a low rate of 
bone formation less 1,25(OH)2D than normal is required for 
adequate mineralisation. 
Bone turnover is known to be low in the elderly 
(Meunier, 1983) and it seems that this may have a 
'protective' effect in reducing the requirement for vitamin 
D. Although many of the patients in the present study had 
low rates of bone formation, as assessed by the surface 
extent of osteoid, several also had thick osteoid seams. 
This implies that there may be some form of mineralisation 
defect but because the rate of activation of new forming 
surfaces is so low vitamin D deficiency can exist for a 
prolonged period of time before osteoid has accumulated to 
such an extent as to satisfy the diagnostic measurements for 
osteomalacia. 
There are a number of practical implications associated 
with these findings. Firstly, measurement of plasma 25(OH)D 
and 1,25(OH)2D concentrations are of no value in screening 
for subclinical osteomalacia complicating femoral neck 
fractures. Reliability must therefore be placed on the 
conventional combination of low plasma calcium concentration 
and. raised alkaline phosphatase activity despite the high 
false positive rate associated with this combination (Wilton 
et al, 1987b). Secondly, in the very old the rate of 
activation of new bone remodelling units may be so low that 
vitamin D deficiency may need to be present for a long 
period before osteoid accumulates to such an extent that it 
fulfils the generally accepted criteria for osteomalacia. 
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Moreover, low turnover may be associated. with a very slow 
response of vitamin D therapy to heal osteomalacia. 
Supplementation of the diet of the elderly with vitamin 
D either on the suspicion of a low vitamin D intake or 
because of low plasma concentrations of vitamin D 
metabolites does not seem likely to improve bone structure 
unless there is overt osteomalacia. Whether long term 
vitamin D supplementation starting at an earlier age may 
improve bone mass, by offsetting the age-related. decline in 
intestinal calcium absorption which is seen in the elderly 
(Francis et al, 1984; Peacock and Nordin, 1980), is 
uncertain at present. Identification of patients with low 
serum concentrations of 25(OH)D and 1,25(OH)2D cannot, by 
itself, be equated with the presence of osteomalacia. Such 
measurements do not help to resolve the problem of 
eliminating the high false positive rate associated with 
biochemical screening of fracture patients for the presence 
of osteomalacia (Wilton et al, 1987b). 
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CHAPTER 8 
CHANGES IN CALCIUM HOMEOSTASIS AITER TOTAL 
THYROPARATHYROIDECTOMY IN MAN 
8.1 INTRODUCTION: 
Surgical excision of squamous cell carcinoma of the 
larynx, hypopharynx and upper oesophagus often includes 
partial or total removal of the thyroid gland (ie. 
thyroidectomy). Both pairs of the parathyroid glands are 
nonnally situated on or beneath the posterior surface of the 
thyroid lobes, located near the junction of the middle 
thyroid artery and the recurrent laryngeal nerve. Only 
rarely are they embedded within the thyroid. Either way, 
during thyroidectomy some if not all of the parathyroid 
glands are removed because identification at thyroidectomy 
is often difficult. On many occasions positive search of the 
glands, with a view to their preservation, is not undertaken 
because of the high risk of damage to their blood supply in 
the process. Nevertheless, it has been shown that three of 
the four parathyroid glands can be resected without 
necessarily inducing hypoparathyroidism (Wade, 1972). 
In 1983 up to 46% of all new cases of laryngeal 
carcinoma in both England and Wales (1689 cases in total) 
underwent laryngectomy (National Cancer Registration, 1987). 
Hypopharyngeal carcinomas are less comnon; 383 new cases 
were reported in 1983 and from this group only 5% underwent 
surgical excision (unpublished data). Thus, the number of 
patients undergoing extensive laryngo-pharyngeal surgery is 
significant and may give rise to a number of metabolic 
problems. 
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The induction of hypocalcaemia in man following. this 
type of surgery has been shown to be within the region of 
11-15% (Harrison, 1973; Isaacson and Snow, 1978). However, 
this value could be an underestimate as most studies have 
relied on the appearance of signs and symptoms of 
hypocalcaemia bef ore proceeding wi th any biochemical 
measurements. There have been no reports to suggest that 
radiotherapy for laryngo-pharyngeal squamous cell carcinoma 
causes hypocalcaemia. The cause of either the temporary or 
permanent hypocalcaemia occurring after thyroidectomy may 
result from hypoparathyroidism either following damage to 
the parathyroid glands at operation or their excision with 
the thyroid. Excision of calcitonin-secreting tissues is 
inevitable at thyroidectomy but would not cause 
hypocalcaemia since its overall contribution to calcium 
homeostasis is minor compared with that of parathyroid 
hormone. 
The aim; of this study was to examine the effect of 
laryngectomy and laryngo-pharyngo-oesophagectomy (LPO) with 
thyroparathyroidectomy on the calcium homeostatic system in 
man and to determine the efficacy of the standard post-
operative treatment regimes. 
8.2 PATIENTS AND METHODS: 
The study was carried out in 10 patients (4 males and 6 
females: mean age 61; range 41-82) with histologically 
proven squamous cell carcinoma of the larynx, hypopharynx or 
upper oesophagus. All had normal pre-operative levels of 
serum calcium, magnesium, creatinine and thyroid hormones. 
Clinical details of the individuals are summarised in Table 
8.1. Of the ten patients, seven underwent laryngo-pharyngo-
oesophagectomy (which involved total thyroparathyroidectomy) 
with pharyngo-gastric anastomosis (LPO). From the first 
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Case 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
LPO 
LTT 
LPT 
Sex Age Diagnosis pr2-op pre-op 
F 
M 
F 
F 
F 
F 
M 
M 
M 
F 
Ca+ Mg 
82 Post cricoid carcinoma 2.44 0.75 
48 Post cricoid carcinoma 2.44 0.93 
62 Post cricoid carcinoma 2.46 0.73 
72 Post cricoid carcinoma 2.42 0.83 
75 Post cricoid carcinoma 2.41 0.82 
68 Post cricoid carcinoma 2.45 0.93 
53 Post cricoid carcinoma 2.43 0.90 
57 Larynx carcinoma 2.56 0.85 
52 Larynx carcinoma 2.50 0.75 
41 Larynx carcinoma 2.27 0.90 
Laryngopharyngo-oesophagectomy 
Total laryngectomy with total thyroidectomy 
Total laryngectomy with partial thyroidectomy 
Post-op treatment commenced (days) 
Calcium i ~ ~ T4 1,25 Oper- IV Oral Oral Oral 
ation 
LPO 1 11 9 11 
LPO 1 12 1 12 12 
LPO 1 ,'- 9 ,'- 9 
'" 
.-
LPO 1 35 9 35 35 
LPO 1 17 1 19 19 
LPO 1 17 1 17 17 
LPO 1 12 9 12 12 
LTT 3 4 4 
LTT 2 7 3 
LPT 6 12 6 
T3 Triiodothyronine 
T4 Thyroxine 
1,25 1,25(OH)2D 
* Died after 17 days 
~ ~ 8.1. Clinical details on the ten patients 
in the study. 
post-operative day total parenteral nutrition (TPN) from a 2 
Ii tre pre-prepared bag was infused via a central venous 
line. The composition of the feeding together with vitamin D 
and mineral supplementation is summmarised in Table 8.2. In 
addition all patients received intravenous triiodothyronine 
(lOfg three times daily) throughout the study. 
Two patients underwent total 
thyroidectomy (LIT) whilst one 
laryngectomy and total 
other had a total 
partial-thyroidectomy (LPT). Post-laryngectomy with 
operative nutrition for these patients, maintained using a 
naso-gastric tube, was supplemented with calcium, 
1,25(OH)2D3 (calcitriol) and thyroxine (150ug/day) -see 
Tables 8.1 and 8.2. 
Fasting blood samples were taken from each patient for 
daily measurements of calcium, phosphate, albumin, 
magnesium, creatinine, electrolytes and the vitamin D 
metabolites. All serum calcium concentrations were corrected 
to a reference albumin concentration of 40g/L (see appendix 
1). Measurements of vitamin D binding protein, osteocalcin 
and parathyroid hormone concentrations were measured in a 
selected group of patients. Free vitamin D indices were 
calculated as in section 6.1. 
Fasting urine samples were taken for measurement of 
sodium, calcium, creatinine and phosphate. Urinary excretion 
of calcium (CaE) and sodium (NaE) were expressed as umol/L 
glomerular filtrate: 
(urinary- Ca or Na [mmol/LJ) x (serum Creatinine [ mol/LJ) 
(urinary Creatinine [mmol/LJ) 
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TABLE 8.2. Calcium, magnesium and sodium replacement after thyroparathyroidectomy. 
Room PREPARATIOO CALCnIf MAGNESIUM SODIUM (DIDOl) (1Il001) (DID01) 
INTRAVENOUS 20% Intralipid (50Oml) 
Yamin 14 (100Oml) 5.0 8.0 100 
50% Dextrose (50Oml) 
Addamel (lOml) 5.0 1.5 
10% Calcium gluconate (lOml) 2.25 
50% Magnesium sulphate (2ml) 4.0 
ORAL Calcitriol (lmg) or 
Alphacalcidiol (lmg) 
Microcrystalline hydroxyapatite 70.0 
Calcium lactate gluconate (1.6g) 40.0 24 
Magnesium hydroxide (lOml) 14.0 
Magnesium amino chelate (200mg) 8.2 
Osmolite (25Oml) 4.5 
The notional setting of renal calcium reabsorption measured 
as the maximal tubular reabsorption of calcium related to 
glomerular filtration rate (TmCa/GFR) was calculated using a 
nomogram (see appendix 8) and compared to that of normal 
subjects. 
Statistics 
Analysis of the results were performed by standard paired t-
tests. The relationship between 'llnCa/GFR and sodium 
excretion (NaE) for normal subjects was determined by 
standard linear regression fitted by the least squares 
method, and the 95% confidence limits expressed. 
8.3 RESULTS 
Parenteral feeding in the laryngopharyngo-oesophagectomy 
group (LPO) was continued for a mean of 17.3 days (range 11-
35). This was replaced by an oral diet with calcium, 
calci triol and thyroxine supplements, once all alimentary 
anastomoses had healed. The laryngectomy group (LPT and LIT) 
were fed by means of a naso-gastric tube for a mean of 10.2 
days (range 7-14 days), thereafter resuming a normal diet 
with added calcium, calcitriol and thyroxine (Table 8.1). 
Table 8.3 sunmarises the mean serum calcium, albumin, 
phosphate, magnesium, sodium, potassium, creatinine, 25(OH)D 
and 1,25(OH)2D concentrations before and 24 hours after 
surgery. Individual responses are given in appendix 8. 
The individual daily calcium concentrations following 
surgery and immediate infusion of calcium are sunmarised in 
figure 8.1a and 8.1b. Mean serum calcium concentrations fell 
significantly from a pre-operative value of 2.44 [+ 0.03J to 
2.02 [+ 0.04J mmol/L after 24 hours [p<O.OlJ and to a nadir 
of 1.83 [+O.06J mmol/L three to thirteen days post-
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TABLE ~ . 3 . . Changes in plasma biochemistry after TPTx. 
Values represent the mean from the 10 patients. t. Sb . 
PARAMETER BASAL 24h AFTER SURGERY 
(±Sl:I) (± s 1:» 
Calcium (nmol/L) 2.44 ( ~ . O : l ) ) 2.02 (0-040 ) 
Albumin (g/L) 36.5 ( \.'1) 28.7 (os) 
Phosphate (nmol/L) 1.10 ( ( ) · o ~ ) ) 1.!6 (0'09) 
Magnesium (nmol/L) 0.87 ( ( H ~ ) ) 0.76 (o.to) 
Sodium (nmol/L) 139 ('l-\c.) 138 ( \. fS ) 
Potassium (nmol/L) 3.88 ( o . ~ c g ) ) 3.37 ( i)-l6C6) 
Creatinine (umol/L) 86 ( II .. :) 87 ( ' l , ~ ) )
25(OH)D (ng/ml) 6.61 ( , " \ . ~ ) ) 3.65 ( 1 . . < ~ ) )
1,25(OH)2D (pg/ml) 36.3 ( ~ . ~ ) ) 21.1 ( H·C?) 
FIGURE 8.1a. Daily serum albumin and corrected calcium 
concentrations following surgery (TPTx) and immediate 
calcium infusion. 
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operatively [p<O.Ol]. Serum albumin also fell (figures 8.1a 
and b) from a mean pre-treatment value of 36.5 [+ 1.9] g/L 
to 28.7 [+ 0.5] gIL post-operatively [p<O.Ol]. There was a 
delay in nasogastric feeding in two of the three 
laryngectomy patients. These two patients became profoundly 
hypocalcaemic and this was not corrected until calcium and 
calcitriol had been given for five to six days (not shown). 
There was only one episode of tetany during this period 
which required treatment with a bolus injection of 10% 
calcium gluconate (2.25rnmols). 
Serum magnesium concentrations remained within the 
normal range throughout. Phosphate concentrations, however, 
increased from a mean pre-operative value of 1.10 [+ 0.05] 
to 1.16 [+ 0.09] rnmol/L on the first post-operative day and 
peaked at 1.79 [+ 0.11] mmol/L seven to nine days after the 
operation [p<O.OOl]. There was no significant change in the 
mean phosphate concentration 24 hours after surgery. 
Circulating serum concentrations of PI'H were monitored 
in four patients (patients 1, 2, 3 and 5; refer to Table 
8.1). Mean PI'H concentrations decreased rapidly from a pre-
operative value of 0.38 [+ 0.07] ug/L to below 0.2 ug/L. 
Unfortunately exact values could not be determined because 
of the insensitivity of the assay used (figure 8.2). PI'H 
values remained at the lower end of the reference range 
throughout the study. 
Measurements of total vitamin D metabolites were 
performed in all patients (figure 8.3a and 8.3b). The mean 
serum concentration of 2S(OH)D before surgery was in the 
lower end of the reference range, taking into account any 
seasonal variation. However, both 1,2S(OH)2D and 24,2S(OH)2D 
concentrations were within the normal reference ranges. In 
general concentrations of the vitamin D metabolites 
decreased after surgery but only 1,2S(OH)2D fell 
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FIGURE 8.2. Serum PTH concentrations in four patients (1, 2, 
3 and 5) before TPTx and post-operative. 
0'6 
0'4 patient 1 0 I, 2. 
.....I 
.......... 
C) 
:::l... 
::J:: 
l-
e.. 
0'2 
-----------------
I 
pre-
operative 
I 
immediate 
post -operative 
Solid line indicates upper limit of normal; dotted line shows 
assay sensitivity. 
II 3 ... 
" 
5 0 
FIGURE 8.3a. Concentrations of the vitamin D metabolites-
pre-operatively and after surgery (TPTx) for patients 1-5. 
161 14 
8 
CI 
::t:: 
CI 
Ii) 4 N 
<0 
.... 
0 
360 
~ 2 4 0 0
::t:: 
.9 
1.0 
N. 
"'" N 120 
<0 
"'0 
45 
30 
~ ~
::t:: 
CI 
1.0 
N 
. 
15 
<0 
.... 
0 
-
o 
TPTx 
it 
J 
o 
pre-op 
I 
2 
I I I 
468 
TIME /days) 
I 
10 
patient 1 0 
" 2. 
3 • 
4 .... 
5 0 
FIGURE 8.3b. Concentrations of the vitamin D metabolites 
pre-operatively and after surgery (TPTx) for patients 6-10. 
Cl 
:c 
CI 
1.0 
N 
co 
-o 
12 
8 
4 
300 
~ ~ 200 
:x: 
Cl 
1.0 
N 
V 
N 100 
'" 
-o 
...... 
CI 
.-t" 
:c 
CI 
1.0 
N 
~ ~
'" 
-0 
50 
40 
30 
20 
10 
r 
o 
pre-op 
I 
2 
f\ ___ 
I \ _---
........... --_ .. -,-
/ \ 
\ 
b 
~ - -",/ ----., 
.....,. -. 
?---
f - - - ~ ~ P 
I " / I '0-/ 
I 
I 
f 
I 
4 
---
I 
6 
_-0 
TIME days 
I 
8 10 
patient 6 A 
7 • 
8 0 
9 0 
10. 
significantly within 24 hours [p<O.OOlJ. These values 
remained below the lower nonnal range and did not change 
significantly until the administration of calcitriol 
[p<O.OOlJ. 
There were also no significant correlations between 
serum 1,25(OH)2D and that of the serum calcium, phosphate, 
magnesium or albumin concentrations. 
Concentrations of DBP were monitored for seven to ten 
days post-operatively in all but patient 4. The individual 
results are depicted in figures 8.4a and 8.4b. The mean pre-
operative value of 374 [+ 80J mg/L decreased significantly 
to 241 [+ 99J mg/L 24 hours after surgery [p<O.OlJ. However, 
after 7 to 10 days there was a significant increase from 
this mean value to 315 [+ 72J mg/L, demonstrating that DBP 
values were able to revert back to nonnality. This is not 
true, however, for the total vitamin D metabolite values. 
There was no correlation between total serum 1,25(OH)2D and 
DBP concentrations either before surgery or after therapy. 
No correlation was seen between DBP and either of the other 
vitamin p metabolites. Nor was there a relationship between 
DBP aDd serum albumin concentrations (not shown). There was 
no correlation between the changes seen in any of the 
vitamin D metabolites and the changes in DBP concentrations. 
To determine whether the low DBP concentrations could 
account for the low 1,25(OH)2D concentrations free 
1,25(OH)2D3 indices were calculated as described in section 
6.1. Figure 8.4 shows the free 1,25(OH)2D3 indices for the 
nine patients. There were no statistically significant 
changes throughout this period. 
Osteocalcin concentrations were measured in patients 6, 
7, 8 and 10, before and after treatment (figure 8.5). 
Although concentrations were within the normal age-matched 
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FIGURE 8.4a. Concentrations of vitamin D binding protein 
(DBP) and free 1,25(OH)2D indices after T P T x ( ~ ) )
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reference range before surgery (refer to Table 6.1 for 
range), values decreased significantly within 48 hours after 
surgery [p<O.OOl] and did not revert back to pre-operative 
values even When treatment with calcitriol had commenced. 
Urinary calcium excretion (CaE) was compared with the 
prevailing concentrations of serum calcium (figure 8.6) in 
all patients. Results show that the infusion of calcium in 
these patients caused an inappropriately high excretion of 
calcium implying that they had a reduced renal threshold for 
calcium reabsorption. This is consistent with loss of the 
effect of PI'H on the distal nephron of the kidney to 
increase renal tubular calcium reabsorption. The 
relationship between serum and urinary calcium was similar 
for both oral and intravenous routes of calcium 
administration. 
Renal handling of calcium and that of sodium are known 
to be interdependent. Because of this association the 
assessment of the influence of any factor on urinary calcium 
excretion must take into account any simultaneous change in 
urinary sodium excretion. The relationship between the 
setting of calcium reabsorption (TmCa/GFR) and the rate of 
sodium excretion is shown in figure 8.7. TmCa/GFR represents 
the overall effect of both the proximal and the distal (PTH-
dependent) renal tubular handling of calcium. Although the 
normocalcaemic state was maintained by increasing calcium 
output (either from enhanced intestinal absorption or by 
calcium infusion) the TmCa/GFR fell post-operatively. In the 
immediate post-operative period, patients were deliberately 
kept hypovolaemic, with very low sodium excretion rates, and 
at this time the setting of TmCa/GFR was within the normal 
range. As volume re-expansion was permitted to occur, sodium 
excretion increased while TmCa/GFR decreased. The setting of 
TmCa/GFR (figure 8.7b) tended to be lower When the patients 
had been persistently hypocalcaemic (ie Ca<2.0 mmol/L for 
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greater than 24 hours). However, thyroid hormone replacement 
had little influence on the setting of renal tubular calcium 
reabsorption. 
8.4 DISCUSSION: 
In the pres en t study hypocalcaemia was an invariable 
consequence of laryngo-pharyngeal surgery where the thyroid 
gland is partially or completely excised. The overall 
incidence of permanent hypoparathyroidism following this 
type of surgery has been reported to be in the region of 5-
15% (Thomson and Harness, 1970) however, transient 
hypocalcaemia is more common (Smith and Quiney, 1987). Thus, 
patients undergoing extensive neck surgery are inmediately 
infused with calcium in order to anticipate the post-
operative hypocalcaemia. The pathogenesis of this temporary 
hypocalcaemia is not clearly understood. One concept which 
has been suggested implicates the release of calcitonin (the 
"calcium-lowering" hormone) during the manipulation of the 
thyroid gland at surgery (Watson et ai, 1981). However, this 
s u g g e s t i ~ n n has been questioned and the most commonly 
accepted reason suggests that the removal or damage of the 
parathyroid gland during surgery results in hypo-
parathyroidism and therefore hypocalcaemia. 
There was no evidence of parathyroid gland function in 
these patients after surgery, as assessed by the presence of 
undetectable concentrations of the circulating hormone. 
However, Buchanan et al (1975) demonstrated a delayed 
response in the gland 200 days after total thyroidectomy. It 
is therefore suggested that the rapid reduction in 
circulating PTH was the major cause for the observed 
hypocalcaemia in this group of patients. With this evidence 
the next stage was to get an insight into the effects of 
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laryngo-pharyngeal surgery on the calcium homeostatic system 
with particular attention to the vitamin D metabolites. 
After laryngo-pharyngeal surgery serum calcium 
concentrations decreased in as ociat ion with temporary 
hypoalbuminaemia. Low albumin concentration is commonly seen 
after any type of surgery and is associated with the stress 
of the surgery. However, the reason for continued 
hypocalcaemia in these patients cannot be reduced albumin 
concentrations because when albumin concentrations returned 
to near-normal serum calcium concentrations still remained 
low. There was no relationship between serum albumin and 
calcium concentrations. 
Post-thyroidectomy hypocalcaemia can also be due to 
either magnesium deficiency (Rude and Singer, 1981) or the 
rapid entry of calcium into depleted bone as concentrations 
of the thyroid hormone fall. Both of these ideas have been 
eliminated in this study. All patients had normal magnesium 
and thyroid hormone concentrations which were sustained by 
intravenous or oral supplementations. 
With the Unmediate post-operative reduction of PTH 
concentrations it was important to investigate the 
concentrations of the vitamin D metabolites throughout the 
study period. The study demonstrates that before surgery all 
patients had serum 1,25(OH)2D concentrations within the 
normal reference range but values fell significantly 
Unmediately after surgery. Potential explanations for this 
rapid reduction in this metabolite include a decrease in 
1 , 2 5 ( O H ) 2 ~ ~ synthesis, an increase in 1,25(OH)2D catabolism 
and a reduction in the serum binding of 1,25(OH)2D. It is 
highly unlikely that the reduced 1,25(OH)2D is related to 
the 25(OH)D concentrations although low concentrations of 
25(OH)D were reported in 30% of the patients. However, there 
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was no correlation, either before or after surgery, between 
the serum concentrations of Z5(OH)D and 1,Z5(OH)ZD. 
Less than 1% of total 1,Z5(OH)ZD concentration in the 
circulation is free and presumably biologically active; the 
remainder is transported by DBP to the target sites. Thus, 
the low concentration of this binding protein could account 
for the observed decrease in total 1,Z5(OH)ZD 
concentrations. Although total 1,Z5(OH)ZD concentrations 
after surgery were low, free 1,Z5(OH)ZD indices were normal 
and did not vary significantly during the post-operative 
study period. Mean concentration of DBP, measured in nine 
patients, was low immediately after surgery, but returned to 
normal a few days later. The reduction of DBP corresponded 
to the low concentrations of serum albumin and is therefore 
probably a consequence of surgical stress. 
The lack of correlation between DBP and 1,Z5(OH)ZD and 
the failure of 1,Z5(OH)2D to rise with DBP suggest that the 
concentrations of DBP were not responsible for the 
continually low concentrations of 1,25(OH)ZD. This therefore 
i m p l i c a t ~ s s a defect in the synthesis of 1,Z5(OH)ZD and this 
deficiency has a profound affect on the synthesis of 
osteocalcin. The close interrelationship between circulating 
1,Z5(OH)ZD and osteocalcin, as outlined in the chapter 6, 
has been reinforced in this study. 
Although osteocalcin measurements were obtained from a 
small number of patients, results clearly demonstrate a 
similar reduction in circulating concentrations immediately 
post-operatively and remained low throughout the 
investigation. The administration of calcitriol, however, 
was unable to raise osteocalcin concentrations to pre-
operative values after six days of treatment. 
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The two important physiological regulators of 1,Z5(OH)ZD 
synthesis and secretion are serum phosphate and PTH 
concentrations. In the present study the mean serum 
phosphate concentration rose after surgery but no 
correlation was found. between the rise in serum phosphate 
concentrations and the change in serum 1,Z5(OH)ZD. The rise 
was most probably related to the mobilisation of phosphate 
from bone to compensate for the prolonged reduction in 
extracellular calcium. 
Pm maintains serum calcium concentrations within the 
normal range is by its action on the 1 alpha-hydroxylase 
activity in the kidney. Reduction or even removal of this 
hormone will therefore upset the synthesis of 1,Z5(OH)ZD. 
This has been clearly y{demonstrated by the rapid reduction 
of the 1,Z5(OH)ZD metabolite ~ e d i a t e l y y after surgery. 
There were no similar reductions in either the Z5(OH)D or 
the Z4,Z5(OH)ZD metabolites. Neither synthesis of which are 
independent of the action of PI'H. Serum concentrations of 
1,Z5(OH)ZD remained in the lower end of the normal reference 
range until the corrmencement of dietary calcitriol. 
The reduction of circulating concentrations of PI'H also 
had a profound effect on the renal reabsorption of calcium 
in these patients. The effect of PI'H is to stimulate net 
calcium transport across renal tubular cells. Over 70% of 
calcium reabsorption occurs in the proximal convoluted 
tubules, and is tightly coupled to sodium reabsorption. 
Factors, therefore, which will enhance sodium reabsorption 
in the proximal tubules (e.g. volume depletion) will also 
enhance calcium reabsorption. Conversely, factors which 
diminish proximal tubular sodium reabsorption (e.g. saline 
infusion) will similarly reduce calcium reabsorption 
(Stewart and Broadus, 1981). 
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Only a small fraction of the filtered calcium load 
remains at the distal convoluted tubules. Calcium 
reabsorption in this segment is not associated with sodium 
reabsorption. It is here where Pm acts on calcium 
reabsorption by enhancing distal reabsorption. The absence 
or reduction of circulating Plli, as seen in these post-
thyroidectomy patients, results in an overall increase in 
urinary calcium excretion, consistent with the loss of the 
effect of PTH on the distal nephrons. 
With respect to treabnent of laryngo-pharyngeal patients 
after surgery it is important to give parenteral feeding 
supplemented to give lOmnol/day of calcium in order to 
produce satisfactory concentrations (around 2.0 rrrnol/L) of 
serum calcium. Additionally, calcium given through a 
peripheral vein may result in a higher level of serum 
calcium but experience shows that this causes problems with 
venous thrombosis. Calcium supplementation with l0mm0ls/day 
allows a wide range of safety while protecting against 
tetany. It also avoids the risk of hypercalcaemia during the 
change over to oral supplements if the latter is commenced 
whilst the patient is still receiving intravenous calcium. 
Such 'an overlap of treatment is reconmended in order to 
avoid hypocalcaemia which, once established, may take 
several days to correct. This was well demonstrated in the 
two patients who became severely hypocalcaemic. 
There are two approches to the prevention and treatment 
of hypocalcaemia in patients receiving oral replacement 
therapy. Firstly, the efficiency of intestinal calcium 
absorption can be increased by the use of large doses of 
vi tamin D, to achieve maximal calcium absorption with a 
normal diet. One disadvantage, however, is the potential 
toxicity of vitamin D. The other alternative is to use 
calcium supplements with smaller doses of vitamin D, 
preferably in the form of 1,25(OH)2D. This allows adjustment 
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in calcium intake to regulate the concentration of serum 
calcium. Whichever approach is adopted it is important to be 
aware that the setting of renal tubular calcium reabsorption 
may rise if the patient becomes salt depleted and also 
increase after restoration of normocalcaemia. This present 
study has demonstrated that persistant hypocalcaemia lowers 
the setting of ThlCa/GFR, resulting in an increased renal 
leak of calcium with a tendency to worsening hypocalcaemia. 
Hypothyroidism (Bouillon and DeMoor, 1974) does not seem 
to be a major factor in regulating calcium reabsorption in 
these patients since the three patients who had become 
profoundly hypocalcaemic after surgery, either due to 
interruption or a delay in the initiation of replacement 
therapy, all had impaired renal tubular reabsorption of 
calcium. In these three cases the additional contributing 
factor was likely to be the loss of the regulatory function 
of parathyroid hormone in controlling skeletal calcium 
influx and efflux. 
Protection from hypocalcaemia is thought to occur in two 
distinct stages (Parfitt, 1976). The immediate but limited 
resporise is the release of stored calcium from a labile 
pool. This is then followed by a more prolonged (and 
quantitatively greater) increase in osteoclastic bone 
resorption. In the presence of inadequate post-operative 
treatment with calcium and vitamin D supplements the labile 
pool may become depleted which together with reduced 
osteoclastic recruitment, 
deficiency, will contribute 
hypocalcaemia. 
due to parathyroid hormone 
to the development of a profound 
Thus, supplementation for patients following laryngo-
pharyngectomy surgery is necessary and also similar 
irrespective of the type of operation performed. Although 
replacement therapy is straightforward, if the 
-145-
administration of appropriate therapy is delayed profound as 
well as prolonged hypocalcaemia can occur. 
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CHAPI'ER 9 
METABOLISM OF 25-HYDROXYVTIMAN D IN OSTEOSARCOMA 
CELL LINE 20S 
9.1 INTRODUCTION: 
The physiological actions of vitamin D require 
activation by hydroxylations in both the liver and kidney to 
produce 1,25(OH)2D. This form of the vitamin is the active 
metabolite which is known to play an important role in 
normal bone homeostasis, both in growth and mineralisation. 
However, the major vitamin D metabolite in blood (Bouillon, 
1983) and bone itself (Haussler & Rasmussen, 1972) is the 
25-hydroxy derivative. In bone, 25(OH)D appears to be 
associated with areas of active mineralisation (Wezeman, 
1976) and it has been suggested that this metabolite may 
play a role in stimulating bone formation. 
A l t h ~ u g h h synthesis of 1,25(OH)2D occurs predominantly in 
the kidney,· extrarenal production has been shown in a 
variety of tissues including placenta (Weisman et aI, 1979; 
Whitsett et aI, 1981), human pulmonary alveolar macrophages 
(Barbour et aI, 1981), human keratinocytes (Bikle et aI, 
1986), transformed lymphocyte (Reichel et aI, 1987b) and 
chick and human bone cells (Turner et aI, 1980; Howard et 
aI, 1981; Puzas et aI, 1987). In vivo evidence has been 
demonstrated by Rosenthal et al (1985) who found elevated 
1 , 2 5 ( O H ) 2 ~ ~ concentrations in some patients with non-Hodgkins 
lymphoma. Since these hypercalcaemic patients had renal 
impairment, suppressed PilI and nephrogenous cAMP it is 
possible that the 1,25(OH)2D originated from the lymphoma 
rather than the kidney, a view which is supported by the 
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decline in 1,25(OH)2D concentrations when the ttnnour was 
removed surgically or treated medically. 
24-hydroxylation of 25(OH)D, like 1 alpha-hydroxylation, 
occurs predominantly in the kidney and is induced by raised 
concentrations of 1,25(OH)2D. It is suggested that renal 24-
hydroxylation may either limit production of 1,25(OH)2D by 
competing for 25(OH)D, or inactivate 1,25(OH)2D by 
conversion to the trihydroxy metabolite (DeLuca and Schnoes, 
1983). Extrarenal 24-hydroxylation has also been reported in 
a variety of tissues including bone cells (Lohnes and Jones, 
1987), calvarial cell (Pusaz et al, 1987), virus-transformed 
lymphocytes (Reichel et al, 1987) and human decidua and 
placenta (Weisman et al, 1979). However, the physiological 
role of 24,25(OH)2D in these cells remains uncertain but 
studies have demonstrated a possible role for this vitamin D 
metabolite in bone mineralisation (Ornoy et al, 1978) and in 
normal fracture repair (Meller et al, 1984). 
An intrinsic function for 24,25(OH)2D in bone formation 
has been proposed (Endo et al, 1980; Lohnes and Jones, 1987) 
and Tam et al (1986) suggest that, in conjunction with PTH, 
24,25(OH)2D may play a role in the regulation of bone 
formation and/or bone mineralisation. Indirect evidence to 
support this comes from Muirhead et al (1980) who observed 
that long-term treatment with 24,25(OH)2D alone in chronic 
renal failure increases plasma alkaline phosphatase activity 
without increasing plasma hydroxyproline. Plasma alkaline 
phosphatase is considered to be a valid index of bone 
formation whereas hydroxyproline an index of bone 
resorption. 
Since knowledge about the production of vitamin D 
metabolites by bone cells and its regulation may be 
essential for understanding the effect of vitamin D on the 
skeleton the present study investigates the metabolism of 
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25(OH)D by the human osteoblast-like osteosarcoma cell line 
20S. This cell line still retains many of the native 
osteoblast phenotype, such as increased alkaline phosphatase 
activity, PIH sensitive adenylate cyclase activity and the 
ability to synthesise osteocalcin and, therefore, is an 
ideal system to study. With this line of investigation and 
by searching for possible receptors for 25(OH)D, 24,25(OH)2D 
and 1,25(OH)2D in this cell line it is proposed that one 
would gain some insight into the active form or forms of 
vitamin D in bone. 
9.2 MEI'HODS: 
For all experimental procedures refer to section 2.3. 
9.3 RESULTS : 
9.3.1 CHARACTERISATION OF THE 20S CELL LINE 
(i) Cellular response of 20S to Parathyroid hormone 
Three osteosarcoma cell lines were kindly provided by 
Dr. J Embleton (cell lines 791T, T278 and 20S) however, 
only cell line 20S produced a satisfactory response to PIH 
stimulation as illustrated in figure 9.1. Treatment with 
different concentrations of human 3-34 PIH produced a dose-
dependent increase in the production of cAMP in both 20S and 
791T but the extent of stimulation of adenylate cyclase by 
PIH in the 20S cell line was far greater (figure 9.1). 
Significant production of cAMP was observed at a dose of 
1.5nM PIH whereas in cell line 791T the dose was 3nM. In 
contrast, cell line T278 totally lacked PIH responsiveness; 
doses of up to 3nM PIH failed to stimulate the production of 
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FIGURE 9.1. Dose response effect for hPTH (3-34) stimulation of 
cAMP in (A) T278, (B) 791T and (C) 20S cells, as described in 
section 2.4.1. 
Each point represented by triplicate determinations ~ ~ SD. 
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cAMP. Because of its retained ability to respond to PTH cell 
line 20S was used for the remainder of experimental work. 
(ii) Presence of alkaline phosphatase activity 
Alkaline phosphatase activity in cell line 20S was 
assessed as described in section 2.3.9. The production of p-
nitro phenol, indicated by the yellow appearance of the 
incubation mixture, clearly established the presence of 
alkaline phosphatase activity in 20S cells. No yellow colour 
appeared when, as controls, the monocytic cell line U937 and 
buffer were incubated with the substrate. 
(iii) Production of osteocalcin by 20S cells 
In order to establish that this human osteosarcoma cell 
line was synthesising and secreting osteocalcin, a 12,000 
molecular weight bone-specific ~ ~ -carboxyglutamic acid-
containing protein, a RIA which can detect nanograms of 
human osteocalcin (see section 2.6) was used to examine a 
24h (or' 48h) sample of serum-free media harvested from 
confluent cultures. The presence of 2Ong/ml of osteocalcin 
in the medium suggest that these cells do synthesise 
os teocalcin. However, no further. experiments were carried 
out to verify that this protein, which cross-reacted with 
the anti-osteocalcin antiserum, was indeed osteocalcin. 
Analysis of the harvested serum-free medium on SDS-
polyacrlamide gel electrophoresis showed the presence of a 
protein band which migrated with an apparent molecular 
weight of 12,000 daltons on 15% SDS-polyacrylamide gel 
(Salhi, A., personal comnunication). This 12,000 dalton 
product may represent osteocalcin synthesised and released 
from the 20S cell line. 
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From these preliminary studies the human os teosarcoma 
cell line 20S appears to maintain its differentiated 
function in culture as indicated by production of alkaline 
phosphatase and osteocalcin, and by its responsiveness to 
parathyroid hormone. 
9.3.2. TIIE METABOLISM OF 25(OH)D BY TIIE OSTEDSARCOMA 
CELL LINE 20S 
The metabolism of physiological concentrations of 
25(OH)D was studied initially. When 20S cells were incubated 
for 3h with 50nM ~ - 2 5 ( O H ) D D a second peak of radioactivity 
was seen on HPLC analysis of the lipid extracts from the 
cells. The radioactive profile of the eluate is shown in 
figure 9.2. The major peak at 3.5min represents the 
substrate 25(OH)D3. The unknown metabolite had a retention 
time (7.5-9.5min) identical to that of authentic 
24,25(OH)2D. This metabolite was not produced in medium that 
did not contain cells nor was it produced when a similar 
quantity of radioactive 25(OH)D was applied directly onto 
the HPLC column. When this second peak was re-
chromatographed on the same HPLC system the radioactivity 
again co-migrated with 24,25(OH)2D. 
Since separation of this unknown polar vitamin D3 
metabolite (denoted metabolite X) from 25(OH)D and 
1,25(OH)2D was successful (figure 9.2) one can postulate 
that this cannot be the hormonally active vitamin D3 
metabolite. These observations prompted more detailed 
investigation of the 25(OH)D metabolising system of these 
cells. The results of time course study is illustrated in 
figure 9.3. The synthesis of this metabolite was linear with 
time for Sh. Little synthesis occured after this time and 
only a small amount was detected in the incubation medium. 
There was no detection of any metabolite more polar than 
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FIGURE 9.2. Analysis by HPLC of radioactive lipid extracts 
of 20S cells incubated with ~ - 2 5 ( O H ) 0 3 . .
Lipid extracts were separated on a Zorbax-Sil straight phase 
HPLC column eluted with hexane:methanol:isopropanol (92:4:4 
by volume). Fractions (30sec) were collected and assayed for 
radioactivity. Arrows mark the retention times of authentic 
vitamin 03 metabolites determined by U.V. absorption. 
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FIGURE 9.3. Time course of the synthesis and secretion of 
25(OH)D3 metabolites by 20S cells. 
Cells were grown to near-confluence and transferred to serum-free 
medium for 18h. They were incubated with O.25nM 25(OH)D3 
containing O.25uCi %-25(OH)D3 per dish. Lipids were extracted 
from cells and incubation medium and separated by HPLC as 
described in methods section. Each point represents mean + SD of 
four determinations. 
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24,25(OH)20 during these incubation times and neither was 
there a redistribution of substrate and product into media 
since the metabolite was recovered almost exclusively from 
cells (figure 9.3). , 
Synthesis was also dependent on substrate 
concentrations, producing a sigmoidal response with 
concentrations up to O.5uM ~ - 2 5 ( O H ) 0 0 (figure 9.4). 
In further experiments, 20S cells were pre-incubated for 
14h with 1mM dibutyryl cAMP (dbcAMP) before repeating the 
substrate concentration experiments in the presence of 1mM 
dbcAMP. Exposure of these cells to this cAMP analogue 
produced an unexplainable decrease in the progressive 
synthesis of this polar vitamin 03 metabolite as substrate 
concentrations increased (figure 9.5). This became 
significantly different at 25(OH)0 concentrations greater 
than O.5uM. 
The identification of the product which elutes with 
24,25(OH)20 was then investigated by mass spectrometric 
analysis. Large scale incubations, involving eighty culture 
dishes (14Omm diameter), were used to generate sufficient 
quantity of the unknown metabolite for analysis. Fractions 
corresponding to the metabolite (retention time 7.5-9.5min) 
(figure 9.6) were combined from the Zorbax-Sil column and 
applied to the silica sep pak column, as described in the 
method section. The corresponding 24,25(OH)20 fractions were 
collected and re-chromatographed a further three times on 
the same HPLC system. The absorbance at 263nm was measured 
in fractions eluting from the fourth chromatographic step 
(figure "9.7). Unfortunately, the efficiency of the 
extraction and purification procedures could not be 
monitored due to the unavailability of a suitable recovery 
standard. A strongly absorbing peak eluted from the column 
after 7.5min and corresponded to that of 24,25(OH)20. The 
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FIGURE 9.4. Substrate concentration dependence of the formation 
of 25(OH)D3 metabolites in 20S cells with increasing concentration 
of 25(OH)D3 containing O.luCi/dish. 
Vitamin D metabolites were extracted and separated on HPLC. Values 
represent the mean of triplicate determinations. 
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FIGURE 9.6. Initial HPLC chromatogram of lipid extracts from 
media and cells. 
Arrows mark the retention times for the authentic vitamin D3 
metabolites. 
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retention time of the 25(OH)D substrate, which also absorbed 
at this wavelength was 3.5-6min. 
Fractions eluting from the column between 7. 5min and 
9rnin were combined, evaporated to dryness under N2 and 
subjected initially to UV analysis followed by mass 
spectroscopy analysis. The mass spectrum obtained from this 
unknown (figure 9.9) was compared with those of the 
authentic vitamin D3 metabolites: 25(OH)D3, 24,25(OH)2D3 and 
1,25(OH)2D3 (figure 9.8). The 25(OH)D substrate extracted 
and purified by similar methods was also analysed by mass 
spectroscopy (figure 9.10). 
Ultraviolet (UV) spectral analysis of the unknown had a 
UV absorption maximum (i\max) at 264nm and an absorption 
minimum (i\rnin) of 228nm, which was typically seen when 
authentic vitamin D3 metabolites were analysed by UV 
absorption (figure 9.11). 
Spectral analysis confirmed the HPLC evidence. The mass 
spectrum of the 24,25(OH)2D sample was obtained using a 
temperature probe of 300°C. (figure 9.9a). Despite the 
presence of some impurities the spectrum obtained for the 
sample clearly shows the presence of 24,25(OH)2D; 
particularly noteworthy is the occurance of the molecular 
ion ( ~ ) ) at m/z 416 and the characteristic fragmentation at 
m/z 383 ( ~ ~ minus H20 and CH3). The follmrlng smaller 
fragmentation ions are also common to both spectra to 
further support the assignment: 
m/z 271 
253 
136 
118 
· .................... . 
· .................... . 
· .................... . 
· .................... . 
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loss of side chain 
271 minus H20 
cis-triene cleavage 
136 minus H20 
FIGURE 9.8. Mass spectral analysis of the authentic vitamin D3 
metabolites. ! 
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FIGURE 9.9. Mass spectra of metabolites extracted from incubation 
of 20S cells with 25(OH)D3• 
Mass spectra were produced using a temperature probe of (a) 4000c 
and (b) 250°C as outlined in method section 1.4.4. 
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FIGURE 9.10. Mass spectral analysis of the 25(OH)D3 substrate 
extracted and purified from 20S cells as detailed in methods 
section. 
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FIGURE 9.11. Ultraviolet absorption spectnnn of the unknown 
metabolite eluting between 7.5min and 9.5min from the final HPLC 
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The spectrum showed no resemblance to tha t produced by 
authentic 25(OH)D indicating that the chromatography steps 
were efficient in separating the two vitamin D metabolites 
completely. 
On analysis of the purified 25(OH)D fraction by mass 
spectroscopy a similar, if not identical spectrum to 
authentic 25(OH)D3 was produced with a characteristic 
molecular ion at m/z 400 (figure 9.10). The major fragment 
ions, also characteristically seen in both spectra, are m/z 
271, 253, 136 and 118. 
At the lower probe temperature of 250°C an unexpected 
second metabolite was detected which exhibited the spectrum 
shown in figure 9.9b, and which was obtained prior to that 
of the 24,25(OH)2D spectrum. The fact that this second 
metabolite co-eluted from the HPLC column with 24,25(OH)2D 
strongly suggests that it is also a tri-hydroxylated 
species. On the basis of this spectrum it is tentatively 
suggested that this unknown metabolite has the S7-CzO 
unsaturated structure A (refer to figure 9.12). 
The base peak at m/z 311 could be due to the relatively 
stable allylic cation (structure B in figure 9.12). Loss of 
water from the molecular ion (which was not observed) would 
account for the m/z 396 while dehydration could give rise to 
the ketone structure C. Fragmentation of this would lead to 
both m/z 325 (structure D) and m/z 353 (structure E) and the 
corresponding protonated species, m/z 354. 
The ion m/z 367 seen in the spectrum could be due to 
dehydration of the secondary alcohol function followed by 
the loss of both methyl groups; m/z 339 would then arise by 
decarbonylation of this fragment. A number of other related 
pathways could also explain these fragments and it is 
stressed that the above is only a tentative assignment. 
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FIGURE 9.12. Structures deduced from the mass spectrum 
produced at 250°C. 
Refer to results section for explanation. 
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9.3.3 BINDING OF 25(OH)D3 10 20S CYTOSOLIC PROTEINS 
(i) Initial incubation with ~ - v i t a m i n n D metabolites 
Incubation of 20S cytosolic proteins with ~ - 2 5 ( O H ) D D
produced a single peak of radioactivity when the sample was 
applied on to a G-25 column. This peak was totally displaced 
by unlabelled 25(OH)D present at l00-fold molar excess. A 
similar peak was also observed when 20S cytosol was treated 
with rabbit antibovine whole serum prior to incubation with 
~ - 2 5 ( O H ) D . . There was little or no difference between the 
amount of radioactivity present in these two peaks (figure 
9.13). No radioactive peak was seen when cytosol was 
incubated with an equivalent amount of 3H-1,25(OH)2D or ~ ~
24,25(OH)2D• 
Results from the double immunodiffusion analysis (figure 
9.14) showed no line of precipitation between the antibody 
and the cytosolic protein therefore demonstrating that the 
cytosolic preparation was free from contamination by serum 
proteins. As controls NCS (at 1,OOO-fold dilution) and BSA 
(0. 25mg/ml) were used, both of which formed lines of 
precipation with the antibody. 
A single peak of radioactivity was seen on Sephadex G-
100 gel filtration of 20S cytosolic proteins incubated with 
~ - 2 5 ( O H ) D D (figure 9.15). The positions of the reference 
proteins are also shown and suggest that the 25(OH)D ligand. 
binds to a protein(s) of molecular weight approximately 
75,OOODa. This molecular weight was confirmed by analysis of 
the cytosolic proteins by sucrose density gradient 
centrifugation (figure 9.16), producing a sedimentation 
coefficient (S) of 4.7. The binding activity of normal serum 
(MW 56,OOODa) is quite separate from that of the cytosolic 
binding protein (refer to figures 9.15 and 9.16) although a 
shoulder on the latter suggests some serum binding protein 
is carried through during the cellular fractionation 
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FIGURE 9.13. Sephadex G-2S chromatography of 20S cytosolic 
proteins previously incubated with (a) ~ - 2 S ( O H ) D 3 3 and (b) rabbit 
antibovine Whole serum (A/B) followed by ~ - 2 S ( O H ) D 3 . .
3H -Counts 20 
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FIGURE 9.14. Double immumodiffusion analysis of 20S 
cytosolic proteins. 
No line of precipitation between the antiserum and the 
cytosolic proteins (c) was observed but both BSA (a) and 
NCS (b) demonstrated antibody-antigen reaction with the 
antiserum. 
c 
.. 
o 
\' 
' a 
FIGURE 9.15. Sephadex G-100 chromatography of 20S cytosolic 
proteins and human serum previously incubated with ~ ~
25(OH)Dy 
~ - 2 5 ( O H ) D 3 3 (80,ooodpm) was incubated at 4°C overnight with 
the preparations and applied to a G-25 column before finally 
applying on to the G-100 column. Fractions (lml) were 
collected and assayed for radioactivity. 
b - bovine serum albumin, M.W. 66,000; 0 - ovalbumin, M.W. 
45,000; c - cytochrome c, M.W. 17,000. 
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FIGURE 9.16. Sucrose density sedimentation analysis of 20S 
cytosolic proteins and human serum previously incubated with 
%-25(OH)D3• 
Samples were applied to a continuous sucrose density 
gradient (4-24% in 0.3M KCl) in 16.5ml centrifuge tubes (7 x 
1.25 em). After centrifugation at 30,000rpm for 56h at 4°C, 
fractions (200ul) were collected and assayed for 
radioactivity. 
b - bovine serum albumin, M.W. 66,000; 0 - ovalbumin, M.W. 
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procedure. No peak of 25(OH)D binding activity was seen by 
either gel filtration or density gradient centrifugation of 
cytosols of U937 or calf thymus cytosol which had been 
incubated with ~ - 2 5 ( O H ) D . . While calf thymus cytosol 
displayed binding activity towards 1,25(OH)2D, as reported 
by Reinhardt et al (1984) no such activity was present in 
20S cytosolic proteins. 
9.4 DISCUSSION 
The human os teosarcoma cell line 20S was chosen as an 
appropriate bone model system for the following reasons. 
Firstly, tmlike the two previous osteosarcoma cell lines 
791T and T278, this cell line still retained its 
osteoblastic phenotype, as illustrated by its responsiveness 
to PTH and its ability to produce alkaline phosphatase and 
osteocalcin. The expression of these characteristics in 
vitro rendered it amenable to experimental investigation. 
Secondly, it offered the advantage of being a cell line 
which c o ~ l d d be maintained in culture after tmlimited 
propagation •. 
This study was unable to demonstrate the presence of 
1,25(OH)2D3 receptors in the human osteosarcoma cell line 
20S. Other studies, however, have been able to characterise 
the receptor in rat osteogenic sarcoma cells (Manolagas et 
al, 1980) as well as in cultured osteoblast-like cells from 
mouse calvaria (Chen ~ ~ aI, 1979), however the latter with 
some difficulty. Problems arose because the concentration of 
1, 25(OH)2D3 receptors varied directly with the rate of DNA 
synthesis in the mouse model (Chen and Feldman, 1981). If a 
relationship between cell growth and receptor concentration 
does exist for this human osteosarcoma cell line, i.e. if 
receptor levels are high at log growth phase and low at 
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confluence, then perhaps the difficulty in demonstrating 
receptors may be due to preparing cytosolic fractions from 
near-confluent cells, thus working at a point in the culture 
cycle near the nadir of the receptor concentration. 
This study, however, revealed the presence of a 
cytosolic binding protein which specifically bound 25(OH)D3• 
1,25(OH)2D3 and 24,25(OH)2D3 had little or no binding to 
this protein. This novel binding protein, of molecular 
weight around 75,OOODa, sedimented at 4.7S over sucrose 
density gradients and was shown, by irmn.modiffusion 
analysis, to be clearly distinguishable from serum DBP. 
Because human serum contains a high affinity 25(OH)D3 
binding protein (MW 56,OOODa) it was important to remove 
this activity from the cells as far as possible. This was 
achieved as follows. The cells were grown in medium 
containing 10% serum and prior to preparation of the 
cytosolic fractions they were washed extensively at 
confluence and cultured in serum-free medium for 48h. The 
25(OH)D3 binding activity of these fractions separated from 
the serum activity on gel exclusion chromatography and 
sucrose density gradient. 
There is evidence from studies using tissue homogenates 
to demonstrate the presence of a 5.8-6.0S binding protein 
which binds both 25(OH)D3 and 24,25(OH)2D3 with high 
affinity (Van Baelen et aI, 1980). However, this is not an 
in vivo phenomenon but is apparently formed after 
homogenisation. In fact, it occurs when serum DBP complexes 
with a cytosolic component, which has been identified as 
actin (Van Baelen et aI, 1980; Manolagas and Deftos, 1981). 
This 20S -cytosolic binding protein is presumably that which 
binds 25(OH)D3 for subsequent metabolism in the cells and is 
not an actin complex of the sreum binding protein. 
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The evidence presented here demonstrates that the major 
metabolite of 25(OH)D3 produced by the human osteosarcoma 
cell line 20S is 24,25(OH)2D3. This is the first report to 
demonstrate a cell line which preferentially synthesises 
24,25(OH)2D3 rather than 1,25(OH)2D3. The structural 
conformation of the metabolite as 24,25(OH)2D3 was supported 
by three lines of evidence: 
(1) the anomalous chromatographic behaviour of the 
metabolite was similar to that of the 24, 25(OH)2D3 
metabolite when applied onto two separation systems. 
(2) The UV absorption spectrum displayed a typical vitamin 
D3 cis-triene chromophore with Amax = 264nm and ~ m i n n = 
228nm. 
(3) The mass spectrum of the metabolite gave a parent 
molecular ion of 416 and fragments m/z of 396, 271 (loss of 
the side chain), 253 (271 minus H20), 136 (cis-triene 
cleavage of m/z 253) and 118 (136 minus H20). The fragments 
m/z 271 and 253 indicate that the secosteroid nucleus of 
vitamin D3 has remained unchanged and that all the metabolic 
alterations have taken place on the side chain. Additional 
fragmentation patterns were indistinguishable from the 
authentic 24, 25(OH)2D3. Consequently, the structural 
assignment as 24,25(OH)2D3 is unambiguous. 
Mass spectral analysis of this fraction suggested that 
it contained two metabolites, one of which, obtained at a 
probe temperature of 300°C was clearly shown to be 
24,25(OH)2D3. At the lower probe temperature of 250°C a 
second spectrum, quite different from 24,25(OH)2D3 was 
obtained. That this second metabolite co-eluted with 
24,25(OH)23 from the HPLC colurrm is suggestive of another 
tri-hydroxylated species. On the basis of this spectrum and 
from helpful comments from Dr M.R. Uskokovic (Hoffman- La 
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Roche, Nutley, New Jersey, USA) regarding the assignment of 
the spectrum it is tentitively suggested that it is the ct7-
C20 unsaturated structure A. 
The discovery of a new vitamin D metabolite, metabolite 
h ,\. . A, has r a ~ s e d d a fundemental q u e s t ~ o n n as to Why these bone 
cells should produce such a metabolite and for What purpose. 
This compound is chromatographically indistinct from 
24,25(OH)2D3 and their relative proportions in the fraction 
which eluted from the HPLC column is unknown. The intensity 
of the two mass spectra suggest that they are present in 
approximately equal amounts. Production of either or both 
metabolites appears to be inhibited by the presence of the 
cAMP analogue dbcAMP When the substrate concentration 
exceeds O.5uM. 
It is suggested that this new molecule may represent 
some form of catabolic process which eventually leads to 
reduced biological activity of the 24,25(OH)2D3 and 
therefore its excretion from the cell. It should be noted 
that pharmacological doses of 25(OH)D3 were required to 
generate this polar metabolite to sufficient quantities for 
analysis. It -could be argued, therefore, that this process 
is only instigated under these conditions, i.e. under 
hypervitamin D. This could therefore represent a pathway 
Whereby in circumstances of large amounts bf 25(OH)D3 bone 
cells can induce the 24-hydroxylase to synthesise 
24,25(OH)2D3 which in turn is metabolically modified to this 
unknown metabolite. 
Experiments using mammalian kidney cells have shown that 
25(OH)D3 may be metabolised through an oxidation pathway to 
yield numerous inactive metabolites which have extensive 
metabolic modification particularly in the side chain. These 
enzymes, which cleave the C23-C24 bond as well as other 
regions of the vitamin D sterol, are only induced by 
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supraphysiological concentrations of 1,25(OH)2D3. A similar 
pathway has been demonstrated in the rat osteoblast-like 
cell UMR-106 but again this pathway was only detectable when 
the cells were exposed to 1,25(OH)2D3. This is in contrast 
with the present study. Production of the new metabolite A 
did not require 1,25(OH)2D3 and its mass spectrum did not 
resemble any of the inactivated compounds in the literature. 
As stated in the introduction the extrarenal production 
of 24,25(OH)2D3 has been reported in a number of tissues but 
apart from its possible role in the regulation of bone 
formation and/or mineralisation its function is unknown. 
This is the first report of a cell system which 
preferentially synthesises 24, 25(OH)2D3 and a second 
metabolite A. Unfortunately, the metabolic role of 
metabolite A and its in vivo actions need further 
investigation. 
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APPENDIX 1 
QUANITFICATION OF ILIAC CREST BONE BIOPSY 
Resin sections from the bone biopsy was stained by the 
Goldner trichrome method in order to demonstrate trabecular 
bone and osteoid regions. Bone quantification was performed 
with the aid of a Kontron computer linked to an electronic 
drawing-board (graphic tablet). 
With the aid of a low powered microscope, the image of 
the bone section was superimposed onto the tablet, enabling 
the outlining of features seen in the microscope field. 
Figure A illustrates a typical field of view under low 
power; the mineralised bone shown shaded and the osteoid 
stippled. The following parameters were measured using the 
scanning pen which fed the information to a computer: 
(1) The area of the field to be estimated. This is 
represented by the bold line in figure A and represents most 
of the biopsy. This area was chosen because it excluded 
cortical bone and the crushed edges of the biopsy. 
(2) The total area of trabecular bone, including the 
osteoid. 
(3) The presences of any holes in the trabeculae (eg. a, b 
and c in figure A). These were caused by tearing when 
cutting the sections. These values, therefore were 
subtracted from the area. 
The f ~ n a l l result gave the area of bone as a percentage 
of the total area viewed. The section was then viewed under 
high power in order to obtain further parameter readings. A 
characteristic high power vision is depicted in figure B. 
a---r-t:.l.. 
Trabecular 
bone 
RCS---- .... 
c 
Figure 
A 
-!lJ I --"7'----b 
8 
The following parameters were obtained: 
(1) The total trabecn) ar area and trabecuJ ar length of the 
surface. The presence of any holes in the trabeculae were 
subtracted from the total area and the length of each hole 
added to the trabecular length. 
(b) The total area. of osteoid and the length of its 
surfaces. 
(c) The length of any rough crenated surfaces (RCS in 
figure B). These surfaces demonstrate where active bone 
resorption has occured. 
(d) The edges of the field where trabecular bone cross 
them. 
These final parameters were measured three times, once 
in the middle of the bone section and twice on either ends 
(excluding any cortex). These values were then fed into a 
BBC computer prograrrme which calculated the final histo-
morphometric parameters used in these clinical studies: 
1. AREA OF OSTEDID -expressed as a % of total area of 
trabecular bone (normal value <10%). 
2. % rorAL SURFACE OF 'mABEXIJLAE 
OOvmED BY OSTEDID -normal value <20% 
3. % rorAL SURFACE OF 'IRABEXIJLAE 
OOvmED BY RCS 
4. INDEX OF SEAM 1HICKNESS 
-expressed as total osteoid area 
total osteoid length 
normal index 0.17 or less. 
APPE2IDIX 2 
SERUM BIOCHEMISTRY MFASUREMENTS 
Routine serum biochemistry was measured in the Department 
of Clinical Chemistry, Queen's Medical Centre, Nottingham. 
Measurement 
oJ. 
"Plasma and 
Urinary 
Calcium 
Plasma and 
Urinary 
inorganic 
Phosphate 
Plasma and 
Urinary 
Creatinine 
Plasma 
Albumin 
Plasma 
Alkaline 
Phosphatase 
Instrument Techriique employed Normal plasma 
Clinicon ea2+ forms a violet complex 
Hitachi with O-cresolphythalein in 
712 alkaline conditions, 
Automatic detected at 600-66Onm 
Analyser wavelength at 37°C 
Multi- Phosphate reacts with 
channel arrmonium molybdate. Stannous 
Technicon ions (stannous chloride) 
Auto- reduces molybdiphosphate to 
Analyser heteropoly molybdenum blue, 
detected at 660nm 
Technicon Crea tinine produces a red 
Auto- colour in saturated alkaline 
Analyser solution of picric acid, 
II detected at 505nm at room 
temperature 
Technicon Albumin reacts with bromo-
SMA Multi- cresyl green dye at pH 4.2 
channel (+ 0.1) to form a coloured 
biochemical complex, detected at 630nm 
Analyser wavelength 
Clinicon 
Hitachi 
712 
Automatic 
Analyser 
Alkaline phosphatase converts 
p-nitro phenylphosphate to 
phosphate and p-nitro phenol 
(yellow in alkaline conditions) 
detected at 405nm at 37°C 
Range 
2.2 - 2.6 
rrmol/L 
0.8 - 1.4 
rrmol/L 
60 - 120 
mol/L 
31 - 51 gIL 
98 - 280 
IU/L 
..... 
"Measured plasma calcium values must be corrected for 
albumin levels as illustrated on the following page. Unless 
otherwise stated, plasma calcium concentrations quoted in 
the result sections were corected for albumin. 
'TIlE CORRECTION OF PLASMA CALCIUM 
(Editorial, 1977) 
There are three definable fractions of calcium in 
plasma: ionised, protein- bound and cornplexed fractions. The 
total plasma calcium is the sum of these three fractions. 
The ionised fraction is the physiologically relevant 
fraction but laboratory analysis of plasma measures total 
calcium. These results may be misleading especially when 
there is a change in plasma protein concentration or pH. To 
overcome this total plasma concentration is corrected 
albumin concentrations. Plasma pH is generally constant and 
has negligable effect on protein binding. 
Correction of plasma calcium is then simply corrected 
for an albumin concentration (Alb) of 40g/L using the 
following formula: 
~ ~ = ea.n + O.02( 40 - Alb ) 
where: 
Cac = corrected plasma calcium concentration (rnmol/L) 
~ ~ = measured plasma calcium concentration (rnmol/L) 
and Alb = measured plasma albumin concentration (gIL) 
APPmDIX 3 
SCATCHARD ANALYSIS IN IMHUNOMETRIC ASSAY 
(Taken from h'alker, 1977) 
In radioimmunoassay, and indeed radioreceptor assay, the 
response is measured in terms of labelled ligand total 
counts, L*, and labelled ligand bound counts, B*. 
Information on: 
(i) the heterogeneity of the binding sites, 
(ii) the binding capacity of either the antibody or binding 
protein (Ab), and 
(iii) the affinity constant of ligand-Ab interaction (Ka) 
are conveniently obtained by using the linear Scatchard 
equation in the form: 
where B" = bound ligand concentration, both labelled and 
unlabelled, L = total ligand concentration, and y = B/L. 
I 
If there is no protein discrimination between labelled 
and unlabelled ligand, y = B*/L*_ With axes y/(l-y) and yL, 
a linear relationship results, with slope -Ka and intercept 
Ab on the yL axis. 
APPENDIX 4 
DOUBLE-ISaroPE CALCIUM ABSORPTION TEST 
The test employs the use of an intravenous dose of 85Sr 
in conjunction with an oral dose of 47ea• To calculate the 
percentage of the oral dose absorbed by the intestine 
accurately, allowance must be made for the removal of 47ea 
into soft tissue and bone. Since 85Sr administered 
intravenously is distributed in the same manner as the oral 
dose of 47ea , the ratio of activity of the two in plasma is 
used to calculate the percentage absorption. 
Using a computer program designed for this study by Dr. 
J.R. Greenwell, University of Newcastle, the following data 
were inserted: 
WORKED EXAMPLE: Patient E.S. 
47ea wt given to patient = 5.0485mg wt standard = O.977g 
85Sr wt given to patient = 5.1200mg wt standard = O.990g 
47ea 85Sr 
(cpm) (cpm) 
Standard counts a) 5877 a) 3082 
b) 5271 b) 3216 
47ea std in 85Sr channel a) 2824 
b) 2573 
85Sr std in 47ea channel a) 5 
b) 8 
Background counts a) 7 a) 14 
b) 7 b) 15 
Imputing the patient values: 
TIME VOL OF SERUM 47ea 85Sr 
(min) (ml) (cpn) (cpn) 
0 4 7 14 
5 4 7 760 
10 4 16 392 
20 4 39 343 
35 4 67 292 
50 4 91 273 
75 4 129 272 
100 4 126 258 
140 4 159 257 
180 4 169 243 
240 4 165 231 
300 4 159 218 
360 4 163 219 
From the above data the computer programne is able to 
(a) calculate the percentage of 47Ca absorbed at a given 
time, and 
(b) plot a graph of the percentage of calcitnn absorbed 
against time. By differentiating this graph the initial 
fractional rate and the total percentage calcitnn absorbed 
after 6h can be estimated. 
1\1':1. I f \ ~ ~ h;,...\ ('.,c.\.L h ~ . ' - D - \ \ t ~ t e e = 6\.M.c:7 '-"\r 
o ~ ~ (c"\C\VN\ ~ s o ( w w a , ~ ~ l ~ { ' . .
1 - 7 
8 - 16 
17 - 27 
28 - 38 
APPmDIX 5 
TREATMENT OF SUBCLINICAL OSTEOMAlACIA IN THE ELDERLY: 
Tables showing individual biochemical and his to-
morphormetric responses after one month's treatment. 
Control patients 
Patients on Vitamin D3 
" " 1 Alpha 
" 
" 1 Alpha + Calcium supplements (Ca) 
BASAL 1 tuml 
CASE AGE SEX Cae P AP Cr t25 tl,25 Cae P AP Cr t25 tl,25 
0I1I01/L mrol/L IU/L unol/L ng/ml. pg/ml 11IOO1/L IIIIlOl!L IU/L \.IIIOl!L ng/ml. pg/m1 
1 75 F 2.31 0.71 413 129 1.8 12.0 2.39 1.04 264 144 25.5 
2 85 F 2.21 0.74 212 148 12.4 16.2 2.26 1.15 709 131 4.0 7.1 
3 80 F 628 131 22.5 20.8 1.B4 LOB 64B 142 12.5 36.6 
4 73 F 2.10 0.81 1352 71 7.5 5.8 1.98 0.71 2240 73 9.2 35.0 
5 85 M 2.04 0.66 518 153 2.00 0.81 1232 124 
6 70 F 2.07 0.91 588 90 2.16 0.74 444 126 
7 89 M 1. 76 1.10 374 197 7.2 13.5 1.94 1.03 505 195 
8 87 F 1.60 0.70 277 114 6.7 29.3 2.22 1.82 275 143 21.7 37.9 
9 86 F 2.42 0.68 464 75 6.2 11.1 2.22 0.85 597 75 22.6 49.1 
10 46 F 1.84 0.67 355 104 2.6 12.8 2.20 1.10 359 105 15.0 68.9 
11 95 F 2.30 0.93 187 104 4.4 14.1 2.33 1.09 484 109 29.7 37.6 
12 71 M 2.21 0.81 1303 70 2.7 20.6 2.12 1.42 2150 76 10.2 58.1 
13 53 F 2.24 0.68 427 153 4.1 22.5 2.12 0.81 417 132 16.5 43.3 
14 57 F 2.17 1.11 373 104 5.4 21.2 2.32 1.45 346 135 34.8 53.9 
15 80 M 2.30 0.92 960 147 2.16 1.09 1211 136 24.5 . 69.2 
16 80 F 1.B4 1.08 61lB 142 2.32 1.45 546 135 12.5 36.6 
17 83 F 2.27 1.13 295 119 15.0 21.4 2.27 0.85 238 132 11.6 41.3 
18 90 F 1.64 1.36 980 203 5.2 13.3 1.94 1.21 877 203 6.8 50.2 
19 80 M 2.21 0.68 195 103 1.3 12.5 2.30 1.12 251 91 2.8 28.0 
20 77 F 2.08 0.87 2925 112 0.8 13.4 2.12 0.87 5840 64 9.1 30.5 
21 81 F 2.23 1.04 241 141 7.4 30.0 2.28 1.19 264 109 3.5 37.8. 
22 79 F 2.23 0.86 130 90 4.5 13.4 2.28 0.78 349 90 1.9 35.2 
23 89 M 1.94 1.03 505 195 7.2 13.5 2.13 1.11 394 201 3.5 35.7 
24 78 F 2.26 1.53 421 79 1.8 19.2 2.18 0.95 294 91 5.9 36.7 
25 76 M 2.25 1.04 427 109 2.1 23.4 2.29 1.01 237 112 16.8 48.1 
26 85 M 2.01 O.Bl 1232 124 1.96 0.73 941 118 9.8 47.5 
27 90 F 1.56 1.34 759 164 3.6 15.4 2.14 1.37 616 141 
28 90 F 2.16 1.31 357 121 3.1 11.3 2.20 1.48 388 98 9.1 65.7 
29 86 F 2.16 0.83 321 74 6.8 4.5 2.26 1.38 218 97 2.9 77 .1 
30 43 F 2.03 0.64 473 53 3.9 4.4 1.99 0.83 455 49 2.4 51.0 
31 52 F 1.45 0.98 131 66 8.7 15.4 2.38 1.23 280 70 5.4 28.3 
32 83 F 2.04 0.77 1000 79 3.7 17.7 2.03 0.94 481 74 11.8 77.0 
33 81 M 2.15 0.76 587 104 2.7 15.2 2.04 0.60 744 129 10.2 34.3 
34 85 F 2.23 1.09 277 57 6.6 16.6 2.25 1.17 242 84 5.9 41.9 
35 88 M 2.13 0.42 227 111 5.8 25.7 2.06 0.53 629 93 3.9 41.5 
36 87 F 2.06 1.05 527 107 1.3 14.0 2.39 1.19 458 114 4.4 13.9 
37 78 F 2.36 0.64 314 91 2.6 3.3 12.1 50.4 
38 86 F 2.21 0.92 307 170 4.0 22.9 2.42 1.04 342 152 
: : 
BASAL 1 MmH 
~ ~ TRF..A1MENl' OA Surf 01 OA Surf 01 
No. 
1 Control 4.9 31.6 0.16 4.1 22.0 0.19 
2 II 16.8 64.4 0.26 6.6 34.5 0.19 
3 II 10.7 45.7 0.23 
4 II 30.3 71.3 0.42 
5 II 53.4 84.9 0.63 51.7 100 0.52 
6 " 17.9 57.9 0.31 8.8 22.1 0.40 
7 " 37.3 85.3 0.44 33.0 85.8 0.39 
8 Vitamin D3 24.5 68.0 0.36 5.9 42.2 0.14 
9 II 9.0 33.7 0.27 6.2 22.2 0.28 
10 II 41.4 91.3 0.45 27.3 89.7 0.30 
11 II 6.6 20.0 0.33 7.3 26.1 0.28 
12 " 45.7 81.2 0.56 31.3 80.0 0.39 
13 II 8.2 37.5 0.22 22.7 52.2 0.44 
14 II 19.1 61.8 0.31 13.1 54.4 0.24 
15 II 40.8 94.6 0.41 22.8 65.8 0.35 
16 II 1.0 
17 1 Alpha 10.7 29.4 0.36 6.6 28.5 0.23 
18 II 30.6 88.1 0.35 23.0 90.1 0.26 
19 II 5.2 23.6 0.22 5.02 18.0 0.28 
20 II 30.1 68.7 0.44 31.9 93.0 0.34 
21 " 3.8 20.2 0.19 3.8 21.0 0.18 
22 II 16.8 59.5 0.28 14.9 75.2 0.20 
23 " 33.0 85.8 0.39 15.8 49.2 0.32 
24 " 13.3 43.6 0.31 12.8 58.3 0.22 
25 " 17.3 41.2 0.42 8.5 60.5 0.14 
26 II 51. 7 100.0 0.52 58.4 93.7 0.62 
27 " 51.8 87.4 0.59 39.7 85.2 0.47 
28 1 Alpha 25.6 61.2 0.42 12.0 38.1 0.32 
29 +Ca 8.4 30.2 0.28 5.7 20.0 0.29 
30 II, 59.9 92.2 0.65 37.6 87.9 0.43 
31 " 5.4 14.8 0.36 2.7 10.4 0.26 
32 " 56.2 92.8 0.61 19.8 70.9 0.28 
33 " 20.9 73.7 0.29 24.9 64.3 0.39 
34 " 21.5 8.8 0.25 1.24 10.0 0.12 
35 " 33.5 96.2 0.35 28.4 78.8 0.36 36 " 13.2 64.5 0.21 11.6 52.2 0.22 
37 " 12.0 41.6 0.29 
38 " 18.5 68.1 0.27 14.7 63.0 0.23 
APPmDIX 6 
CHANGES IN OSTEOCALCIN AND VITAMIN D METABOLITES AFTER 
FRACTURE OF TIlE FEMORAL NECK: 
Table showing individual biochemical and histomorphormetric 
values at the time of the fracture and one week later. Note, 
two patients histomorphometric data were mislaid. 
CASE AGE SEX SAMPLE 
No. 
1 92 F b 
1 wk 
2 65 F b 
1 wk 
3 78 F b 
1 wk 
4 86 F b 
1 wk 
5 68 F b 
1 wk 
6 79 F b 
1 wk 
7 83 F b 
1 wk 
8 72 F b 
1 wk 
9 62 F b 
1 wk 
10 71 F b 
1 wk 
11 63 H b 
1 wk 
12 92 F b 
1 wk 
13 67 H b 
1 wk 
14 65 F b 
1 wk 
15 89 F b 
1 wk 
Cae P AP Cr GGT 8ill ALT t25 tl,25 DBP f1,25 0Ca1 OA Surf or 
nmol/L nmol/l IU/l lJDOl/L IU/L unol/L IU/L ng/ml pg/ml ...vr. ~ ~ x x ng/ml 
2.20 1.30 260 115 
2.11 1.16 327 115 
2.30 0.92 106 100 
2.32 1.04 174 100 
2.13 0.90 123 105 
2.20 1.01 194 107 
2.59 0.88 356 
2.43 0.81 411 
94 
95 
2.21 1.07 178 60 
2.15 0.75 295 82 
2.33 1.13 619 143 
2.17 1.21 447 143 
2.13 1.05 118 88 
2.16 0.98 127 91 
2.12 0.99 112 69 
2.30 0.98 970 84 
2.04 1.09 84 92 
2.28 1.04 116 67 
2.08 0.96 138 100 
2.07 0.86 167 107 
2.07 1.70 126 87 
2.07 0.86 167 107 
2.28 1.22 148 110 
2.20 1.17 131 68 
2.17 
2.25 
1.10 170 77 
1.15 251 55 
2.17 0.85 182 67 
2.17 0.98 211 72 
2.12 1.36 183 109 
2.17 0.98 252 81 
39 7 
22 13 
26 7 
38 10 
40 7 
294 9 
17 9 
224 12 
33 10 
12 1 
10 ·10 
12 12 
22 20 
30 6 
4 9 
19 2.4 9.2 267 0.48 1.7 0.95 5.46 0.17 
8.8 305 0.41 2.4 
32 
18 
2.6 
3.0 19.8 231 1.21 1.4 5.60 37.7 0.15 
3.4 30.2 366 1.16 3.0 
3.0 21.8 328 0.84 2.3 2.17 7.96 0.27 
2.7 32.0 317 1.42 3.5 
14 3.4 17.1 180 1.34 2.2 0.66 4.26 0.16 
28.3 167· 2.39 3.5 4.7 
9 5.0 34.0 395 1.21 2.4 0.37 2.38 0.16 
1.9 9.8 255 0.54 0.6 
14 2.1 6.4 404 0.22 2.4 3.08 16.08 0.19 
6.7 466 0.20 2.1 2.4 
14 0.5 5.0 302 0.23 1.3 1.11 4.51 0.25 
8.6 299 0.41 1.4 
34 
1.0 
5.6 
4.6 
8.7 265 0.46 0.9 2.33 14.4 0.16 
14.1 313 0.63 2.5 
26 5.5 16.4 294 0.79 1.7 4.56 17.1,3 0.26 
5.7 33.1 346 1.35 4.0 
6 5.0 5.4 261 0.29 2.6 . no bone biopsy 
6.9 9.4 193 0.69 2.8 
40 11.2 10.5 379 0.39 3.0 2.41 12.74 O.try 
9.1 18.3 414 0.62 5.5 
14 4.7 5.3 290 0.26 6.5 1.24 10.49 0.12 
4.8 11.5 306 0.53 5.5 
17 2.3 
3.8 
9.0 343 0.37 2.9 1.15 5.75 0.2(· 
12.1 394 0.43 3.7 
4 5.3 10.9 290 0.53 5.3 no bone biopsy 
5.7 9.8 326 0.42 5.3 
12 1.7 4.7 261 0.25 3.8 1.43 17.05 O.Ot 
3.1 9.9 394 0.35 6.1 
CASE lICE SEX SAMPLE 
No. 
16 70 F b 
1 wk 
17 86 F b 
1 wk 
18 58 F b 
1 wk 
19 84 F b 
1 wk 
20 86 F b 
1 wk 
21 82 F b 
1 wk 
22 84 F b 
1 wk 
23 90 F b 
1 wk 
24 79 H b 
1 wk 
25 80 F b 
1 wk 
26 80 F b 
1 wk 
27 82 F b 
1 wk 
28 78 F b 
1 wk 
29 85 F b 
1 wk 
30 85 F b 
1 wk 
Cae P AP Cr GGT 8111 ALT t25 tl,25 DDP fl,25 OCal Surf or 
omol/L omol/L IU/L UDOl/L IU/L UDOl/L IU/L ng/ml pg/ml mg/L i ~ ~ ~ ng/ml 
2.19 0.66 208 
2.27 1.28 293 
77 
64 
20 38 
2.24 
2.41 
1.44 152 
1.34 212 
2.25 1.01 102 
2.66 1.44 144 
106 
105 
69 
71 
2.32 0.86 302 120 
2.35 0.90 757 90 
2.15 0.90 147 81 
2.29 0.95 203 77 
2.03 0.69 151 108 
2.37 1.02 170 122 
2.23 1.20 157 
2.27 1.33 231 
2.30 1.97 221 
2.18 1.33 134 
84 
89 
87 
85 
2.28 1.16 130 138 
2.46 1.20 291 110 
2.19 1.08 159 85 
2.30 1.33 217 113 
2.17 0.72 201 94 
2.44 1.21 222 109 
2.50 1.94 304 114 
2.26 0.96 215 114 
2.36 0.84 150 111 
2.32 1.27 165 150 
26 
19 
17 
17 
35 
25 
8 
21 
45 
32 
37 
2.37 1.31 159 98 25 
2.03 .1.10 201 115 
2.61 1.09 742 108 135 
2.50 1.21 388 281 
14 
9 
20 
17 
17 
31 
8 
15 
12 
15 
7 
10 
31 
13 
24 
9 
6 
13 
74 
4.4 
3.6 
3.2 
2.7 
15.2 264 0.81 6.5 2.50 13.51 0.19 
6.0 448 0.19 5.5 
14.1 384 0.3 2.3 2.03 13.3 0.15 
14.1 331 0.61 2.0 
5.7 ·.30.0 289 1.46 1.0 2.11 7.91 0.27 
5.6 16.9 474 0.50 0.7 
1.7 
1.4 
2.5 
2.8 
2.2 
1.5 
15.2 221 0.97 5.3 1.17 6.91 0.17 
16.4 492 0.47 7.2 
14.2 200 1.00 3.8 0.72 4.85 0.15 
19.1 348 0.77 4.9 
11.2 236 0.67 3.8 0.91 5.73 0.16 
12.6 302 0.59 4.8 
12.9 19.6 269 0.91 2.7 1.75 20.79 0.08 
11.0 12.6 341 0.62 3.3 
13 10.9 28.5 458 0.88 3.0 3.80 12.5 0.30 
7.0 19.5 350·0.78 3.3 
9 
15 
9 
21 
27 
27 
13 
6.2 16.2 191 1.19 1.6 2.80 11.35 0.25 
8.0 18.9 228 1.17 2.3 
4.3 15.2 339 0.63 4.7 0.27 1.87 0.15 
2.0 11.1 435 0.36 5.3 
4.2 10.6 336 0.44 6.1 0.21 2.27 0.09 
2.9 27.1 352 1.08 7.7 
4.6 20.2 313 0.91 0.7 0.86 3.97 0.22 
2.6 25.9 406 0.90 1.4 
7.2 22.5 272 1.16 2.1 0.79 3.75 0.21 
9.2 33.7 343 1.38 5.2 
5.5 26.8 276 1.37 6.6 2.69 12.46 0.22 
3.4 25.0 366 0.96 5.7 
3.2 30.6 300 1.44 1.5 3.78 12.36 0.31 
3.0 22.0 346 0.90 1.0 
.APPaIDIX 7 
VITAMIN D DEFICIENCY AND FEMORAL NECK FRACIURE 
Table showing individual biochemical and histomorphormetric 
values for the three groups studied: 
Table A: Osteoporotic patients who had sustained a 
fracture of the femoral neck. 
Table B 
Table C 
Osteomalacic patients who had sustained a 
fracture of the femoral neck. 
Osteomalacic patients without fractures. 
CASE AGE SEX 
No. 
N 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
ll, 
84 F 5 
63 F 1 
90 M 13 
71 F 4 
79 F 8 
78 F 0 
86 M 0 
68 F 1 
92 F 0 
83 F 0 
92 F 0 
67 M 0 
58 F 0 
90 F 0 
81 F 0 
80 F 0 
86 F 0 
84 F 0 
82 F 0 
80 F 0 
82 F 0 
78 F 0 
85 F 0 
85 F 0 
Ca P AP Cr 
nmo]jL nmo]jL IUIL uno]jL 
2.42 
2.30 
2.13 
1.80 
2.20 
2.13 
2.59 
2.21 
2.20 
2.13 
2.24 
2.17 
2.66 
2.30 
2.28 
2.19 
2.15 
2.32 
2.03 
2.17 
2.50 
2.36 
2.61 
2.31 
0.84 
1.13 
0.46 
0.90 
0.90 
0.88 
1.07 
1.30 
1.05 
1.22 
1.10 
1.97 
1.16 
1.08 
0.90 
0.90 
0.69 
0.72 
1.94 
0.84 
1.3 
605 
202 
175 
123 
123 
356 
178 
260 
118 
148 
170 
221 
130 
159 
11,7 
302 
151 
201 
JO/, 
150 
7l,2 
159 
98 
180 
105 
105 
105 
94 
60 
115 
88 
110 
77 
87 
138 
85 
81 
120 
108 
94 
114 
111 
108 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
JO 
31 
32 
33 
34 
80 F 0 2.23 1.09 277 
98 
57 
195 
135 
143 
35 
36 
37 
38 
70 M 0 
81 F 3 
79 F 0 
72 F 0 
71 M 0 
85 M 4 
89 F 0 
70 F 0 
86 F 0 
84 F 0 
90 f 10 
94 F 0 
82 F 5 
2.32 1.98 
2.36 0.98 
2.33 1.13 
2.12 0.99 
2.07 1. 70 
2.13 0.80 
2.12 1.36 
2.19 0.66 
2.24 1.44 
2.23 1.20 
2.JO 1.34 
2.JO 1.07 
2.23 1.04 
220 
169 
619 
112 
126 
125 
183 
208 
152 
157 
276 
139 
2l,1 
69 
87 
76 
109 
77 
106 
84 
INS 
89 
tt,! 
t25 . 
nglml 
8.1 
9.8 
2.6 
3.6 
1.9 
3.0 
3.4 
5.0 
2.4 
0.5 
4.8 
2.3 
5.7 
10.9 
6.2 
4.3 
2.5 
1.7 
2.2 
4.3 
4.6 
7.2 
3.3 
5.5 
6.5 
3.8 
3.5 
2.1 
5.6 
11.2 
1.6 
1.7 
4.4 
3.2 
12.9 
10.9 
2.4 
7.4 
DDP £1,25 
mg/L ind@x 
xio-' 
9.4 312 
4.7 297 
6.5 316 
6.5 211 
21.5 201 
21.9 328 
17.1 180 
34.0 395 
9.2 267 
5.0 302 
15.3 290 
9.0 343 
JO.O 289 
20.2 458 
16.2 191 
15.2 339 
14.2 200 
15.2 221 
11.2 236 
10.6 336 
20.3 313 
22.5 272 
JO.6, 300 
26.8 276 
16.6 
0.42 
0.22 
0.29 
0.43 
1.50 
0.84 
1.33 
1.21 
0.48 
0.23 
0.26 
0.53 
1.47 
0.88 
1.19 
0.63 
1.00 
0.97 
0.67 
0.45 
0.91 
1.17 
1.44 
1.37 
14.6 
5.3 
6.4 
8.8 
10.5 
21. 7 
4.7 
15.2 
14.1 
254 1.03 
381 0.20 
404 0.22 
265 0.46 
379 0.39 
19.6 
28.5 
16.3 
30.0 
261 0.25 
264 0.81 
384 0.52 
269 1.02 
392 0.88 
355 (J.83 
PATIENfS WIm OSTIDPOROSIS + FEMJRl\t NEQ{ FRACIURE 
A 
SurE 01 
2.0 9.1 0.22 
1.5 10.4 0.14 
o 0 0 
2.81 11.3 0.25 
0.74 6.4 0.12 
2.17 7.96 0.27 
0.66 4.26 0.16 
0.37 2.38 0.16 
0.95 5.46 0.17 
1.11 4.51 0.25 
1.24 10.5 0.12 
1.15 5.75 0.20 
2.11 7.91 0.27 
3.80 12.5 0.30 
2.80 11.4 0.25 
0.27 1.87 0.15 
0.72 4.85 0.15 
1.17 6.91 0.17 
0.91 5.73 0.16 
0.21 2.27 0.09 
0.86 3.97 0.22 
0.79 3.75 0.21 
3.78 12.4 0.31 
2.69 12.5 0.22 
2.10 8.9 0.25 
3.63 10.9 0.33 
3.30 24.9 0.13 
3.08 16.1 0.19 
2.33 14.4 0.16 
2.41 12.7 0.19 
3.56 15.7 0.23 
1.43 17.1 0.08 
2.50 13.5 0.19 
2.03 13.3 0.15 
1.75 20.8 0.08 
3.80 12.5 0.30 
3.90 14.3 0.28 
3.80 20.2 0.19 
B 
CASE AIJE SEX N Ca P AP Cr ill tl,25 DBP fI,25 OA Surf 01 
No. 1IIJI01/L 1IIJI01/L IU/L uool/L ng/ml pg/ml mg/L i n d e ~ ' i i
xlu-
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
78 F 
87 F 
90 F 
92 F 
80 F 
81 M 
87 M 
86 F 
90 F 
78 F 
78 F 
83 F 
80 M 
77 F 
75 F 
83 F 
76 M 
75 F 
86 F 
86 F 
83 F 
89 M 
85 F 
87 F 
76 M 
o 2.26 1.53 
o 2.06 1.05 
o 2.35 1.46 
o 2.03 0.98 
11 2.03 1.52 
2 2.15 0.76 
10 1.60 0.72 
431 
527 
352 
917 
715 
587 
428 
6 2.21 0.92 307 
2 2.16 1.31 357 
o 2.36 0.64 314 
1 2.23 0.86 130 
6 2.04 0.77 1000 
8 2.17 1.02 328 
5 2.08 0.87 2925 
o 2.13 0.81 1352 
o 2.30 0.92 206 
22 2.26 0.81 
5 2.31 0.71 
1 2.42 0.86 
7 2.16 0.83 
7 2.27 1.13 
11 1. 76 1.10 
o 2.21 0.74 
5 2.03 0.81 
2 2.21 0.68 
289 
413 
464 
321 
295 
374 
212 
252 
195 
ins 
107 
289 
77 
165 
104 
114 
170 
121 
ins 
90 
79 
ins 
88 
71 
100 
109 
129 
75 
89 
119 
197 
148 
49 
103 
1.9 
1.3 
5.5 
0.8 
22.5 
2.7 
6.7 
2.5 
3.1 
2.6 
4.5 
3.7 
2.5 
0.8 
9.2 
3.0 
23.0 
1.8 
6.2 
6.8 
15.0 
7.2 
12.4 
2.4 
1.1 
19.5 
14.3 
11. 7 
21.0 
20.8 
15.3 
29.3 
23.0 
11.3 
3.0 
13.5 
17.8 
19.5 
13.5 
5.7 
20.1 
21.3 
12.0 
11.1 
4.5 
21.4 
13.5 
16.4 
14.7 
12.1 
258 
272 
447 
271 
278 
307 
328 
254 
328 
151 
231 
283 
292 
392 
392 
PATIENI'S WITlI OS"l1nW..ACIA + A Fm>RAL NECX FRACTURE 
13.3 43.6 0.31 
0.77 13.2 64.5 0.21 
0.61 28.2 68.1 0.43 
0.65 37.4 92.0 0.41 
10.7 45.7 0.23 
20.9 43.3 0.29 
24.5 68.0 0.36 
1.18 18.5 68.1 0.27 
25.6 61.2 0.42 
0.15 12.0 41.6 0.29 
0.61 10.9 55.4 0.20 
0.76 56.2 92.8 0.61 
1.08 5.9 31.1 0.19 
0.58 30.1 68.7 0.44 
0.53 30.3 71.3 0.42 
1.16 5.6 37.7 0.15 
17.3 41.2 0.42 
0.59 4.9 31.6 0.16 
0.57 9.0 33.7 0.27 
0.16 8.4 30.2 0.28 
10.7 29.4 0.36 
33.0 85.8 0.39 
0.59 16.8 64.4 0.26 
15.7 63.2 0.25 
5.2 23.6 0.22 
c 
CASE AGE SEX N Co P AP Cr t25 tl,25 OOP fl,.25 01\. Surf 01 
No. 1D1I01/L 1II1101/L lUlL unol/L ng/ml pglml oWL i n d e ~ ~
xl 
64 43 F 0 2.02 0.64 473 53 3.9 4.6 59.9 92.2 0.65 
65 46 F 0 1.84 0.67 355 104 2.6 13.0 41.4 91.3 0.45 
66 90 F 0 1.56 1.34 759 164 3.7 16.0 51.8 87.4 0.59 
67 81 M 0 2.21 0.81 1303 70 2.7 21.0 45.7 81.2 0.56 
68 71 F 0 1.87 1.17 1058 43 0.7 14.8 51.9 811.8 0.61 
69 70 F 0 1.17 0.98 817 104 1.0 23.9 351 0;94 16.2 52.0 0.31 
70 52 F 2 1.45 0.98 131 60 8.7 16.0 426 0.52 5.38 14.8 0.36 
71 53 M 1 2.24 0.68 427 153 2.5 22.9 8.2 37.5 0.22 
72 29 F 0 2.26 1.33 276 ins 3.9 47.1· 15.1 53.4 0.28 
73 57 F 0 2.17 .1.11 373 104 5.4 21.5 19.1 61:3 0.31 
74 88 M 0 2.13 0.42 227 111 4.1 26.1 386 0.31 33.5 96.2 0.35 
APPENDIX 8 
CHANGES IN CALCIUM HOMEOSTASIS AFTER TOTAL 
TIIYROPARATIIYROIDECTOMY IN MAN 
Tables showing individual biochemical values for the 10 
patients studied: 
Patlent 1 
HOSPITAL NUMBER " 5', 31 92 
AGE 82 
PLIISMII 
Date 21/2 23/2 2',/2 2512 26/2 2712 28/2 113 213 313 1,/3 513 6/3 713 6/3 9/3 10/3 
Time Po/op 1 2 3 I, 5 6 1 8 9 10 11 12 D 14 
Creatinine 10 76 81 91 63 13 80 51 13 6', 66 33 67 78 61 70 71 
Urea 3.9 3.5 1,.1 5.1 1,.0 r..6 5.6 6.8 0.2 8.1 6. 1, 9.2 8.0 5.2 5.2 1,.0 2.9 
Sodium 132 138 136 11,0 130 1/,2 139 138 11,0 1/,0 139 135 132 126 130 128 1!?9 
Potassium '1.'1 3.1, 3.0 3.5 2.0 3.1 ',.1 ".5 3. 1, 1 •• 0 6.6 3.8 3.3 3.9 3.9 1,.1 
Bicarb 26 20 18 17 2" 23 22 17 18 21 18 
Calcium 2.1'2 2.35 2.2
" 
1.99 1.76 1.90 2.12 2.15 1.99 2.05 1.85 1.90 1.8'. 1.79 1.91 2.12 2.21 2.10 
Corr Ca 2. 1,6 2.,,5 2.',0 2.19 2.00 2.22 2.32 2.39 2.27 2.35 2.07 2.11. 2.10 2.05 2.27 2.1,4 2. 1,1 2.1,6 
Phosphate 1.32 1.26 1.20 1.65 0.19 0.11. 0.1'1 0.63 0.81 1.33 1.64 1.60 1.38 1. /.9 1.1.0 1.5" 1.59 1.',2 
Magnesium 0.15 0.13 0.91 0.1,0 0.01 0.91 0.90 0.95 0.93 0.68 0.71 
IIlk Phos 220 100 163 11,1 113 133 139 11,3 159 167 195 203 219 212 1228 113 269 11,7 
1I1bumin 31 35 32 30 20 20 30 20 26 25 29 28 27 27 124 2" 27 26 
Globulin 
GGT 25 25 23 13 I', 11, pI 41 "If 67 16 81 ~ 6 6 55 
BHi,'ubin 5 9 9 16 21 12 13 11, 15 15 15 0 0 9 
ALT 9 20 9 19 10 10 I', 11 12 5 2 
" 
1 I, 
Glucose 
FIISTING UnINF; 
Creatinine 2.5 3.0 ~ . 7 0 0 9.0 9.3 9.7 2.1 12.<1 
Calcium 1.1,5 2.5 2.02 ~ . l ' , ,
.70 16·76 3.75 ".69 3.81 .40 
Phosphate 6.30 1.6 20.3 0.66 0.60 0.06 35.83 49.4 6.66 17.02 
Sodium 30 10 12', 96 ',6 ',0 32 100 roo 
CaE 1,1 65 296 169 50.3 3',.4 ,,0.0 121 53 
NaE 8',0 260 11,92 19153 201," 3,,3 906 274 3190 1195 
TmCa/GFn 1.90 1.70 1.35 l.10 .1,3 1. 75 1.65 1.55 1.25 .65 
IMP/OFn 1.20 1.06 P.I'6 >1.', 1.31, 
2', lin unINE 
Volume 1660 621 313 1105 12653 21,69 2556 13,,5 Lost 1509 1094 6610 Lost 1201 Lost <171 
CreatinIne 5.1 5.4 1.9 6.6 ~ . 4 4 r>.2 ~ . 6 6 k 
CaU:lum 
".2 ',.1, 3.2 3.9 ~ . I ' ' :>.2 10.0 fr.1 
Phosphate 1.7 0.3 ~ . O O 1',.0 ,.00 
Sodlum 1,3 17 115 07 
NAME ratlent 2 
HOSPITIIL NUMBER N 51, 37 89 
nGE 1,8 
PI.IISHII 
Date 5/2 6/2 11/2 12/2 lJ/2 1,/2 ~ 5 / 2 2 t6/2 1712 18/2 19/2 20/2 21/2 212 23/2 2712 3/3 
Time Po/op 1 2 iJ , 6 7 8 9 10 11 12 13 11, 
Creatinine 63 63 97 67 tT2 ~ 6 6 ~ 2 2 2 1,9 "I, 65 67 68 51 71 
Urea 
Sodium 
Potassium ',.1, 3.7 p.3 t2.9 ~ . 2 2 .2 p.8 1,.1 1,.0 3.9 1,.1 1'.6 1,.1 
Oicarb 
Calcium 2.33 2.51, ~ . 1 5 5 b.03 ·91 t2.00 .93 1.80 1.90 1.91, 1.96 1.61, 1.1,9 1.53 1.87 
Corr Ca 12. 37 2.37 12.58 Iz .1,7 b.21 2.11 2.22 2.17 1<.08 2.16 2.18 1.98 1.82 1.71 1.69 1.93 
Phosphate 
.27 l.51 1..1,3 .06 0.76 1.62 .67 1.91, 1.71, 1.81, 1.77 1.67 1.96 1.81, 
Magnesium p.93 0.66 0.73 0.57 0.66 p.61 ~ . 6 0 0 0.66 0.69 p.01 0.70 
/Ilk Phos 52 170 02 73 90 108 III 122 172 161, 1270 56 221 i233 
Albumin 30 38 21, 31 30 29 28 26 ~ I ' ' 22 29 pI .0 p2 l:lJ 
Globulin 1 I, 26 
GGT 26 18 16 18 52 ,8 ,1 
l311irubln 6 24 17 11 13 6 6 
liLT 17 38 19 15 13 16 liS 
Glucose 
fllSTING URINE 
Creatinine 4.6 10.2 12.2 1,.6 0·9 7.1. 4.3 2.3 3.7 7.0 
Calcium 3.5 10.0 0.20 1.1, 0.75 0.55 0. 1'5 1.1, 2.7 3.t, 
Phosphate 0.85 57. 1, 27.5 ,,5.1, 0.1,0 0.62 29.1 21.5 15.7 16.0 
Sodium 33 1,1 66 170 102 67 182 156 115 73 
CaE 31. 7 61.7 1.09 I,.J. 3.29 15·9 51.6 59.7 25 
NaE 171, 253 560 362 2069 1,90 2071, 2984 2020 135 
TmCa/GfR l.90 1.65 2.10 >2.5 1.85 2.05 2.35 1.75 1.55 1.55 1.32 
TMP/GfR 1.16 0.91, 1. 1,6 1. 1,6 l.66 1.1,4 
21, IIR URINE 
Volume 2230 165 71,0 2665 1796 759 21,05 1312 2616 2380 906 641 850 1067 580 6101 
Creatinine 8.0 1.66 6.11, 7. 1,6 7.72 l.1,1, 5.0 7.06 6.76 5.71 5.3 4.6 6.7 1,.0 2.1 
Calcium 1.65 .1. 70 3.70 1.49 0.83 1.6 0.32 I, .9 5.11, 0.52 0.94- 0.74 
rhosphate 9.5 16.2 23.5 1. 1,0 3.37 2.5 25.6 1,0.3 38.9 19.6 3.3 
Sodium 85 68 1,7 309 276 1013 360 1',7 397 192 7 5 610 , 
NAME Patient 3 
HOSPITAL NUMBER N 55 10 23 
AGE 62 
PLASMII 
Date 2411, 2711, 2811, 2911, 3011, 115 215 3/5 1015 5/5 6/5 715 8/5 9/5 1015 1115 1215 
Time Po/op 1 2 3 I, 5 6 7 8 9 10 i.1 12 13 11, 
Creatinine 61, 63 71 107 88 71 61 61 62 59 50 50 56 51, 60 1,7 62 
U"ea 2.6 3.6 5·3 5.3 6.5 6. 1, 6.5 5.3 6. /, 6.1 1,.0 5.5 5.1 6.1 5.5 6.9 6.0 
Sodium 136 11,2 139 139 lToI 1',0 11,0 136 137 136 136 133 133 136 13
'
, 132 1.]/, 
Potassium 3.5 3.7 I, .1 I, .1 3.9 1,.3 3.9 1,.2 1,.2 3.0 1,.1 3 9 1 •• 1 3.8 I, .1 1,.2 3.9 
Bicarb 2
" 
23 25 26 27 25 22 25 
Calcium 2.1,3 2.20 2.31 1.80 1..92 1.90 1. 72 1.51 1.60 1.63 1.51 1.58 1.72 1.62 1.63 
Corr Ca 2.51 2.1,1 2.5
" 
2.00 2.lf, 2.18 2.08 1.85 1.91, . 1.97 1.91 1.9/, 2.00 2.00 1..95 
Phosphate 1.20 1.12 1.33 1.0
'
, 0.7
" 
0.88 1.3
" 
1.2/, 1.23 1.1'9 1.65 1.1,6 1.59 1.65 1..71 
Magnesium 0.78 1.10 0.17 0.72 0.9
" 
0.7
" 
0.73 0.84 0.82 0.68 
Alk rhos 333 155 25 /, 112 62 125 12/ 1',1. 139 212 lIll, 229 220 252 262 )1,7 
Albumin 36 23 35 30 29 26 2
" 
22 21, 23 23 23 22 26 22 2
'
, 
Globulin 
GGT 15 2
" 
30 0 11, 11, 10 18 JI. 65 
Bilirubin 10 5 10 16 12 10 11 11 11 21 
ALT I, 0 1,3 27 25 1 7 7 9 2 
Glucose 1', <9 
r-ASTING URINE 
C.'eatl.nine 5.6 5.6 16.1, 11,.0 9·7 1,.9 1,.7 6.3 5.8 5.1 
-
Calcium 1,.8 3.3 0.2 6.5 1,.8 ·2.03 2.19 2.6 1.6lo 2.5 
Phosphate 6.1 8.3 0.12 1.55 2/ .3 7.9 20.1. 23.7 19.1 2/,.8 
Sodium 2/ 1,0 2 I, 51 151 96 122 118 
CaE 5', 1,2 1.3 1,1 38 25 27 23 20.6 
NaE 270 507 1/,50 12.6 32 635 1895 853 973 
TmCa/GFR 1.813 1.83 2.1,3 1.60 1.65 1.65 1.1,3 1.55 1.53 
TMP7GFR 1.28 1.101 1..06 0.67 1.
'
,6 0.99 1.52 
2
'
, lin UnINE 
Volume 1387 
Creatinine 1.6 
Calcium 3.3 
Phosphate 1.3 
Sodium 103 
NAME Patient I, 
HOSPITAl. NUMBER N 55 22 65 
AGE 72 
Pl.ASMA 
Date 11/6 15/6 16/6 1716 16/6 19/6 20/6 21/6 2216 23/6 24/6 25/6 26/6 2116 28/6 29/6 
Time 1'010 1 2 3 Ii 5 6 7 6 9 10 11 12 13 
Creatinine 85 101 101 95 105 102 61 57 70 73 68 69 78 69 56 73 
Urea 4.4 5.5 5.5 6.5 9.7 10.5 9.4 6.9 1.9 10. /, 9.2 7.3 6.4 9.1 10.0 11.6 
Sodium 136 1/,/, 11,1, 139 11,0 141 11,3 IItl 142 139 139 138 139 141 137 1',1 
Potassium 3.9 3.6 3.6 3.0 3.2 3.6 3.1, 3.4 3.5 3.B 3.9 3.1 3.B 3.6 3.6 3.3 
Bicarb 25 2'. 23 25 24 21 20 21 22 
Calcium 2.29 2.32 2.01 1.B2 1.13 1.86 1.75 1.6't 1.56 1.6't 1.67 1.61 1.55 1.6't 
Corr Ca 2./,1 2.31 2.52 1.9/ 1.83 2.20 2.09 2.00 1.94 2.00 1.85 1.95 1.89 1.9/, 
Phosphate 1.23 1.61 1.11 1.50 1. /,7 1.50 1.75 1.96 1.78 1.74 2.09 2.21 2.11 2.07 
Magnesium 0.81 0.85 0.50 0.66 0.56 0.51 0.54 0.11 0.63 0.64 0.70 
/Ilk Phos 112 161 171 132 107 126 237 231 217 312 386 384 405 (,33 550 
Albumin 31 31 30 25 3/, 35 2/, 24 22 22 22 21 23 23 25 
Globulin 20 29 29 30 
GGT 25 23 13 79 100 150 
Bilirubin 10 7 10 12 15 16 
Al.T 5 5 1', 13 11 7 
Glucose 19 
FASTING URINE 
Creatinine 8.5 12.5 H.O 6.6 1.6 9.1, 7.1 6.2 6.8 6.1 8.4 
Calcium 1.42 1.21 0.9/, 2.8/, 2.11 2.24 0.10 0.34 0.39 0.6 0.57 0.31 
Phosphate 10.2 15.5 23.B 1.62 12.36 1. 74 36.8 36.2 23.2 40.5 2/,.1 I,B.3 
Sodium 1/,0 18 37 60 127 57 23 85 114 56 b9 41 
CaE 11, .I, 21.6 32.6 9.B <1 3.2 1,.3 6.9 6.4 2.5 
NaE 593 921 179 8i
" 
1269 6 /,2 100 273 
TmCa/GfR 2.05 1.55 1. /,0 1.50 1.15 .90 2.10 
mP/GfR 
21, I1R URINE 
Volume 1130 
Creatinine I-S 
Calcium 
Phosphate 
Sodium 141\-
NAME PatIent 5 
HOSPITAL NUMBER 
AGE 15 
PLASMA 
Date 212 3/2 1"2 5/2 6/2 712 8/2 9/2 10/2 11/2 12/2 13/2 14/2 15/2 16/2 1712 10/2 
Time Po/op 1 2 3 4 5 6 7 8 9 10 11 12 113 14 11" 
Creatinine 6', 51 88 72 58 50 57 69 65 62 611 67 176 53 16, 1':1 
Urea 6.0 6.8 1.0 8.2 9.7 9.3 9.5 10.7 10·9 10.8 12.2 12.2 11.0 11.5 10.3 8.4 
Sodium I'll 139 139 135 136 137 139 130 142 137 139 131 134 131 131 132 
Potassium 3.3 3.3 3.2 3.8 3.6 3.2 3.6 3.9 ".0 1'.3 I,. t 1,.2 1'.3 4.1, 3.g J.g 
Oicarb 27 15 26 23 22 24 17 22 21 16 
C .. lcium 1.85 1.06 2.2/, 1.07 1.81, 1. 78 2.13 2.02 2.0/, 1.90 
Corr Ca 1.96 2.11 2.06 1.08 2.30 2.20 2.35 2.00 
Phosphate 1.20 1.35 1.56 1.6it 1.68 1.1,8 1.63 1.80 1.6't 
Magnesium 0.70 0.51 0.52 0.50 0.92 0.71 , 
Alk Phos 122 1',0 11'5 1',6 210 JI,I, 1tl9 390 1,70 ~ 4 5 5 556 
Albumin 35 33 20 30 29 35 31 32 ~ 1 1 131 27 
Globulin 22 21 21 35 
GGT 15 16 12 13 37 03 123 100 151 
Bilirubin 32 33 20 19 10 2/, 29 0 21 
ALT 17 13 10 9 16 18 9 ~ 1 1 15 
Glucose , 
FASTING URINE 
Creatinine 16.3 11.1, 7.6 10.5 1,.3 6.6 
Calcium 1.06 5.1,6 0.5 t, 0.60 0.6 1.11 0.1, 
Phosphate 1.38 2.10 26.6 18.12 38·9 2.82 "5.6 
Sodium 01 01 16 10 12 13 
CaE 5.8 1,2 3.2 9.1 10.4 
NaE 253 625 51, 101 122 
TmCa/GfR 1.92 1.80 2.00 2.0 
TMP/GfR 
2/, I1R URINE 
Volume 1025 1510 1085 1636 11,57 16611 211,9 1891 8141 619 461 
Creatinine 6.5 6.B 6.0 6.4 5.9 1,.3 6.0 (,.1 1,.6 3.1 '2.0 
Calcium 2.2 4.3 2.1 2.6 2.7 1.6 0.4 0.3 0.8 
Phosphate 0.7 1.0 11.1. 10.2 8.7 21.1 22.5 21.9 6.0 
Sodium 118 177 61 136 122 116 135 161 39 25 9.0 
NAME Patient 6 
HOSPITAL NUMBER 
IIGE 68 
PLIISMII 
Date 15/1 16/1 1011 19/1 20/1 21/1 221J. 2311 24/1 25/1 26/1 21/1 26/1 29/1 30/1 3111 1/2 
Time 1 2 3 I, 5 6 7 6 9 10 11/ 12 13 
Creatinine 63 07 0/, 62 96 75 6', 67 55 63 69 62 64 61 63 6', 65 
Urea 3.6 4.6 1,.7 3.7 5.6 5.6 7.6 6.5 7.6 7.5 2.2 6.2 6.1 6.6 6.9 6.5 9.5 
Sodium 137 139 136 136 136 136 11'0 1',1 1',', 1'12 136 137 140 137 136 133 131, 
Potassium 1,.0 ',.1, J.9 3.2 3.2 3.3 5.0 1,.3 1,.1 1,.1 3.7 3.3 3.5 3.5 1,.1 3.9 3.9 
Bicarb 29 JD 20 22 20 20 2 / 21, 20 22 23 26 
Calcium 2.33 2.1,1, 2.1,2 2.33 1.62 1.97 1.97 2.05 2.10 1.65 1.91 1.72 1.75 1.73 1.92 2.05 
Corr Ca 2.39 2.50 2.50 2.39 1.90 2.21 2.29 2.1,7 2.26 2.15 2.27 2.12 2.15 2.11 2.30 2.1,3 
Phosphate 1. /,0 1. /,7 1.51 1.27 1.05 0.61 0·59 0.79 1.00 1.36 1.3J 1.32 1.51 1.37 1.59 1.1,1 1.1,0 
Magnesium 0.9" 0.6/, O. (2 0.60 
-
1I1k Phos 19" 96 125 101 00 101, 1"3 122 136 115 120 11,0 291 327 691 616 
Albumin 37 37 36 37 32 26 2;, 19 26 31 25 22 20 20 21 21 21 
Globulin 19 "I 
GGT 1'2 36 30 60 1,9 207 
Bilirubin 6 7 13 25 9 11, 
liLT II, 12 231 32 19 
Glucose 
fllSTING URINE 
Creatinine 1,.0 6.6 ', .. " 0.0 11.0 1.6 lJ.5 5.2 3.6 5.0 11.3 7.9 12.0 12.1 0.1 12.0 9.7 
Calcium 3.7 3.1. 1.1, 2.0 1.21 3.6 1.6 0.60 2.1 1.12 1.2 1.73 0.66 
Phosphate 6.2 15.9 15.0 16.0 2".0 6.5 1'7.1 10.0 40.3 12.3 01.0 49.0 76 
Sodium 66 50 26 26 7 1313 6 13 107 96 1,0 6ft 60 60 77 33 33 
CaE 77 39.7 26.7 20.7 10 10 11 16.5 6.0 6.0 13. /, 3.5 
-
NaE 1761, 6100 1,96 266 61 37.3 167 1210 2/,/, 502 362 302 599 176 221 
TmCa/OfR 1.65 1.9/, 2.01 1.90 1.79 2.10 2.10 1.95 2.10 2.06 1.65 
TMP/OfR 
21, ItR URINE 
Volume 1200 971, 062 ,,59 
Creatinine 0.1 7.3 5.0 ~ . 7 7
Calcium 3.0 0.70 1.30 12.7 
Phosphate 33-1 19.9 29.5 126.3 
Sodium 95 71 59 ,,3 
NAME ratient 7 
IIOSPITAL NUMBER 
AGE 53 
PL/ISMA 
DlItl! 29/H 2/11 3/11 r%p /,/11 5/11 6/11 7111 0/11 9/11 10/11111/11 12111 13/11 1',/11 15/11 16/11 17111 
Time 
Creatinine 95 106 137 99 125 120 125 130 106 69 87 97 100 90 93 
Urea 2.9 3.1 5.1 5.3 5.0 ".5 5.1 1.0 1.1 1.3 5.4 4.6 1,.1 /,.1 /,.5 
Sodium 137 139 130 135 1101 1',3 1'01 11,8 11,1 1',8 146 145 I ~ J J 116 11,2 
Potassium 4.0 ',.1 1,.3 3.2 3.6 3.5 ',.8 ".9 ',.1, 3.0 3.5 1,.8 ',.5 3·9 5.0 
Bicarb 25 23 23 27 23 22 26 25 
Calcium 2.27 2.53 2.1,1 1.8" 1.79 2.27 2.38 2.1", 2.',/, 2.28 2.11, 2.01 2.29 2.26 2.29 2.31 
Corr Ca 2."7 2.63 2.51 2.02 1.93 2.39 2.60 2.02 2.02 2.68 2.60 2.55 2.13 2.12 2.11 2.11 
Phosphate 0.02 1.39 1.18 1.50 1.28 1.11 0.0/, 0.04 0.0/, 1.63 1.39 1. /,1 1.71 1.50 1.69 1.15 
Magnesium 0.61, 0.80 0.0/, 0.84 0.93 0.95 
/Ilk Phos 10/, 178 166 ',', 80 11 /, 163 1/,1 1/,7 149 155 11,0 222 220 199 200 
Albumin 30 35 35 31 33 JI, 25 21 21 20 11 16 18 11 19 20 
Globulin 16 33 
GOT 111 120 JI, 30 1,5 61 131 16/, 161 
Bilirubin II, 13 30 20 3/, 25 25 09 17 
ALT 26 1,1 26 )I, 25 28 20 31 25 
Glucose 
F/ISTING URINE 
Creatinine 9·3 10.3 0.0 21.5 15.5 11,.9 11.3 13.5 17.0 15.0 17.3 
Calcium 4.3 3.1 6.1 0.1, 1.9 9.2 B.3 1.2 5.1 0.9 1.7 
Phosphate 15.3 21.1 3B.6 1.1 1.7 1.9 5.9 23.2 35.9 30.B ~ 3 . 7 7
Sodium 13B 1,5 5 17 2 3 9 3 13 126 135 II, 7 
CaE 1,3.9 36.1 10.9 2.3 15.1 00.3 77.9 0.7 30 5.1, 
NaE 1/,10 1,63 11.2 26.2 122 905 79 /, 0', ,14 
TmCa/GfR 
TMP/GfR 
2" UR UnINE 
Volume 990 1,93 1',56 
Creatinine 7.0 H.O 15.3 
Calcium 3.B ',.2 
Phosphate B.O 27.3 
Sodium 69 1', 20 
NAME Patient 0 
HOSPITAL NUMBER S 60 02 03 
/lGE 57 
Pl.ASMA 
Date 12/10 13/10 11,/10 15/H 16/1C 17/10 10/lC 19/10 20/10 21/10 22/10 
Time Po/op 
Creatinine 65 71 77 02 76 77 13 05 76 00 
Urea 3.5 i,.3 5.5 6.6 5.0 3.6 4.1 3·9 3.1 3.7 
Sodium 139 13/, 136 130 139 130 139 130 130 130 
Potassium 1 •• 0 I,.', 4.1 4.0 I, .1 1,.1 4.0 i,.5 1,.7 1,.5 
Bicarb 31 20 30 30 20 27 20 27 29 20 
Calcium 2.42 2.10 1.72 1.70 1.5 1.75 1.07 1.7/, l.71 2.20 2.06 
Corr Ca 2.56 2.32 1.00 1.B6 1.70 l.05 1.95 l.O/, 1.01 2.3/, 2.16 
Phosphate 1.15 1.00 0.60 0.67 0.59 2.01 1.75 1.79 1. /,5 
Magnesium 0.05 0.65 0.70 0.75 
Alk Phos 309 269 259 23 /, 235 
Albumin 33 29 32 33 26 35 36 35 35 37 35 
-
Globulin 
GGT 
Bilirubin 
ALT 
Glucose 
tASTlNG URINE 
Creatinine 0.6 1.1 11.2 l3.2 9.0 9.3 1tf .1 
Calcium 6.2 12.3 13.1 6.7 6.5 3.9 3.9 
Phosphate 2.7 5.3 2.2 2.2 0.7 1',.3 17.1 
Sodium 51 102 23 56 129 0/, 20 
CaE {,6.9 123 96.2 1,1.6 50.1, 31.0 2/,.3 
NaE 3 5 5 . ~ ~ 1020 150 3 i,7 127 659 17/,.£ 
TmCalGfR 
TMPIGfR 
2/, IIR URINE 
.-
Volume 1. 70 1.611 1. /,0 1. 1,1, 1.30 1.53 
Creatinine 
Calcium 
Phosphate 
Sodium 
NAME Patient 9 
nOSPITAL NUMBER N 67 07 20 
AGE 52 
PLASMA 
Date 27/" 28/', 20/" 29/" 30/" 115 215 3/5 4/5 
Time PolOI 
Creatinine 72 02 104 8', 80 71 00 102 79 
Urea 5.7 5.0 6.5 6.2 3.8 6.7 ".9 6.2 
Sodium 1'.0 136 138 135 131 133 131 137 
Potassium 5.0 6.6 ',.7 6.1 3.1, 1,.0 6.1, 6.5 
Bicarb 28 31 26 29 26 20 25 30 
Calcium 2.1,3 2.37 2.3/, 1.91 2.06 2.09 2.12 2.27 2.3', 
Corr Ca 2.39 2.33 2.5 2.09 2.18 2.17 2.10 2.29 2.3" 
Phosphate 0.93 1.06 1.05 1.02 1.05 0.55 0·93 0.8', 1.2 
Magnesium 0.75 
Alk Phos 292 278 195 201 227 273 
Albumin 42 1,2 32 31 3', 36 37 J9 ,,0 
Globulin 75 59 
GGT 61 ',0 
Bilirubin 6 11 
ALT 18 I, 
Glucose 
fASTING URINE 
Ct"eatinine 22.9' 15.5 11.1 17.2 6.1 9.9 1',.1 10.2 21.6 
Calcium 11.3 5.2 6.3 ',.1 1.1, 7. 1, 5.9 7.0 13.8 
Phosphate 22.5 19.6 9.0 16.3 ".9 ".6 3.0 4.0 9.6 
Sodium 76 75 80 5" 23 102 182 136 113 
CaE 35.5 27.5 59 20 10 53 33 70 50 
NaE 397 750. 2610 301 731 1032 1360 ,,13 
TmCalGfR 1.85 1.85 1.80 1.70 1.8', 1.57 1.68 1.60 1.71 
THP/GfR 
21, IIR URINE 
Volume 0.92 10·9 .79 ~ . O O .07 .35 
Creatinine 1/,.7 1,.4 
Calcium .4 
Phosphate J.8 
Sodium 
NAME Pattent 10 
1l0SPITAt. NUMBER 30 31 53 
AGE 41 
PLASMA 
Dat.e 18/9 1819 19/9 20/9 21/9 22/9 23/9 21,/9 2019 29/9 30/9 1110 5110 
Time Polor, 
Creatinine 83 85 7', 78 68 62 68 63 71 6/, 86 60 72 
Urea 
Sodium 11,2 139 135 139 11,1 139 139 139 135 135 130 139 139 
Pl:ltassium 4.5 J.O 2.8 3.1 3.3 3.2 3.7 3.6 1,.2 (,.2 1,.3 1,.5 
, Bicarb 32 29 28 3" 3J 30 30 30 32 31 30 30 
Calcium 2.1,5 2.06 1.91 1.95 1.73 1.77 1.70 1.61 1.71 1.97 2.0" 2.15 2.28 
Corr Ca 2.27 2.20 1.83 1.89 1.73 1.75 1.60 1.57 1.87 2.09 2.20 2.27 2.32 
Phosphate 0.95 1.02 0.87 1.37 0.52 0.86 1.36 1.',8 1.12 0.82 1.,,5 
Magnesium 0.90 0.65 0·90 0.75 0.75 0.85 
Alk Phos 177 1.16 172 179 150 
Albumin "9 JJ 1,1. 1,3 ,,0 'tl ,,5 1,2 32 3/, 32 3/, 38 
OJ.obul1n 
GGT 29 33 25 
Bilirubin 15 5 6 
ALT 15 10 13 
Glucose 
fASTING URTNE 
Creatinine 13.1, 9.1 5.5 16 9.7 3.1, 12.2 7.5 6.5 
Calcium 3.7 3.0 1.0 1. /, 0.9 1.6 7.6 9.1 7.5 
Phosphate 20.1 0.1 1,.6 2.3 3.5 2.6 21.5 16.1 20.2 
Sodium 1,9 90 24 16 ',3 ,,3 3" 30 35 
CaE 22.9 29·9 21,.f, 11,.2 9·9 5. 1, 6.3 29.6 ',1,.2 77.6 75.6 
NilE 303 777 732 3/,0 18/, 62 301 797 191 256 35/, 
TmCa/GfR 1.87 1.82 1.1,5 1.60 1.55 1.70 1.50 1.20 1.35 1.1,3 1.5
" 
TMP/GF'R 0.87 1.0/, 0.93 1.68 0.68 1.2', 1.12 1.86 
2', IIR URINE 
Volume 
Creatinine 
Calcium 
Phosphate 
Sodium 
P.AT:IEm: 1 PATImT 2 
I Pre 
-' i
op 1 2 3 4 5 6 7 
<0.25 I-- i-mr (ug/L) 0.37 <0.25 <0.25 <0.25 i 
1.25(aI>,. (pg/til . 33.0 10·1 E ~ ~ 32.6 19.6 23.6 ~ ~
1---1 
24.25(OIIl,0 (pg/od) 'SO 47 '" 48 ~ 7 6 6 60" 
-- 1------
2>(aIlO (nglml) 4.6 ~ T ~ . : : . ' . - - - , ~ ~ I I
Os<-'cin (og/mi) I l-l 
-1--3 ;--, DBP (mg/L) 383 200 197 340 1260 ~ ~ 324 309 ::;,;/;61"')1° l.0 0.59 iU1 0.60 I ~ ~ 0.77 1 10." [0." 
Pre I op 1 2 3 4 5 6 7 9 10 
< 0 . 2 5 1 ~ ~ --, PTH (ug/L) <0.25 <0.25 <0.25 <0.25 
\22.2 \ ~ ~ I- I-.1,25(00)20 (pg/tol) 3.8 3.3 3.4 9.4 5.1 
24,25(OH)20 (pg/tol) 360 220 250 190 190 250 160 120 
------
I-
--
25(OH)O (ng/tol) 2.8 1.6 1.0 1.4 2.5 1.5 1.3 1.9 
~ - - - - - - -Osteocalcin (ng/toll 
I ------------------
I OBP (mg/L) 406 1164 1211 216 311 289 290 330 399 393 
Free 1,25(00)20 
,0." 10'" 0.21 0.18 ,°.,31°." - 0.18 ::=J. in:Iex x 1QJ 
P..u::JJ!Nr 3 PA:I:IF.:Rr 4 
~ ~ j' Ij ,I ,1 6 I 7 ,8 
-I ~ - ' ' ----PIH (ug/L) 
1,25(OH)2D (pg/ml) 31.2 9.1 I ~ ~ 9.3 
I 
Pre-<>? 1 2 3 4 5 6 7 8 
---- ----
,-
mr (uglL) 
1,25(QH)ZD (pg/ml) 44.9 27.1 16.4 10.2 4.45 11.9 7.S 
.. 
11.9 13.0 11.6 
----
24,25(OH)2D (pg/ml) 250 32 11 50 24,25(OH)2D (pg/ml) 360 100 107 160 93 120 116 147 
25(OH)D (ng/ml) 3.6 1.4 1.2 ~ ~I- I------- ,---I-25(OH)D (ng/ml) 14.8 3.7 7.22 3.94 3.65 2.6 6.13 1.4 2.91 2.13 -- ----,-
Osteocalcin (ng/ml) Osteocalcin (ng/ml) I 
~ - ! - T I - - -DBP (mg/L) ::, ~ j : : : 1 1 - - - - I ~ ~Free 1 , 2 5 ( ~ ) 2 D D
index x 10 
--__ -1 __ 1_-
--OBP (mg/L) I 
I 
J ~ ~ -- ,----Free 1,25(gH)ZD irxiex x 10 
--,-----
PATIENt 5 PAI:IEHr 6 
Pre 
op 1 2 3 4 6 7 8 
<0.25 1<0.251<0.25 1<0.25 I P'IR (ug/Ll 
~ ~ l l 2 3 4 5 6 7 8 1 9 I II I 12 
- P ' I R - - C - u g - / L - l - - - - I _ I - ~ - - - - - - - ~ - - = =
35.51 37 . 3 27.9 15.0 31.5 27.7 39.6 22.8 17.9 ~ ~ _ J ~ ~ , ~ ~1,25(OO)2D (pg/mll 1,25(QHl2D Cpg/ml) 
-24-,-,-2S-(-QH-)-Z-D-C-P-g/-ml-) -l10.15 10.26 0.11 0.07 0.12 ~ 0 . 1 4 4 109 120 140 1105 
'5(OR)D 'ogIml) 1 1 D · 2 1 ~ 2 . " " I'" ~ - ; : ; ; - ~ 2 . 7 3 3 ~ ~ 2 . " "75( _ ORlD (ng/mll 
OS1:eocal . cm (ng/ml) 
DBP (mg/L) 
Free 1 , 2 5 ( ~ ) 2 D D
in:iex x 10 
PAIIENr 7 
~ ~ 12345167819 
\1- Pn{-(-uglL--)----I---I---r-
I
_ 1_ =1_ 1= 
1,25(CE)20 (pg/ml) 43.9 47.8 31.2 26.1 i ~ ~ ~ ~__ 23 •. 1 ~ 4 8 . 3 3
24,25(CE)20 (pg/ml) 140 120 80 100 110 70 50 100 150 160 
I 25(CE)0 (ng/ml) 5.38 - 4 . - 0 - 1 ~ ~ - 2 . - 0 - 1 ~ ~ -3.-6-2 - ' ~ ~ ~ - 4 . - 1 - 7 7
Os1:eocalcin (ng/ml) 3.6 4.6 3.6 1.7 ,2.0 1.4 \1.3 0.6 1.2 
--,--
DBP (mg/L) 383 323 210 131 1240 
--1--------------------
I 
Free 1,25(OH)20 1.33 1.72 1.72 12•31 1.21 
iIxlex x lcP 
________ 1. __ • ______________________ _ 
OS1:eocalcin (ng/ml) 5.1 
267 I ~ l l ' ~ j j 2 0 7 7= , ' ~ ' I ~ ) 2 D D 11.54 1:] · I ~ I I__ :J 0= [ DBP (mg/L) 
PATImr 8 
, 
Pre 
op 1 2 3 4 5 6 7 8 9 
------------
PIH (ugIL) 
1
26
•
6 
1-
--------
I-
--
1,25(00)20 (pg/ml) 40.9 29.6 16.4 42.0 38.2 33.3 38.4 27.7 
~ = =----------24,25(OH)20 (pg/ml) I- i-25(OH)O (ng/ml) 11.7 8.0 4.58 3.61 5.75 7.17 7.81 6.92 
-- ~ ~ ~ ---- --Osteocalcin (ng/ml) 2.9 3.1 3.4 i-
--
DBP (mg/L) 560 386 293 298 
------------------
Free 1,25W)20 1.03 1.08 0.65 ' 1.49 
index x 1 
_ _____ 1 ___________ 
E'AnENr 9 PATImr 10 
1 I:: 1 _ 1 _ 1 ~ _ ' '[J-' I ~ ~ ~
I ?m (",ILl I ~ - l ~ - L ~ ~ ! ~ ~ ~ 1 
1
1
,25(OO)2D (pg/ml) \32.3 15.3 18 •6 I ~ ~ 11 ___ 110 II 
I ",'5(00),0 (pg/ml) 1 ~ 1 7 0 0 1"0 1 ~ 7 3 3 1 ! ~ 1 0 0 0 [J 
I :S(OH)O (ng/ml) 13.1 /S.6 15.0 112.5 Is.2 I Iz;!S.1 I I I O ' ~ n n (og/ol) I [ J ~ = J ~ - i j = I - ; ;
I asp (.,/L) 1304 1329 l ~ ~ - - J J1 I ~ _ _
~ r e e e L,2S(OH)2D \2.0710.23 :j.37 ~ J J iJO.35! l.ndex :( 10) I 
-1 -' 
I l i ~ e e 1 I 2 I 3 I 4 1. 5 I 6 I 7 I 8 I 11 
I E'IH (ug;1.) I - I - - ! - I - I - ~ ~
I i l-l __ t-'-l-l-::::-=-l-l-
11,25(00)20 (pg/ml) \41.1 i ~ ~ J 3 4 . 5 5 ~ 5 2 . 6 1 ~ 1 ~ . ~ ~ ~ . - - ' ~ ~ 47.0 
1
24
,25(00)2
0 
(pg/ml) ~ ~ ~ ~ - - ~ J J I ~ ~__ ~ ~
I 2S(OH)O (ng/ml) 18.6 13.6 3.5 5.4 8.8 8.1 l i ~ 7 . 6 6 7 ~ 6 6 7.3 
I I I I. 
I ',<=loin ("';ol' ' ~ ~ 11.& '=',.3 1,.3 i,·5 - - I ~ I = =
I DSP (mg/L) i 383 I ~ I I___ ._ ~ . .__ I ~ ~ ~ I __ 
I ~ : X l ~ ~ ~ ) 2 0 0 :J:J __ l j _ I : J ~ ~ _ _
Nomogram to estimate ThlCa/GFR (nmol/L) 
C' 
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- FINIS CORONAT OPUS -
(The end crowns the work) 
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Changes in osteoca1cin after femoral neck fracture 
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SUMMARY. In a group of elderly patients with osteoporosis and femoral neck fracture, 
osteocalcin concentrations rose significantly in the first week after fracture fixation. 
The changes in osteocalcin correlated well with the changes in plasma 1,25-
dihydroxycholecalciferol (P < 0·00 I). 
Osteomalacia is an important'" but uncommon' 
treatable accompaniment of femoral neck frac-
ture. Current biochemical screening tests which 
rely on measurements of serum calcium and 
alkaline phosphatase have a high false positive 
rate.' This is largely because alkaline phosphate 
arises from both bone and liver: hepatic dysfunc-
tion is common in the elderly fracture popula-
tion.' 
The recent availability of radioimmunoassays 
for osteocalcin, a bone specific protein that is 
released during osteoblastic activity" 7 and is 
stimulated by 1,25-dihydroxyvitamin D (1,25-
(OH),D)8 .• raises the possibility that it may be a 
more specific test for .osteomalacia than serum 
alkaline phosphatase. The problem is that there is 
no information about changes in osteocalcin 
concentration during the immediate post-fracture 
period when it might be used for screening. 
In the present study we describe the changes in 
osteocalcin concentration which occur in the first 
week after a femoral neck fracture and its fixa-
tion. We have also examined its relationship to 
alkaline phosphatase, 1,25-(OHhD and bone 
histomorphometry. 
Patients and methods 
The study was based on 26 consecutive patients 
(3 male, 23 female; mean age 78·2 years, range 
58-92 years) who had sustained a traumatic 
fracture of the femoral neck. Perioperative iliac 
crest bone biopsies had excluded osteomalacia in 
all cases: osteoid area < 3·5%; surface extent of 
osteoid < 25%, osteoid seam thickness index 
Correspondence: Dr 0 J Hosking, Department of 
Medicine, City Hospital, Nottingham NGS IPB, UK. 
< 0·14. < 4 osteoid lamellae/seam.'·' II No patient 
took calcium or vitamin D supplements either 
before or during the study. 
Fasting blood samples were taken pre-operati-
vely, within 24 h of the fracture in all patients, and 
were repeated one week later by which time all 
fractures had been treated by internal fixation. 
Blood samples were collected into lithium 
heparin tubes and the plasma stored at - 20Q C 
until assay. Plasma calcium, phosphate, creati-
nine, albumin concentrations and alkaline phos-
phatase were measured by standard autoanalyser 
techniques.'· Calcium concentrations were 
adjusted to a plasma albumin of 40 g/L." 
Plasma osteocalcin concentrations were mea-
sured by radioimmunoassay (CIS(UK) Ltd, Lon-
don, UK) using a rabbit antibody raised against 
bovine osteocalcin. 1,25-(OH),D was extracted 
from plasma and purified by straight phase high 
performance liquid chromatography on a Zor-
bax-Sil column." The 1,25-(OH),D peak was 
collected and quantitated by a competitive pro-
tein binding assay using calf thymus cytosol.'· 
Vitamin D binding protein (DBP) concentrations 
were measured by radial immunodiffusion. IS ... 
The free 1,25-(OH),D index was calculated as the 
molar ratio of I.25-(OH),D/DBP x 10'. This 
gives a good estimate of the free 1,25-(OH),D 
concentration." Parathyroid hormone (PTH) 
concentrations were measured using a C-terminal 
assay." 
Reference values for osteocalcin, J,25-(OH),D 
and DBP were derived from a group of healthy 
elderly normal subjects (8 male, 13 female; mean 
age 69·6 years, range 60-8 J years). Both patients 
and cO"ltrol subjects were studied throughout the 
year. Iliac crest bone biopsies were quantitated as 
described previously."" 
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TABLE I. Biochemical changes after femoral neck fracture 
Calcium (mmol/l) 
Phosphate (mmol/l) 
Alkaline phosphatase (IU/l) 
Crealinine (mmol/l) 
OSleocalcin (ng/ml) 
Vitamin DBP (mgjl) 
TOlal 25-(OH)D (nmol/l) 
TOlal 1,25-(OHhD (pmol/l) 
Free 25-(OH) 0 index (x 10') 
Free 1,25-(OH),D index (x 10') 
Femoral neck fracture 
(n=26) (mean±SD) 
Basal I Week 
2-26±0'15 2·28±O·14 
1·15±0·34 1·11 ±O'18 
221 ± 150 281±196t 
98·0± 19·9 10Io4±54·6 
3·12± I·g 3·73 ±2·0" 
299±69 354±76"" 
1I·6±7·6 8·9H·5 
39·6±20·3 43'7±20'0 
2·32± 1·37 202± 1·5 
0'78±Oo4 0·77 ±0-46 
Reference 
runge 
2·2-2-6 
0,8-104 
98-280 
60-120 
3'2-8'1 
284--373 
15'1-53'5 
26· 5-72-3 
2'57-9-45 
0·44-1·28 
Tesl of significance between basal and one week values:" P<0·02"" P<O'OI 
t P<O·OOI. 
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FlO. I. Changes in serum alkaline phosphatase, osteocalcin and vitamin 0 binding protein in the first week after a 
femora! neck fracture and its fixalion. Reference range for each variable shown hatched. . <, 
Statistical analysis 
Differences between and within group were 
assessed using Student's I-test, the paired I-test or 
the Wilcoxon signed-ranks test as appropriate. 
Results 
The changes in the measured biochemical vari-
ables within the first week after femoral neck 
fracture are summarised in Table I. There were 
significant increases in osteocalcin (P < 0·02), 
DBP (P<O·OI) and alkaline phosphatase 
(P < 0·001: Wilcoxon signed-ranks test). All the 
initial values of osteocalcin lay below the upper 
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FlO. 2. Plasma osteocalcin and alkaline phosphatase 
concentrations in relation to surface extent of oSleoid in 
osteoporotic patienls with femoral neck fractures. The 
vertical line indicales the upper limit of normal for Ihe 
surfaceextent of osteoid. The hatched area indicates the 
reference ranges for oSleocalcin and alkaline phospha-
lase. t,25-(OH),D: 0,10-25 pmol/L; e, 25-50 pmol/L, 
x, > 50 pmol/L. 
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limit of the reference range, even in those selected 
because of a raised alkaline phosphatase (Fig. I). 
Moreover, the increments in osteocalcin which 
occurred within the first week after the fracture 
also lay below this limit. Of the 21 patients with a 
normal alkaline phosphatase on admission only 
two rose to a level above the upper limit of normal 
after one week. 
There was no statistically significant relation-
ship between the admission concentrations of 
osteocalcin or alkaline phosphastase and the 
surface extent of osteoid, an index of bone 
formation (Fig. 2) nor with osteoid area or 
osteoid seam thickness. This seemed to be 
because some patients with apparently adequate 
bone turnover as judged by the extent of osteoid 
surfaces had low values of osteocalcin. However, 
when these patients were stratified according the 
prevailing level of free 1,25-(OH),D the low 
osteocalcin values appeared to be associated with 
very low levels of vitamin D. 
There was no correlation between the absolute 
concentrations of osteocalcin and alkaline phos-
phatase, DBP, or free and total 1,25-(OH),D. 
There was however a strong correlation between 
the changes in osteocalcin and the changes in free 
(r=0·56; P<O·OOI) or total (r=0·81; P<O·OOI) 
1,25-(OH),D (Fig. 3). There was no correlation 
between the changes in osteocalcin and DBP nor 
was there any relationship between alkaline·phos-
phatase and 1,25-(OH),D. 
Serum PTH concentrations were either unde-
tectable or at the lower end of the reference range 
throughout the study. 
Neither the type of fracture, its degree of 
comminution or displacement nor the type of 
operative fixation appeared to inftuence the mag-
nitude of the change in osteocalcin over the 
course of the study. 
Discussion 
Evaluation of the significance of osteocalcin 
concentrations after femoral neck fracture 
requires an appreciation of the factors inftuencing 
both the initial post-fracture value and its sub-
sequent change as healing occurs. Since osteocal-
cin originates only from bone it is potentially a 
more specific marker of osteoblastic activity than 
alkaline phosphatase. II ... In the present study 
patients without osteomalacia but with normal or 
low bone turnover, assessed from the surface 
extent of osteoid, had admission values of osteo-
calcin which lay below the upper limit of the 
reference range. In contrast alkaline phosphatase 
was elevated in several of the same patients. 
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FIG. 3. Correlation between the changes in osteocalcin 
and the changes in total and free 1,25·(OHhD concen· 
tralions in the first week after femoral neck fracture. 
Unlike previous studies of younger women with 
osteoporosisI8- 20 we were unable to find a correla-
tion between osteocalcin and bone formation 
(surface extent of osteoid). The problem seemed 
to be that a significant proportion ofthe patients 
with osteoid surface values towards the upper 
part of the reference range had low levels of 
osteocalcin. A number of possible explanations 
for this observation need to be considered. 
Plasma osteocalcin has a short half lifell and 
may be depressed by the stress associated with the 
fracture. A similar mechanism has been proposed 
for the reversible depression of vitamin D binding 
protein,16 which was also seen in the present 
study. However the lack of a correlation between 
these two variables in the week after the fracture 
argues against a common mechanism. However, 
stress might depress osteocalcin through adrenal 
stimulation since such an effect has been reported 
with the use of glucocorticoids." Unfortunately 
plasma cortisol was not measured in the present 
study. Our patients were much older than those in 
previous studies, but since osteocalein tends to 
rise with age" this canot be the explanation for 
our findings. 
The disproportionately low levels of osteocal-
cin tended to be associated with very low ( < 25 
pmol/L) levels of 1,25-(OH)2D. That 1,25-
(OH),D may be an important factor is supported 
by the further observation that although there 
was no correlation between the absolute concen-
trations of osteocalcin and 1,25-(OH)2D, there 
was a relationship between the changes in these 
variables in the first week after the fracture. This 
is consistent with the observation that. while 
osteoblast production of osteocalein is stimulated 
by 1,25-(OH)2D, both in cell culture" 8 and in 
experimental animals," it does not appear to be 
vitamin D dependent. 
The role of osteocalein in bone mineralisation 
remains uncertain and plasma concentrations 
probably reflect the portion of newly synthesised 
protein not bound to the mineral phase of 
bone.24-26 It may be that as the fracture heals 
caleification of callus results in a slight fall in 
serum calcium, stimulation of parathyroid hor-
mone secretion and augmentation of 1,25-
(OH)2D production with further enhancement of 
osteocalcin production. The necessary increases 
in PTH and 1,25-(OHhD were not seen in the 
present study but this may be because of the 
insensitivity of our assays to small changes or 
because those changes had diminished when 
sampled a week after the fracture. 
It remains to be seen whether osteocalcin is 
useful in screening very elderly patients with 
femoral neck fractures for osteomalacia. Exper-
ience with the use of osteocalcin for this purpose 
is surprisingly limited. The generation of diagnos-
tically useful raised values may depend critically 
on the opposing effects of I ,25-(OHhD deficiency 
and the ability of the very elderly to increase both 
parathyroid hormone secretion and bone forma-
tion. The timing of samples is also critical. The 
present study shows that osteocalcin concentra-
tions remain within the reference range within the 
first week after a fracture. Other studies where the 
timing of samples was not stated, found elevated 
values26 further complicating, and diminishing, 
the diagnostic usefulness of this measurement. 
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